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Squamous cell carcinomas (SCCs) of the aerodigestive tract often recur because of 
incomplete excision or the appearance of second primary or second field cancers. 
Recent evidence suggests that the omega-3 polyunsaturated fatty acids (PUFA) have 
antitumorigenic activities. In the present study the potential of omega-3 PUFA to act 
as selective chemopreventive and therapeutic agents against oral and epidermal 
SCCs was tested and the mechanism of action was investigated. The effect of 
omega-3-PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on 
oral and epidermal malignant SCC and pre-malignant cell lines and also normal 
keratinocytes were examined. The PUFA inhibited growth dose-dependently after 4 
days, as measured by MTT cell viability assays. The PUFA appeared to be more 
selective against malignant and premalignant than normal keratinocytes. It was 
demonstrated that PUFA caused apoptosis by the annexin V apoptosis assay and 
cleavage of caspase 3 by western blotting. The cleavage of caspase 9 and 8 
demonstrated the involvement of the intrinsic and extrinsic apoptotic pathways, 
respectively. Moreover, DHA and EPA decreased cell proliferation by the 
3
H-
thymidine uptake assay. PUFA appeared to increase ROS production and DNA 
damage after 16 hours, especially at the higher concentrations. However, the use of 
anti-oxidants could not rescue the cell. Furthermore, the role of telomerase in PUFA 
mechanism of action was not confirmed as overexpression of TERT, TERT-HA and 
CMYC did not protect the cells from the growth inhibitory effect of PUFA and serum 
albumin was identified as an antagonist of PUFA inhibitory effect. PUFA caused a 
rapid and sustained phosphorylation of ERK1/2 which is inhibited by MEK and EGF 
receptor inhibitors. The phosphorylation of ERK1/2 was accompanied by an increase 
in COX-2 expression. An increase in the phosphorylation of JNK, especially in 
higher doses, but no effect on Akt phosphorylation, was observed. It is hypothesised 
that PUFA may secrete a ligand which causes the suprastimulation of EGFR and 
over-activation of ERK1/2 pathway which leads to apoptosis. In summary, the 
omega-3-PUFA DHA and EPA display a marked anti-tumour effect against SCC 
keratinocytes at concentrations that do not eliminate normal cells, thus giving them a 
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Chapter 1: Introduction 
 
1.1 Oral mucosa  
 
All covering and lining tissues of the body are composed of two layers: a surface 
epithelium and an underlying fibrous connective tissue separated by a basal 
membrane. The primary function of the epithelium is to create a barrier from the 
external environment, protecting the underlying tissues and organs from mechanical 
force, dehydration and harmful chemicals and pathogens. The connective tissue 
provides mechanical support and nutrients for the epithelium. The oral mucosa, as 
well as the mucosa of the esophagus, is very different from the other mucosae of the 
body, for example the digestive tract. It has more similarities with the skin than with 
the intestinal mucosa (figure 1-1).  The two layers of the oral mucosa are specifically 
called oral epithelium and lamina propria (the oral connective tissue) (figure 1-1B). 
Skin, oral mucosa, and esophagus are covered by a stratified epithelium (figure 1-1) 
composed of multiple layers of cells that show various patterns of differentiation (or 
maturation) between the deepest cell layer and the surface. The oral mucosa mainly 
consists of squamous (flat and thin) epithelial cells. The main cells are the 
keratinocytes, which are filled with cytokeratins and are tightly linked with each 
other by desmosomes. The covering tissue of the stomach and the intestines, on the 
other hand, consists of a simple epithelium with only a single layer of cells, which 
enables the absorption of the nutrients. In many regions of the oral cavity, such as 
the cheeks, the lips, and parts of the hard palate, there is a layer of a loose fatty or 
glandular connective tissue, called submucosa, under the lamina propria. This tissue 
contains the major blood vessels and nerves of the oral mucosa and determines the 
flexibility of its attachment to the underlying structures. In other areas of the oral 
mucosa, such as the gingiva and parts of the hard palate, the submucosa is absent, 
resulting in a firm and inelastic attachement of the oral mucosa directly to the surface 
of the bone (periosteum), which is called mucoperiosteum (Liu et al, 2010; Squier & 
Kremer, 2001). Many regions of oral and esophageal epithelium contain cell types 
other than the epithelial cells, including melanocytes, Langerhans‟ cells, Merkel 
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cells, and inflammatory cells such as lymphocytes. These cells are calculated to 





















Figure 1-1. The structure of skin and oral mucosa  
The diagrams show the main layers and tissue components of the skin and oral mucosa and 
illustrate the similarities but also the differences of the two types of mucosa. 
(A) The diagram illustrates the structure of the skin that consists of the epidermis, the dermis 
and the hypodermis layer. The sweat glands, the hair follicles, nerves and blood vessels are 
also included in the picture (adapted from http://health.allrefer.com/pictures-images/skin-
layers.html) 
(B) The diagram depicts the structure of the oral mucosa consisting of the oral epithelium, 
the fibrous lamina propria (oral connective tissue), and the submucosa that includes the 
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(specialised pigment cells) produce melanin in melanosomes and are situated in the 
basal layer of the oral epithelium and the epidermis. Melanin contributes to the color 
of the oral mucosa together with the hemoglobin of the blood. Langerhans‟ cells 
sometimes appear in the suprabasal layers of epidermis and oral and esophageal 
epithelium. These are dendritic cells coming from the bone marrow and can move in 
and out of the epithelium and migrate to the lymph nodes. They are immune cells 
that recognise and process antigens that enter the epithelium, and present them to 
helper T lymphocytes. The Merkel cells are situated in the basal layer of the oral and 
esophageal epithelium and epidermis. The Merkel cells are sensory cells responding 
to touch. They are characterised by small, membrane-bound vesicles in their 
cytoplasm, sometimes adjoining to a nerve fiber. Finally, the transient presence of 
inflammatory cells has been reported in the nucleated cell layers. These cells can be 
lymphocytes (most frequently), macrophages, leukocytes or mast cells (Harmse et al, 
1999; Squier & Kremer, 2001). 
 
The soft tissues of the oral cavity and esophagus consist of a layer of a stratifying 
squamous epithelium. This epithelium serves to protect the underlying tissue from 
the mechanical forces of mastication, any possible fluid loss or harmful 
environmental agents entering the oral cavity with the food like microbial toxins, 
enzymes, pathogens and carcinogens. It is classified into i) the keratinized, ii) the 
non-keratinized and iii) the specialised epithelium. In areas that come in primary 
contact with food and are subject to mechanical forces associated with mastication, 
such as the gingival and the hard palate, there is a keratinized epithelium tightly 
attached to the underlying tissues by the collagenous lamina propria. These areas are 
called masticatory mucosa and are very similar to the epidermis of the skin. A non-
keratinized epithelium covers other areas, like the floor of the mouth, the esophagus 
and the cheeks, providing them with the flexibility they require for talking, chewing 
or swallowing because of the elastic connective tissue of the lining mucosa. A 
specialised epithelium covers the upper side of the tongue, which is as a mixture of 
keratinized and non-keratinized epithelium attached tightly to the tongue muscle (Liu 
et al, 2010; Squier & Kremer, 2001). The distribution of the three different types of 
oral mucosa is shown in figure 1-2. The lining mucosa represents approximately 
60% of the oral mucosa, the masticatory mucosa 25% and the specialised mucosa 
15% (Collins & Dawes, 1987; Squier & Kremer, 2001). 

































Figure 1-2. The distribution of the different types of mucosa within the oral cavity 
The detailed diagram shows the anatomic location and extent of masticatory (keratinized 
epithelium), lining (nonkeratinized epithelium) and specialised mucosa (keratinized and 
nonkeratinized epithelium) in the oral cavity (Wilson, 2008). 
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1.1.1 The epithelium 
 
The epithelium of the masticatory mucosa (keratinized) contains four distinct layers: 
the basal layer (stratum basale), the spinal layer (stratum spinosum), the granular 
layer (stratum granulosum) and the surface cornified layer (stratum corneum) (figure 
1-3). The cells of the basal layer are cuboidal or columnar. The basal cells are 
separated from the connective tissue by a membrane called basal lamina. Stratum 
spinosum is characterised by many layers of oval to polygonal cells. The stratum 
granulosum consists of cells that contain keratohyalin granules. Finally, the stratum 
corneum contains thin, flat cells without nuclei and filled with soft keratin (Avery, 
2000; Berkovitz et al, 2009)  
 
The epithelium of the lining mucosa (non-keratinized) is composed of three layers: 
the stratum basale, the stratum spinosum and the stratum superficiale. The cells of 
the stratum superficiale generally consist of flattened cells with small oval nuclei. 
The lamina propria of this mucosa is composed of the papillary and reticular layers 
(Avery, 2000; Berkovitz et al, 2009). 
 
The tongue is covered with the specialised mucosa which contains 3 types of 
epithelial structures called papillae. The vast majority are filiform papillae, which are 
threadlike keratinized extensions of the epithelium. The other type is the fungiform 
papillae, which are a few mushroom-shaped structures near the tip of the tongue. 
There are only 10-14 circumvallate papillae located between the body and the base 
of the tongue. Finally 4-11 foliate papillae are located on the lateral posterior sides of 
the tongue and contain taste buds. The taste buds are barrel-shaped structures located 
among the papillae of the tongue although some also appear on the soft palate, 
epiglottis, larynx and pharynx. They are the sense organs of the chemical sense of 
taste (Avery, 2000; Berkovitz et al, 2009). 
 
The different oral epithelium layers represent a progressive process of cell 
maturation. The cells are moving to the upper layers as they differentiate and mature, 
so cells from the surface layer are continuously removed and replaced by others. The  
 


























Figure 1-3. The structure of the oral mucosa 
The diagram (A)(Avery, 2000) and a tissue section (B) (Berkovitz et al, 2009) show the 
structure of the oral mucosa and the different layers of the oral epithelium. For the tissue 
section the letters represent: A= stratum basale; B= stratum spinosum; C= stratum 
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turnover time varies depending on the region. The turnover time for the epithelia 
adjusted to the tooth surface is about 5 days, for the lining mucosa it is about double 
that time (10 days) and for the masticatory mucosa a little more than that (Berkovitz 
et al, 2009). 
 
The feature of the epidermis and the oral epithelium that enables them to maintain 
tissue homeostasis, repair after injury and, also for the epidermis, regenerate hair, is 
stem cells. Many definitions of the stem cell have been suggested. Slack defines 
them as cells that are able to reproduce themselves and give rise to differentiated 
cells throughout the life span of the animal (Slack, 2000). The stem cells of the 
epidermis are located in the adult hair follicle, the sebaceous glands and also the 
basal layer of the epidermis. The skin tissue is very similar to the oral tissue, so the 
stem cells of the oral mucosa are most likely to be located in the basal layer of the 
epithelium. The stem cells were previously thought to constantly give rise to transit –
amplifying (TA) cells which migrate to the surface, while undergoing terminal 
differentiation (Calenic et al, 2010; Fuchs, 2008; Potten, 1974) but this has recently 
been questioned (Jones et al, 2007; Lopez-Garcia et al, 2010). The exact location of 
these stem cells is not known, as there are no specific stem cell markers. There have 
been several attempts of development of stem cell markers like adhesion markers 
such as β1-integrins, β-catenin, keratins 15 and 19 which some researchers claim can 
be used to identify stem cells in the oral mucosa and the skin (Calenic et al, 2010; 
Izumi et al, 2000; Slack, 2000; Squier & Kremer, 2001). They are thought to reside 
mainly at the bottom of the epithelial ridges that project into the lamina propria were 
most of the dividing cells tend to appear (Berkovitz et al, 2009; Squier & Kremer, 
2001). Cell colonies in vitro that have a high capacity of self-renewal are called 
holoclones. The clones progressively lose their clonogenic capacity and form 
paraclones, which eventually terminally differentiate and this may be related to stem 
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1.2 Head and neck cancer 
 
1.2.1 Frequency and risk factors  
 
Head and neck cancer, including oral cancer, is the sixth most frequently occurring 
malignancy in the United Kingdom and worldwide. The most common type of head 
and neck cancer is squamous-cell carcinoma (HNSCC). More than half a million 
patients are diagnosed with HNSCC worldwide each year (Haddad & Shin, 2008). 
Despite the fact that oral cancer represents just 0.6% to 5% of the cancers in Western 
Societies, it is very prevalent in countries like India, where it accounts for nearly 
45% of all cancers (Kirsch, 2007). Current therapeutic approaches like surgery, 
chemotherapy and radiotherapy often result in cytotoxic effects and development of 
resistance to therapy. Unfortunately, advances in current treatment have not led to a 
significant improvement in the patients‟ survival rates (Hsu et al, 2004; Hunter et al, 
2005). Approximately 83% of the patients with cancer of the oral cavity and pharynx 
survive for 1 year. The 5 year and 10 year survival rates are 61% and 50% 
respectively (American Cancer Society, 2010). 
 
The main risk factors for HNSCC are tobacco usage and alcohol consumption, 
accounting for approximately 80% of oral cancer cases in Western countries (Hunter 
et al, 2005), (Morita et al, 2010). Oral cancer shows an association to alcohol in 
never smokers and with tobacco smoking in moderate drinkers. Moreover, it is 
suggested that the two factors have a synergistic effect when combined. Heavy 
consumption of both alcohol and tobacco results in an over 48-fold increased risk in 
young people (Rodriguez et al, 2004). Smoking is a very severe problem, as more 
than 47 million adults and 4 million non-adults smoke cigarettes in the USA only. 
The rates of smoking have decreased significantly lately; however, it still represents 
a major health issue and it still causes severe chronic diseases and many deaths 
around the world (http://www.netwellness.org/healthtopics/smoking/). Diet 
characterised by low consumption of fruits and vegetables is another important 
factor implicated in the aetiology of HNSCC (Macfarlane et al, 1995). Other risk 
factors may be the use of marijuana and tobacco chewing in countries such as India 
and Indonesia, where chewing of betel quid is prevalent (Hunter et al, 2005).  It has 
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also been suggested that human papilloma virus (HPV) has a role in HNSCC 
pathogenesis (Gillison et al, 2000; Mork et al, 2001) because viral DNA, mostly of 
HPV type 16 (HPV-16), has been found in tumour tissue and patients who are 
positive for HPV antibodies have an increased risk of HNSCC (D'Souza et al, 2007). 
 
   
 1.2.2 Oral pre-malignancies and genetic alterations 
 
Patients with HNSCC develop a series of premalignant lesions (dysplasias) and 
malignant lesions. There are two main types of HNSCC premalignancies, which are 
called leukoplakia and erythroplakia. They can and should be identified by oral 
examination during regular visits to the dentist. Leukoplakias are white patches and 
erythroplakias are red patches in the mouth (figures 1-4) (Hunter et al, 2005). 
Erythroplakias are much more prone to progress to squamous cell carcinoma (SCC) 
(more than 50% in a decade) than leukoplakias (2–5% in the same period) 
(Mashberg, 1977). However, most patients present initially with carcinomas because 
of infrequent routine dental checkups, or the possibility that dysplasias are not 
recognisable macroscopically. 
 




Figure 1-4. Oral pre-malignant dysplasias 
Photographs of (A) an area of leukoplakia on the floor of the mouth and part of the tongue 
and (B) an area of erythroplakia on the right tonsillar pillar (Hunter et al, 2005). 
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In HNSCC, chromosomal changes increase at each progression step, from benign 
hyperplasia to dysplasia, to carcinoma in situ, to invasive cancer (Hunter et al, 
2005). Some of these mutations are mentioned here. The most common changes 
occur at chromosomes 9p (CDKN2A, encoding INK4A and ARF), 3p and 17p (TP53) 
(Califano et al, 1996). TP53 is one of the earliest Tumour Suppressor Genes (TSG) 
discovered and it is involved in apoptosis and cell cycle regulation (Ha et al, 2008). 
The silencing of the TP53 gene due to point mutations leads to tumour development 
in HNSCC (Somers et al, 1992). As regards chromosome 3p, the genetic changes 
that occur at two main regions in HNSCC are: a deletion at 3p14 which might be the 
site of the candidate suppressor gene, fragile histidine triad (FHIT) and the changes 
in the 3p21-p26 region, one of which might contain a telomerase-repressor gene 
(Cuthbert et al, 1999). Other genetic changes in oral dysplasias have also been 
identified at chromosome 8q24, which is probably the MYC locus (Garnis et al, 
2004b), 11q13 which is probably the gene encoding cyclin D1, and 7p11 which is 
probably the epidermal growth factor receptor (EGFR) gene (Garnis et al, 2004a). 
EGFR is an oncogene which is overexpressed in the majority of HNSCC tumours. 
Loss of the FAT gene at 4q35 was also detected in HNSCC. FAT is thought to play a 
role in cell-cell adhesion within the cadherin family (Nakaya et al, 2007). In 
addition, 8-oxoguanine DNA glycosylase 1 (OGG1) is a DNA repair enzyme whose 
reduction in function has been shown to be a risk factor in head and neck cancer 
(Paz-Elizur et al, 2006). Another possible oncogenes involved in HSNCC include c-
Jun NH2-terminal kinases (JNK), which are involved in T cell differentiation and 
apoptosis (Gross et al, 2007). Finally, it was reported that there is an accumulation of 




1.2.3 Treatment, recurrence and ‘field cancerisation’ 
 
Patients with stage I or II head and neck cancers are usually treated with surgery or 
radiation, while a combination of surgery, chemotherapy or radiation is used to treat 
advanced stage III or IV of the disease. Surgery is one of the main therapeutic 
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approaches and continues to evolve towards being as minimally invasive as possible. 
Furthermore, improved reconstruction and tissue transfer methods are being used. 
Radiotherapy is improving with the use of intensity-modulated radiation therapy 
which delivers radiation more precisely to the tumour than the normal surrounding 
tissues. Chemotherapy, e.g cisplatin, is usually used in advanced stages of the 
disease before radiotherapy, or in conjunction with radiation (concurrent chemo-
radiotherapy). Finally, some targeted agents have been used in combination with 
radiotherapy or not. One of them is cetuximad, a monoclonal antibody which blocks 
EGFR and it is used in combination with radiotherapy or as a single agent in patients 
resistant to cisplatin (Haddad & Shin, 2008; Vermorken et al, 2007). 
 
The biggest problem in HNSCC treatment is the recurrence of the tumours. The 
frequency of second primary tumours (SPTs) in patients with upper aerodigestive 
tract cancer is approximately 20%. Many of the secondary tumours that frequently 
develop throughout the head and neck region are genetically related (Hunter et al, 
2005). More than 50 years ago, Slaughter et al, used the term „field cancerisation‟ 
for the first time, in a study of 783 patients with oral cancer (Slaughter et al, 1953). 
He suggested that „abnormal‟ or pre-neoplastic tissue exists somewhere in the oral 
mucosa of the patient. These abnormalities might be due to epigenetic changes 
induced in a field of cells, or due to spread of genetically altered cells within the oral 
cavity (Jang et al, 2001). Nowadays, field cancerisation is defined as the presence of 
fields consisting of genetically altered epithelial cells which are linked to the 
carcinogenesis process. Also, the field lesion has a monoclonal origin, and does not 
show invasive growth and metastatic behavior, the hallmark criteria of cancer 
(Braakhuis et al, 2003). 
 
 According to the „carcinogenesis model‟, initially, a stem cell acquires one (or 
more) genetic alterations (such as TP53 mutations) and forms a patch with 
genetically altered daughter cells. Subsequent genetic alterations result in the escape 
of the stem cell from normal growth and its development into an expanding clone. 
The patch gradually converts into a field into the normal epithelium. As the lesion 
becomes larger, the accumulation of additional genetic alterations gives rise to 
various subclones within the field which share a common clonal origin (Tabor et al, 
2001). Eventually, a subclone evolves into invasive cancer which is called a second-
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field tumour (SFT). Alterations in the cyclin D1 gene, located at 11q13 were shown 
to be important for the progression from field to cancer (Izzo et al, 1998) (figure 1-
5). The chance of an SFT to develop in a patient will be proportional to the number 






















Figure 1-5: Proposed model of HNSCC carcinogenesis  
Firstly a patch develops, consisting of TP53-mutated cells (17p chromosomal location). Next 
the patch expands to a field, consisting of cells with cancer-related genetic alterations (the 
chromosomal locations of which are: 3p, 9p, 8p, 18q), which continues expanding. Finally 
the field progresses to cancer.  The amplification of 11q13 is considered to be important for 
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The theories which have been proposed to explain the origin of multiple secondary 
tumours are the following (Braakhuis et al, 2003; Braakhuis et al, 2002): firstly, two 
tumours can develop independently and have a different molecular fingerprint. These 
are the SPTs.  Secondly, the second tumour can develop from the first tumour 
(metastasis). Single cells or small clusters may migrate through the submucosa or are 
shed in the oral cavity at one place and re-grow at another (Califano et al, 1999). 
According to the third theory, multiple clonally related neoplastic lesions develop 
from a genetically altered field of the epithelium (Simon et al, 2001; Tabor et al, 





















































Figure 1-6: The three theories of the development of second oral tumours 
A. The new tumour develops independently from the previous one and is called second 
primary tumour (SPT). 
B. The second tumour comes from the first tumour after cells or clusters are spread in the 
oral cavity.  
C. Multiple clonally related tumours develop from a genetically altered field of the 
epithelium which expands, so these tumours are called second field tumours (SFTs).  
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1.3 Cancer and nutrition 
 
It has been reported that 30–40% of cancers are directly linked to nutrition 
(Weisburger & Horn, 1982). Since there is a direct link between diet and cancer 
incidence, several studies are trying to identify natural chemopreventive agents from 
nutritional sources. In addition to cancer chemoprevention strategy investigations, 
the development of effective therapeutic treatments for cancer is also essential. 
Current chemotherapeutic treatments are not selective for malignant cells and display 
cytotoxic effects on normal cells, decreasing the patients‟ quality of life 
(Constantinou et al, 2008). Recent evidence in the literature suggests that natural 
dietary products, such as polyunsaturated fatty acids, have antitumourigenic 
activities so they might be successful chemopreventive compounds and adjuvant 




1.3.1 Long chain omega-3 polyunsaturated fatty acids 
 
Fatty acids are essential for our body structure and metabolism. They are oxidised in 
the mitochondria producing energy. They can either be incorporated into 
phospholipids participating into plasma membrane structure or be packaged into 
triglycerides for storage and use (Molendi-Coste et al, 2010). Polyunsaturated fatty 
acids (PUFA), specifically, are important compounds in all organisms and display a 
large number of important biological functions. The most important PUFA series are 
the omega-3 and the omega-6 fatty acids. The omega-3 (or n-3) fatty acids refer to a 
class of PUFA which have the first double bond in the n-3 position (three carbons 
from the methyl end of the carbon chain). Omega-3 fatty acids must be obtained 
from the diet since they cannot be synthesised by mammals (Biondo et al, 2008).  
Omega-3 fatty acids, like alpha-linolenic acid, are found in soybeans, walnuts, dark 
green leafy vegetables, seeds and their oils (flaxseed, mustard seed and canola oil) 
(Berquin et al, 2008). Dietary omega-3 fatty acids include the cis-5,8,11,14,17-
eicosapentaenoic acid (EPA) which contains 20 carbon atoms and five double bonds 
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(20:5n-3) and the cis-4,7,10,13,16,19-docosahexaenoic acid (DHA) which contains 































Figure 1-7. The structure of DHA and EPA 
(A) The 3-dimensional models of DHA (http://www.3dchem.com/molecules.asp?ID=23) and 
EPA (http://www.3dchem.com/molecules.asp?ID=239) and (B) the chemical structure of 
DHA and EPA (Biondo et al, 2008). 
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These long chain omega-3 PUFA are contained in oily cold-water fish such as 
salmon, trout, mackerel, anchovies and sardines. Fish take DHA and EPA from 
phytoplankton and zooplankton. The amount of omega-3 fatty acids in fish vary 
widely depending on the type of fish and habitat in which they live. Generally, 
higher concentrations of EPA and DHA are found in sardines, salmon, mackerel, 








EPA DHA  n-3/n-6 
                   g/100 g (% of total fatty acids)  
Cod, Atlantic 0.7 traces 0.06 (13.2) 0.17 (34.4) 11.11 
Haddock 0.6 traces 0.05 (12.2)   0.10 (24.4) 7.67 
Herring, Baltic 9.3 0.29 (3.5) 0.56 (6.7)  0.83 (9.9) 2.94 
Herring, Pacific 18.5 0.32 (1.9) 1.03 (6.2)  1.63 (9.8) 5.88 
Mackerel, Atlantic 16 0.29 (2.0) 0.89 (6.2)  1.56 (10.8) 7.14 
Perch, all varieties 1.3 0.01 (1.6) 0.08 (8.7)  0.19 (21.4) 4 
Pike 0.7 0.01 (1.1) 0.04 (7.6)  0.16 (33.0) 7.14 
Salmon, Atlantic 12 0.18 (1.7) 0.49 (4.5)  1.33 (12.3) 3.85 
Salmon, Pacific 5.2 0.05 (1.1) 0.63 (13.5)  0.88 (18.9) 16.67 
Sardines  
(in tomato sauce) 
14.8 0.22 (1.6) 1.24 (8.8)  1.77 (12.6) 11.11 
Trout, rainbow 9.6 0.15 (1.7) 0.60 (7.0)  1.76 (20.4) 5.26 
Tuna, in water 1.2 0.01 (1.6) 0.09 (11.3)  0.16 (19.4) 6.67 
 
Table 1-1. Omega-3 fatty acid composition of fish from different species or geographical 
areas 
Amounts of total fat (fatty acids), a-linolenic acid (LNA), EPA, DHA, and ratios of omega-3 
(n-3) to omega-6 (n-6) fatty acids in different species of fish or fish from a different habitat 
are shown. The percentage of total fatty acids are shown in parentheses and traces ≤ 0.005 
g/100 g (Larsson et al, 2004). 
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1.3.2 PUFA biosynthesis and transport 
 
Humans are able to produce EPA and DHA from the omega-3 fatty acid α-linolenic 
acid (LNA), which serves as a precursor. The omega-3 and omega-6 PUFA 
biosynthetic pathways (figure 1-8) are characterised by a series of chain desaturation 
and elongation steps in the endoplasmic reticulum, until 24:5n-6 and 24:6n-3. In 
more detail the omega-3 biosynthetic pathway starts with the desaturation of LNA 
followed by elongation. Then Δ5-desaturase catalyses another desaturation that 
produces EPA, which is further elongated, and after another desaturation produces 
24:6n-3. Then, 24:5n-6 and 24:6n-3 are translocated to the peroxisome, where the 
chains are shorted by C2 by one cycle of the β-oxidation pathway to form 22:5n-6 
and 22:6n-3 (DHA), respectively, which are translocated back to the endoplasmic 
reticulum for esterification into aminophospholipids (Dyall & Michael-Titus, 2008). 
However, only 5–10% of LNA is converted to EPA (Jump, 2002), so EPA and DHA 
are acquired mainly through dietary consumption. 
 
 PUFA have the ability to signal through G-protein-coupled receptors (GPCRs), 
causing insulin release and the toll-like receptors (TLRs) of the immune system in 
some types of cells and tissues (Doege & Stahl, 2006; Li, 2004; Steneberg et al, 
2005). However, they generally need to cross the plasma membrane in order to elicit 
their diverse effects. The uptake of fatty acids from the circulation into cells includes 
the following steps: adsorption, transmembrane movement and desorption. In more 
details (1) the PUFA are generated, mostly through hydrolysis of triglyceride (TG)-
rich lipoproteins by lipases inside the endothelial lumen, and then the majority of 
them bind to albumin. Next (2) they must dissociate from albumin in order to bind to 
the plasma membrane proteins or integrate into the lipid bilayer and (3) be 
transported across the plasma membranes, into the cytoplasm (4) where they are 
associated with fatty acid binding proteins (FABPs) and long chain fatty acyl-CoA 
binding proteins (ACBPs) (Abumrad et al, 1998; Storch & Thumser, 2000). The 
mechanism by which fatty acids (FA) cross the plasma membrane is not yet 
completely clear. There has been a debate about this for several years and different 
ways of transfer have been proposed. 
 


























Figure 1-8. Omega-3 PUFA biosynthesis and dietary sources 
A summary of the biosynthetic pathways of omega-3 and omega-6 PUFA (modified from 
(Dyall & Michael-Titus, 2008) where LA= Linoleic acid, GLA= Gamma-linolenic acid, 
DGLA=Dihomogamma-linolenic acid, AA=Arachidonic acid, DPA=Docosapentaenoic 
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At first, it was suggested that PUFA are transferred through the lipid bilayer by 
passive diffusion (flip-flop), without any involvement of protein mediators (figure 1-
9) (Hamilton et al, 2002; Hamilton & Kamp, 1999). However, it was demonstrated 
that protein-mediated transport takes place in tissues with high PUFA metabolism 
and storage such as skeletal muscle, adipose tissue, liver, and heart (Doege et al, 
2006; Doege & Stahl, 2006; Schaffer & Lodish, 1994; Stremmel, 1989) (figure 1-
10). The crucial role of proteins for efficient PUFA uptake has been supported by a 
number of knockout (KO) or over-expression model systems with impaired or 
enhanced fatty acid (FA) transport (Binas et al, 1999; Martin et al, 2003; Newberry 
et al, 2006). The occurrence of both PUFA uptake mechanisms is now widely 
accepted and is likely to be dependent on different cell types and tissues. Several 
PUFA carrier- proteins have been proposed, such as FA translocase (FAT/CD36) 
(Coburn et al, 2001), FABPs (Storch & McDermott, 2009; Storch & Thumser, 
2010), long chain fatty acyl-CoA synthetases (ACSL) (Gargiulo et al, 1999), ACBP 
(Knudsen et al, 2000) and FA transport proteins (FATPs) (Doege & Stahl, 2006). 
Moreover, lipid rafts are also involved in FA influx and efflux (Ehehalt et al, 2006). 
 
The family of FABPs are intracellular proteins which are expressed in many tissues 
having tissue specific homologs. In humans nine FABPs have been identified (Storch 
& McDermott, 2009; Storch & Thumser, 2010). All FABPs have a high affinity 
binding site for a saturated or unsaturated long-chain PUFA, except from liver FABP 
(LFABP), which binds two FAs (Storch & Thumser, 2010). Tissues that exhibit high 
rates of FA uptake and metabolism appear to have higher expression of FABPs. The 
large diversity of FABPs correlates with the diversity of their functions in the 
different types of tissues (Storch & McDermott, 2009; Storch & Thumser, 2010). In 
vitro studies revealed that different FABPs transfer FA to membranes by two 
different ways. The majority of FABPs, such as the adipocyte, keratinocyte, 
intestinal, brain, myelin, and heart/muscle types, transfer their FA by direct 
interaction with the membrane, while LFABP transfers their ligand to and from 
membranes by aqueous phase diffusion (Storch & Thumser, 2000). LFABP has been 
hypothesised to be involved in lipid absorption by the enterocyte and hepatocytes. 
Lfabp KO mice show a defect in FA β-oxidation, which might represent a defect in 
FA transport (Martin et al, 2003). Adipocyte FABPs (AFABP) and the keratinocyte 
FABP (KFABP) are both expressed in adipocytes and macrophages.  























Figure 1-9. Uptake of PUFA into the cells 
In order to cross the plasma membrane, PUFA can diffuse through the lipid bilayer or be 
transported by a protein. Free diffusion occurs by flip-flop of the un-ionised form of free 
FAs (FFA) across the plasma membrane. As regards the protein-mediated transport, the 
anionic form of FFAs binds to a transmembrane protein either from the external phase or 




KFABP is also expressed in skin, liver, brain, lung, and cancerous tissue (Storch & 
McDermott, 2009). KFABP binds not only fatty acids (FA) but also retinoic acid 
(RA) which may explain its suggested role in cancer. RA can either inhibit cell 
growth by binding to the nuclear RA receptor (RAR); or promote cell growth by 
binding and activating PPARβ/γ (Schug et al, 2007). RA binding to either PPARβ/γ 
or RAR depends on the ratio of KFABP/cellular RA binding protein II (CRABPII). 
When the ratio is high, RA activates PPARβ/γ, when the ratio is low it results in 
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RAR activation. In a breast cancer mouse model resistant to RA, when the KFABP-
CRABPII ratio in mammary tissue decreased, then RA was diverted from PPARβ/γ 
to RAR and suppressed tumour growth (Schug et al, 2008; Storch & McDermott, 
2009). The small intestine is responsible for the absorption of the dietary lipids and 
the reuptake of bile acids via the enterohepatic circulation (Storch & Thumser, 
2010). Small intestinal enterocytes express IFABPs (intestinal FABPs) and LFABPs. 
Ifabp
-/-
 mice showed increased triacylglycerol levels in serum, weight gain, hepatic 
steatosis, and insulin resistance demonstrating the role of IFABP in lipid processing, 
and suggesting its protective role against metabolic syndrome (Newberry et al, 
2006). In muscle tissue, the most important FABP is HFABP (heart FABP) (Storch 
& Thumser, 2010). The central nervous system expresses also HFABP in the adult 
brain, whereas BFABP (brain FABP) and KFABP are expressed in the pre- and 
perinatal whereas myelin FABP (FABP8) is found predominantly in the peripheral 
nervous system (Storch & Thumser, 2010). The HFABP plays an important role in 
the transport and metabolism of FA, as Hfabp-/- mouse showed dramatic reduction 
in FA uptake into the heart and skeletal muscle and reduced muscle FA oxidation 
(Binas et al, 1999). 
 
The family of FATPs consists of six members (FATP1-6) that are similar in humans 
and mice. There is an ongoing debate about the function of FATPs: 1) FATPs might 
be just transmembrane FA transport proteins that associate with other proteins, such 
as ACSLs, or 2) membrane-bound long-chain (LC) and very-long-chain (VLC) acyl-
CoA synthetases which role is to trap long chain FA in the cytoplasm after FA 
diffusion across the plasma membrane, or 3) combine both the transport function 
with the acyl-CoA synthetase activity for optimal uptake, or, 4) are multifunctional 
proteins that also mediate long chain FA transport (Doege & Stahl, 2006). FATP1 is 
mainly expressed in adipose tissue but also found in skeletal muscle and, to a lesser 
extent, in the heart. Heart-specific overexpression of FATP1 in a transgenic mouse 
model caused eightfold increase in FATP1 expression in heart muscle, long chain 
fatty acid (LCFA) accumulation, increased cardiac lipid metabolism and, finally, 
lipotoxic cardiomyopathy (Chiu et al, 2001). On the other hand, FATP1 deletion in 
vivo caused reduced triglyceride accumulation and dietary FA deposition in skeletal 
muscle and adipose tissue and also demonstrated that FATPs are predominantly 
involved in the uptake, but not in the export of the LCFA (Wu et al, 2006). FATP2 is 
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found almost exclusively in liver and kidney while FATP3 shows a broader 
expression pattern, with higher expression levels in the lung (Stahl, 2004). FATP4 is 
the only FATP protein in the small intestine localised at the area responsible for the 
absorption of dietary lipids. FATP4 is also expressed in adipose tissue, brain, liver, 
skin, and heart (Doege & Stahl, 2006). FATP4 deletion studies demonstrate the 
importance of this protein for early development and skin lipid metabolism, which 
will be discussed later (chapter 7). Also, FATP4 is involved in fat absorption in early 
embryogenesis, while its depletion results in early embryonic lethality in mice 
(Cunningham & McDermott, 2009; Gimeno et al, 2003). FATP5 is expressed only in 
the liver and exhibits FA transport activity in vitro. Long chain FA uptake in primary 
hepatocytes isolated from FATP5 KO mice is reduced by 50% (Doege et al, 2006). 
Finally, FATP6 is expressed predominately in the heart (Stahl, 2004). 
 
Work in vitro and in vivo has provided evidence that FAT/CD36 (CD36) has a role 
in FA transport.  CD36 is expressed and involved in FA transport in various tissues 
such as adipose tissue, stomach, upper intestine, heart and skeletal muscle (Coburn et 
al, 2001) and also have been found in placental tissues extracts (Cunningham & 
McDermott, 2009; Larque et al, 2006). Also CD36 is co-expressed and co-regulated 
with FABP in various tissues (Spitsberg et al, 1995). FAs induce CD36 expression in 
preadipocytes (Amri et al, 1995) and in neonatal cardiomyocytes (van der Lee et al, 
2000) and in the heart of mice fed a high-fat diet (Heuckeroth et al, 1987). 
Transgenic mice with CD36 overexpression in muscle (MCK/CD36) have less body 
fat, and lower serum FAs, triglycerides and cholesterol (Ibrahimi et al, 1999). FA 
uptake by heart, skeletal muscle, and adipose tissues from CD36-null mice is 
significantly reduced (50–80%) while that of glucose is highly increased (Febbraio et 
al, 1999). 
 
ACSL (long chain fatty acyl-CoA synthetase) catalyses the esterification or 
activation of long-chain FAs (10–20 carbons) (Gargiulo et al, 1999). In this initial 
step, free FAs are quickly activated and coupled to coenzyme A (CoA) by the 
catalysis of ACSLs or by FATPs. ACBP or FABPs facilitate the intracellular 
unloading of the transporters and the synthetases and can also function as an 
intracellular FA buffer (Doege & Stahl, 2006). The acyl-CoA esters are later 
substrates for β-oxidation, phospholipid and triglyceride biosynthesis (Gargiulo et al, 
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1999). ACS1 is highly expressed in the heart and is also found at the plasma 
membrane of cultured adipocytes, where it functions in coordination with FATP1 to 
facilitate long chain FA movement across the plasma membrane of mammalian cells 
(Gargiulo et al, 1999). Transgenic mice with overexpression of ACSL in the heart 
showed marked cardiac myocyte triglyceride accumulation and developed 
cardiomyopathy (Chiu et al, 2001). ACBP (long chain fatty acyl-CoA binding 
protein) is an 86–103 residue protein with a highly conserved amino acid sequence. 
In mammals, l-ACBP is predominately found in the liver, evenly distributed in all 
hepatocytes and also expressed in other high energy metabolism tissues, such as 
steroid-producing cells of the adrenal cortex and testis (Bovolin et al, 1990; Knudsen 
et al, 2000). l-ACBP binds medium- and long chain acyl-CoA esters with very high 
affinity, with a preference for C:14-C:22 acyl-CoA esters (Faergeman et al, 1996). 
The second isoform is the testis specific t-ACBP and the third one is the brain 
specific b-ACBP. The fourth group of ACBP is a group of longer sequences, with up 
to 533 amino acids. Some of these longer sequences are suggested to be membrane-
bound ACBP domain proteins (Knudsen et al, 2000). Generally, ACBP is thought to 
act as an intracellular acyl-CoA transporter and affect FA-mediated regulation of 




1.3.3 The role of PUFA in disease 
 
Long chain PUFA are essential dietary components and they play a significant role 
in a variety of physiological processes. As mentioned before, they are involved in 
plasma membrane synthesis and metabolic energy production and storage, and also 
affect gene expression (Doege & Stahl, 2006; Jump & Clarke, 1999). Moreover, they 
influence innate immune response through TLR signalling (Li, 2004) and cause 
insulin release via GPCR activation (Steneberg et al, 2005). PUFA play a highly 
significant role in foetus development. DHA is essential for the development of the 
brain and retina of the foetus making it a necessary component of the pregnant 
women‟s diet (Cunningham & McDermott, 2009; Herrera, 2002). 





























Figure 1-10. A model for the protein mediated PUFA transport  
Extracellular PUFA might bind to FATP (FA transport protein) and be transported into the 
cell or could firstly bind to CD36 which transfers them to FATP dimers. When PUFA reach 
the cytoplasm, they are coupled to coenzyme (CoA) by ACSL (long chain fatty acyl-CoA 
synthetase) which prevents their efflux. FABPs (FA binding proteins) act as a cytoplasmic 




































Not only the absolute intake of omega-3 fatty acids but also the ratio of omega-6 to 
omega-3 fatty acids plays a significant role in general health. Lately, the total fat 
intake and the ratio of omega-6 to omega-3 fatty acids have increased in the Western 
diet. This ratio is between 15–20 : 1 in western Europe and the USA, whereas during 
evolution it was 1 : 1 or even less (Simopoulos, 2004). Because of the physiological 
significance of long-chain PUFA, lipid imbalances can cause a plethora of 
abnormalities and pathologies, like hyperlipidemia, obesity, type 2 diabetes, non-
alcoholic fatty liver disease (NAFLD), cardiovascular problems and cancer (Kushi & 
Giovannucci, 2002; Lichtenstein et al, 1998; Marchesini et al, 2001; Masuzaki et al, 
2001; Saltiel & Kahn, 2001). All these pathologies could be summarised by the term 
of metabolic syndrome (MetS) which has reached epidemic proportion nowadays 
(Molendi-Coste et al, 2011). 
 
This also means that omega-3 fatty acids may play an important role in decreasing 
the incidence and development of these diseases, including cardiovascular, 
inflammatory, neurodegenerative and immune disorders, and cancer. There is an 
inverse correlation between diets high in fish and fish oil and coronary heart disease 
(Madsen et al, 2001) and biomarkers of inflammation like tumour necrosis factor-α 
(TNFα) and interleukin-6 (IL-6) (Lopez-Garcia et al, 2004; Zhao et al, 2004). 
Human trials have confirmed that PUFA supplements significantly reduce 
triglyceride levels in MetS patients (Mattar & Obeid, 2009) and lower the mortality 
of patients with cardiovascular problem or MetS (Ebrahimi et al, 2009). Recently, it 
was also shown that DHA and EPA signal through GPR120, mediating anti-
inflammatory effects by inhibiting both TLR and TNF-α pro-inflammatory signalling 
pathways. Since chronic tissue inflammation is related to insulin resistance in 
obesity, a GPR120 knock out model was used to demonstrate that the anti-
inflammatory action of omega-3 PUFA also led to insulin sensitising effects in vivo 
(Oh et al, 2010). Moreover PUFA play an important role in the immune system 
development from the fetal stage (Enke et al, 2008). As mentioned, PUFA decrease 
the production of pro-inflammatory cytokines like IL-1 and TNF, having an 
important protective effect against inflammation and immune disorders like asthma, 
rheumatoid arthritis, inflammatory bowel disease (Crohn‟s disease and ulcerative 
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colitis) and psoriasis (Simopoulos, 2002). The first evidence for this was the 
observation of the low incidence of autoimmune and inflammatory disorders in a 
population of Greenland Eskimos compared to a population from Denmark 
(Kromann & Green, 1980; Simopoulos, 2002). Generally, Greenland Eskimos and 
the Japanese have a diet enriched in omega-3 PUFA from seafood which leads to a 
low incidence in inflammatory, autoimmune and heart diseases (Hirai et al, 1980; 
Simopoulos, 2002). 
 
PUFA are also involved in neurological diseases as the nervous system and 
especially the brain are enriched in PUFA and need high levels of the omega-3 and 
omega-6 fatty acids in order to function normally (Dyall & Michael-Titus, 2008). 
The accretion of DHA during development is essential for preventing neuronal cell 
death and supports neuronal differentiation. Also, DHA is crucial for neuronal and 
retinal functions (Kim, 2007). It was suggested that there is a relationship between 
higher levels of omega- 3 PUFA and a decreased appearance of dementia and 
cognitive decline with age (Johnson & Schaefer, 2006; Kalmijn et al, 2004). 
Specifically, there is evidence that links DHA and EPA levels and Alzheimer‟s 
disease (Corrigan et al, 1998) and a decrease in DHA levels correlate with the 
severity of the disease (Tully et al, 2003). In animal models, dietary omega-3 PUFA 
depletion caused decrease of NR2B, which is a receptor associated with age-related 
loss of memory and learning ability (Calon et al, 2005) while a diet enriched in DHA 
and EPA could reverse the decrease in NR2B (Dyall et al, 2007). Moreover, there 
are studies which suggest that PUFA may be beneficial in other neurological 
diseases, like Parkinson‟s disease, Huntington‟s disease and multiple sclerosis 
(reviewed in Dyall & Michael-Titus, 2008). Omega-3 PUFA also show a significant 
neuroprotective and neuroregenerative effects after acute neurological injury such as 
spinal cord injury. DHA administrated intravenously 30 min after injury, caused a 
significant reduction of the inflammation and improved neuronal survival and 
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1.3.4 PUFA in cancer: in vivo, in vitro and human studies 
 
PUFA appear to have a great potential to become useful prophylactic and therapeutic 
tools in cancer. EPA and DHA have been observed to induce apoptosis in human 
cancer cell lines including breast cancer (Schley et al, 2005) colon cancer (Chen & 
Istfan, 2000; Eitsuka et al, 2005) and lymphoma cell lines (Heimli et al, 2002). The 
pro-apoptotic effect of omega-3 PUFA has also been observed in a number of other 
types of cancer cells such as leukemia cells (Finstad et al, 1998) lung, pancreatic and 
prostate cancer cell lines (Edwards et al, 2008; Merendino et al, 2005; Serini et al, 
2008), and different molecular mechanisms of action have been proposed. 
 
Animal studies provide evidence that there is a negative relationship between diets 
rich in omega-3 PUFA and respectively a positive relationship between diets with a 
high proportion of omega-6 PUFA and breast, prostate, and colon cancer (Edwards 
& O'Flaherty, 2008; Tsubura et al, 2009). Fish oil with high levels of omega-3  
PUFA, such as EPA and DHA, reduced the risk of mammary and colon 
carcinogenesis in an animal model (Bartsch et al, 1999).  EPA and DHA suppressed 
mammary and colon cancer cell growth (Yuri et al, 2003) and the incidence and 
multiplicity of these specific types of cancers were lower in rats fed a diet high in 
EPA (Minoura et al, 1988; Sakaguchi et al, 1984). Moreover, dietary EPA and DHA 
suppressed breast tumour growth and lung metastasis in athymic mice transplanted 
with human breast cancer cells (Rose et al, 1996). EPA-enriched diet appeared to 
suppress liver metastasis of ACL-15 colon carcinoma cells (Iwamoto et al, 1998). In 
rats orally administrated with PUFA, DHA in particular, but also EPA, significantly 
decreased lung metastasis compared with control rats (Suzuki et al, 1997). In 
xenograft models of prostate cancer, diets rich in omega-3 PUFA inhibited tumour 
growth (Kobayashi et al, 2006). 
 
Recently, Kang et al, generated a fat-1 transgenic mouse expressing the 
Caenorhabditis elegans fat-1 gene which is absent in mammals and encodes for an 
omega-3 fatty acid desaturase that converts omega-6 to omega-3 fatty acids (Kang et 
al, 2004). The fat-1 transgenic mice are capable of producing omega-3 fatty acids 
from the omega-6 type, causing abundant omega-3 fatty acids and reduced levels of 
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omega-6 fatty acids in their organs and tissues, without the need of a specific diet. 
The fat-1 transgenic mouse is now being used widely and is a novel tool for studying 
the benefits of omega-3 fatty acids and the molecular mechanisms of their action. 
Several studies with fat-1 mice demonstrated that an increased tissue status of 
omega-3 fatty acids, as well as decreased omega-6/omega-3 ratio, protect against 
inflammation. DSS-induced colonic inflammation was significantly less severe in 
fat-1 than wild type (WT) mice which correlated with enhanced formation of anti-
inflammatory derivatives of omega-3 fatty acids and down-regulation of pro-
inflammatory factors/cytokines (Hudert et al, 2006). Also, protection from 
inflammatory injury was observed in chemically-induced hepatitis fat-1 mice 
(Schmocker et al, 2007). Fat-1 mice with implanted mouse melanoma B16 cells 
showed a striking reduction in melanoma development and progression. The levels 
of omega-3 fatty acids and their anti-inflammatory metabolite PGE3 were much 
higher but the omega-6/omega-3 ratio was much lower in the tumour and 
surrounding tissues of fat-1 mice compared to WT. Also, the tumour suppressor 
PTEN gene was up-regulated in the fat-1 mice. These results were confirmed in vitro 
(Xia et al, 2006). It was also demonstrated that fat-1 transgenic mice had lower 
incidence and growth rate of colon tumours (Nowak et al, 2007) and reduced risk of 
breast cancer (Liu et al, 2007b; Ma et al, 2006). Furthermore, a Pten-knockout plus 
fat-1 mice suppressed tumour growth and had an extended lifespan compared to 
Pten-knockout mice (without fat-1) (Berquin et al, 2007).  
 
Several human studies have shown that consumption of a diet enriched in omega-3 
PUFA may offer protection against a number of malignancies, including breast 
(Sasaki et al, 1993), prostate (Terry et al, 2004) and colon cancer (Yang et al, 2003). 
Many of these studies have relied on estimates based on national consumption or 
dietary intake information from self-reported questionnaires. However, some of them 
have used the levels of fatty acid in tissues as a measure of exposure to dietary fats 
(Edwards & O'Flaherty, 2008). The large study of Simonsen et al. provided evidence 
that the balance between omega-3 and omega-6 PUFA probably plays a role in 
breast cancer. Adipose tissue from breast cancer patients and healthy donors was 
examined, and showed that the ratio of long chain omega-3 to omega-6 PUFA was 
inversely associated with breast cancer in four out of five centers (Simonsen et al, 
1998). When human prostate tissue was examined, it was demonstrated that lower 
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levels of EPA and DHA, as well as lower omega-3 to omega-6 PUFA ratios were 
associated with cancer compared to benign prostate hyperplasia (Mamalakis et al, 
2002). These results were supported by the analyses of fatty acid profiles in serum 
from patients with prostate disease (Yang et al, 1999). In pancreatic cancer patients, 
3 months of dietary supplementation with EPA and DHA led to a significant weight 
gain, accompanied by a stabilization of resting energy expenditure (Wigmore et al, 
1996). Additionally, 60 patients with generalised solid tumours were given dietary 
supplements containing either fish oil or a placebo daily until death. Omega-3 PUFA 
restored the immunodeficiency of the patients and prolonged their survival (Gogos et 
al, 1998).  
 
Several studies have also demonstrated that omega-3 PUFA are able to sensitise 
tumour cells to anticancer drugs in vitro and in cancer animal models. In vitro, DHA 
and EPA improved the cytotoxic effects of several anticancer chemotherapy agents 
in breast, colon, bladder, neuroblastoma, and glioblastoma human cancer cell lines 
(Biondo et al, 2008; Lindskog et al, 2006; Maheo et al, 2005). In animal cancer 
models, chemotherapy in combination with dietary supplementation of DHA and 
EPA decreased tumour size, prolonged survival and reduced side effects (Cha et al, 
2002; Colas et al, 2006; Hardman et al, 2002). Few clinical trials have been 
conducted to examine the effects of omega-3 PUFA on tumour response to 
chemotherapy with human cancer patients. EPA and DHA enriched supplements 
consumed by patients with advanced colorectal cancer had as a result an increase in 
body weight and energy levels during chemotherapy (Read et al, 2007). Finally, 
breast cancer patients with higher concentrations of DHA in breast adipose tissue at 
the time of cancer diagnosis were reported to respond better to chemotherapy 
(Bougnoux et al, 1999). The phase II clinical trial evaluated the safety and efficacy 
of the addition of 1.8 g DHA daily to an anthracycline-based chemotherapy in breast 
cancer patients. Median overall survival was 22 months and reached 34 months in 
the sub-population of patients with the highest plasma DHA incorporation. They 
concluded that DHA during chemotherapy was devoid of adverse side effects and 
could improve the outcome of chemotherapy when it is highly incorporated 
supporting its potential to specifically chemosensitise tumour (Bougnoux et al, 
2009). 
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1.3.5 Molecular mechanisms involved in the effects of PUFA 
 
Several molecular mechanisms have been reported to be involved in the apoptotic 
effect of PUFA in cancer cells. PUFA have been reported to increase the levels of 
the pro-apoptotic proteins Bak and Bcl-xS and reduce those of the anti-apoptotic 
proteins Bcl-2, Bcl-xL (Calviello et al, 2005; Danbara et al, 2004) in colon cancer 
cells. Also, PUFA have been reported to increase the activity of caspase-3 and -9 in 
lymphoma cells (Heimli et al, 2002). Moreover they increased the expression of both 
caspases 8 and 9 and cytochrome c release from mitochondria in leukaemia (Arita et 
al, 2001). This demonstrates that omega-3 PUFA can cause apoptosis through 
activation of caspase-8 of the extrinsic pathway as well as the intrinsic mitochondrial 
pathway.  
 
Apart from the effect of PUFA on mediators of apoptosis, they also affect several 
signalling pathways. Ras plays a key role in tumour development and progression, 
since Ras proteins (H-Ras, K-Ras, N-Ras) promote cell growth, survival and 
resistance to apoptosis. Several studies have reported effects of omega-3 PUFA on 
Ras signalling, such as decreased H-ras activity and levels, and decreased Ras 
localization to the plasma membrane (Collett et al, 2001). It has been also suggested 
that PUFA can promote apoptosis through the mitogen-activated protein kinase 
(MAPK) pathway, which is linked to Ras signalling, causing the up-regulation of 
MAPK phosphatase 1 (MKP-1) and down-regulation of phospho-extracellular signal 
regulated kinases 1/2 (p-ERK1/2) and p-p38 expression (Serini et al, 2008). 
 
The phosphatidylinositol 3-kinase (PI3K) pathway regulates a number of cellular 
functions including proliferation, apoptosis, differentiation, and its activity is 
elevated in many types of human cancer. Akt is a primary mediator of the PI3K 
signalling pathway. EPA and/or DHA have been reported to prevent Akt 
phosphorylation and activity in several cell types (Lee et al, 2003; Schley et al, 
2005).  
 
Long-chain omega-3 PUFA also decrease NFκB activity and expression (Narayanan 
et al, 2003; Schley et al, 2005). Active NFκB promotes cellular survival and inhibits 
Chapter 1. Introduction 
48 
 
apoptosis, promoting tumourigenesis. It has been suggested that these fatty acids 
modulate upstream signalling involved in the activation of NFκB, such as Akt 
activation (Lee et al, 2003; Schley et al, 2005), TNF-α signalling (Novak et al, 2003; 
Weber et al, 1995), phospholipase C activation (Weber et al, 1995) and IκBα 
phosphorylation (Novak et al, 2003).  Moreover, it has been reported that down-
regulation of COX-2 may be a crucial mechanism underlying the apoptotic effect of 
omega-3 PUFA in colon cancer cells (Narayanan et al, 2004). 
 
In addition, it has been suggested that omega-3 PUFA may enhance the efficacy of 
chemotherapy drugs by increasing the reactive oxygen species levels, thus causing 
elevated apoptosis (Sturlan et al, 2003).   
 
Furthermore, it has been proposed that the omega-3 PUFA inhibit telomerase in cell-
free assays and in vitro systems, using DLD-1 human colorectal adenocarcinoma 
cells. Telomerase is the enzyme that maintains the ends of mammalian chromosomes 
inhibiting senescence and apoptosis and consists of a catalytic subunit called hTERT 
and an RNA component, hTERC. Omega-3 PUFA appeared to inhibit the expression 
of the hTERT gene, in parallel with CMYC and protein kinase C (PKC) (Eitsuka et 
al, 2005).  
 
In summary, there are many different signalling pathways potentially linked to the 
effect of omega-3 PUFA and various suggested mechanisms which may be cell type 
and/or context dependent. These mechanisms involved in the effect of omega-3 
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1.3.6 Omega-3 PUFA derivatives 
 
AA and EPA are the precursors of lipid mediators that consist of 20 carbon atoms 
and are called eicosanoids.  These are the prostaglandins (PG), thromboxanes (TX), 
prostacyclins (PGI) and leukotrienes (LT). The omega-6 AA is the precursor of the 
2-series of prostanoids (PG, TX and PGI) and the 4-series of leukotrienes. The 
omega-3 EPA and DHA are precursors of the 3-series of prostanoids and the 5-series 
of leukotrienes (figure 1-11) (Simopoulos, 1991).  
 
Cyclooxygenase (COX) enzymes catalyse the conversion of AA to prostanoids such 
as prostaglandins and thromboxane A2. Leukotrienes are biosynthesised through the 
lipoxygenase (LOX) pathway. Generally, the majority of the eicosanoids produced 
by AA are pro-inflammatory and cancer-promoting. PGE2 produced by AA is pro-
inflammatory and has a predominant role in promoting cancer (Wang & Dubois, 
2010). It is the most abundant prostaglandin found in human tumours like colon 
(Rigas et al, 1993), lung (McLemore et al, 1988), breast (Wang & Dubois, 2004) and 
HNSCC (Camacho et al, 2008). Moreover, AA-derived LTB4 and LTD4 promote 
tumour growth and metastasis (Wang & Dubois, 2010). LTB4 is increased in human 
colon (Dreyling et al, 1986) and prostate cancer (Larre et al, 2008), and inhibition of 
LTB4 synthesis by an LT4 hydrolase inhibitor reduced oesophageal adenocarcinoma 
in a rat model (Chen et al, 2003). The CysLT1 receptor expression is increased in 
human colon and prostate cancers, which correlates with the ability of LTD4 to 
induce proliferation and inhibit apoptosis. 
 
Nowadays, omega-6 fatty acids are the predominant PUFA in all diets in the 
developed countries, especially Western diets. When diets are supplemented with 
omega-3 fatty acids, they partially replace the omega-6 fatty acids in the membranes 
of the cells. There is a competition between the omega-6 and omega-3 fatty acids in 
the formation of prostaglandins. Specifically, EPA competes with AA for 
prostaglandin and leukotriene synthesis through the COX and LOX pathways 
respectively (Simopoulos, 2002). Omega-3 PUFA metabolism produces less 
inflammatory or anti-inflammatory eicosanoids (3-series prostanoids and 5-series 
leukotrienes) (Molendi-Coste et al, 2010). EPA and DHA consumption causes a 
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decreased production of PGE2, thromboxane A2 and LTB4 formation, and results in 
an increase in thromboxane A3 (a weak platelet aggregator and a weak 
vasoconstrictor), PGI3 (active vasodilator and inhibitor of platelet aggregation) and 
LTB5 (a weak inducer of inflammation and a weak chemotactic agent) (Simopoulos, 
1991).  
 
Recently, new omega-3 lipid mediators have been discovered, called resolvins, 
protectins and maresins, as well as lipoxins, which are termed specialised pro-
resolving mediators (SPM) (figure 1-11). Acute inflammation can progress to 
chronic inflammation or to complete resolution, which results in the return of the 
local tissue to the normal non-inflamed state. Resolution was previously thought to 
be a passive process; however, it is an active process that involves the biosynthesis 
of local mediators such as SPM (Serhan, 2009; Serhan & Chiang, 2008). Generally, 
the catabasis of the tissue to the homeostatic healthy state is accompanied by lipid 
mediator switching from pro-inflammatory PGs and LT to the biosynthesis of anti-
inflammatory and pro-resolving mediators, which include the SPM. This process is 
called „eicosanoid class switching‟ (Serhan & Chiang, 2008). The first pro-resolving 
mediators identified were lipoxins (Serhan, 2005) such as lipoxin A4 (LXA4) and 
LXB4, which are anti-inflammatory. Lipoxins are lipoxygenase-derived eicosanoids 
produce from omega-6 AA. During resolution, lipoxins signal macrophages to 
phagocyte the remainings of apoptotic and necrotic cells in the area of inflammation 
(Godson et al, 2000). They exert their anti-inflammatory effect in picogram and 
nanogram levels in tissues (Serhan & Chiang, 2008). Resolvins and protectins are 
local lipid mediators identified in the resolving exudates of inflammation. Resolvins 
(resolution phase interaction products) are bioactive mediators biosynthesised from 
the omega-3 fatty acids EPA and DHA. The E series of resolvins (RvE) derives from 
EPA and the D series (RvD) from DHA (Serhan et al, 2002). Resolvins can also be 
produced by a COX-2-dependent pathway, in the presence of aspirin, generating 
their aspirin triggered form. Growing evidence indicates that resolvins exert anti-
inflammatory and immunoregulatory actions, such as blocking the production of pro-
inflammatory mediators and regulating leukocyte trafficking (Serhan, 2009; Serhan 
& Chiang, 2008). Protectins are biosynthesised from DHA via a separate pathway 
(Serhan et al, 2006), and their name comes from the observed protective and anti-
inflammatory action of these molecules (Hong et al, 2003). The term neuroprotectin 
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refers to the protectins found in neuronal tissue such as neuroprotectin D1, which 
show neuroprotective action (Serhan et al, 2006). Protectins have been demonstrated 
to reduce polymorphonuclear leukocytes (PMN) infiltration in vivo and also act in an 
additive way with resolvins to stop the inflammation process (Hong et al, 2003). The 
most recent members of SPM are maresins (macrophage mediators in resolving 
inflammation). Serhan et al identified a new biosynthetic pathway for these novel, 
anti-inflammatory and pro-resolving mediators derived from DHA by macrophages 
(Serhan et al, 2009). They have similar anti-inflammatory potency with resolvins 
and protectins, and they are produced via the 14-LOX pathway. 
 
In summary, the omega-3 PUFA DHA and EPA not only possess therapeutic actions 
on their own, but also produce mediators which are anti-inflammatory and play a 












Figure 1-11: Metabolism of omega-6 and omega-3 PUFA 
The metabolism of omega-6 and omega-3 PUFA after the activation of phospholipase 
(PLA2) which causes their release from the membrane phospholipids. PUFA then act as 
substrates for different enzymes,  a process which leads to the production of the final lipid 
mediators including eicosanoids and the novel pro-resolving mediators lipoxins  
(lipoxygenase-derived eicosanoids), resolvins (resolution phase interaction products), 
protectins and maresins (macrophage mediators in resolving inflammation) via COX and 
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1.4 Aims of the study 
 
The aims of this project were:  
 To test the ability of omega-3 PUFA to specifically inhibit neoplastic 
keratinocyte growth including epidermal and oral malignant keratinocytes. 
 To test the effect of omega-3 PUFA on normal keratinocytes. 
 To investigate the biological mechanism of any growth inhibition (inhibition 
of cell proliferation or cell death). 
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Chapter 2. Materials and Methods 
 
2.1 Cell lines  
 
Malignant and normal keratinocyte cell lines were used in this study. SCC-13 and 
SCC-25 are tumourigenic keratinocyte lines, epidermal (facial epidermis) and oral 
(tongue) respectively (Rheinwald & Beckett, 1981), and SVHFK is an SV40 virus-
transformed epidermal keratinocyte line that is not tumourigenic at early passage 
(Brown & Gallimore, 1987) and can be considered pre-malignant. NHEK-131 and 
HEK-127 (Invitrogen, Paisley, UK) are normal foreskin epidermal keratinocyte 
lines. The five cell lines were maintained in keratinocyte basic medium (KBM) 
(Cambrex-Lonza, Walkersville, MD) supplemented with bovine pituitary extract 
(BPE) (0.03 mg/ml), human epidermal growth factor (EGF) (0.1 ng/ml), insulin (5 
g/ml), hydrocortisone (0.5 g/ml), and antibiotics/antimycotics GA-1000 (gentamicin 
at 50 g/ml and amphotericin B at 50 ng/ml) to make Keratinocyte Growth Medium 
(KGM). The cells were maintained in a humidified atmosphere with 5% CO2 and 
95% air, at 37°C. The cells were passaged before they became more than 50% 
confluent. In order to investigate the effect of PUFA in a serum medium, SCC-25 
were maintained in Flavin Adenine Dinucleotide medium (FAD) which consisted of 
3 parts of Dulbecco's Modified Eagle Medium (DMEM) 4.5 g/L glucose (Gibco-
Invitrogen) and 1 part of Ham‟s F12 (Gibco-Invitrogen) with 10% (v/v) foetal 
bovine serum (Hyclone FetalClone II) (Thermo Fisher Scientific, Loughborough, 
UK), 20 mM HEPES, 100 U/mL penicillin, 100 U/mL streptomycin and 2 mM L-
glutamine (Lonza), supplemented with 1.8 x 10-4 M adenine, 5 µg/mL insulin, 5 
µg/ml transferrin, 0.4 µg/ml hydrocortisone and 8.4 ng/ml cholera toxin (Sigma-
Aldrich, Gillingham, UK). 
 
Three oral dysplasia cell lines were also used: D19, which is a severe 
erythroleukoplakia of lateral tongue, D20, which is a lateral tongue moderate 
leukoplakia, and D17, which is buccal mucosa mild/moderate leukoplakia 
(McGregor et al, 2002). D19 progressed to SCC within 6 months of the biopsy being 
taken (Dr Keith Hunter, University of Sheffield - personal communication) and is 
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invasive in certain organotypic cultures. Two normal oral mucosa immortal cell lines 
were also included in the study; OKF6/TERT-1 (Dickson et al, 2000) and 
OKF4/TERT/p53DD/Cdk4 (Rheinwald et al, 2002) both oral floor of mouth 
keratinocytes which were generous gifts of Dr James Rheinwald (Brigham and 
Women‟s Hospital- Harvard Medical School, Boston, U.S.A.). Moreover, three more 
oral normal primary cultures were used: NHOK-810, NHOK-846 and NHOK-881 
(normal oral human keratinocytes) which were kindly provided from Dr Angela 
Hague (University of Bristol, UK). These normal cells and the dysplasias were 
maintained in 10% CO2 in the Keratinocyte-Serum Free Medium (K-SFM) with L-
glutamine which is supplemented with human recombinant 0.19 ng/ml EGF and 25 
μg/ml BPE, 0.39 Mm calcium chloride (Invitrogen) and 10 μg/ml penicillin and 
streptomycin (Lonza). 
 
Additionally, HaCaT cells were included which are immortalised human epidermal 
keratinocytes cells which are non-invasive and non-tumourigenic. HaCaT-TERT 
expressing wild-type TERT, HaCaT-TERT-HA expressing TERT-HA that cannot 
lengthen telomeres (non canonical function only) and the HaCaT-PURO with the 
empty vector (pBabePuro) were created by retroviral transduction (E.K.Parkinson –
unpublished data) and the mRNA expression was tested by quantitative polymerase 
chain reaction (qPCR) (B.Cereser - unpublished data). HaCaT-MYC cells are HaCaT 
cells transfected with the CMYC oncogene (Cerezo et al, 2002) and are a generous 
gift from Prof. Petra Boukamp of the Deutche Krebsforschungzentrum in 
Heidelburg.  DLD-1 was obtained from the American Type Culture Collection and is 
a colon cell line derived from human colorectal adenocarcinoma. It was used as a 
control, as there are published experiments with DHA and EPA performed using this 
cell line (Eitsuka et al, 2005). Cells were maintained at 37ºC in 5% CO2 and 95% air 
in RPMI 1640 medium (Lonza, Walkersville, MD) containing 10% v/v foetal bovine 
serum (Hyclone FetalClone II) (Thermo Fisher Scientific) containing 2 mM L-
glutamine, 25 mM HEPES and 10 μg/ml penicillin and streptomycin (Lonza). 
 
The cells were passaged with 0.1% trypsin (Worthington, Lakewood, USA)/0.01% 
EDTA (Sigma-Aldrich, Gillingham, UK) in phosphate buffered saline (PBS) when 
they reached around 50% confluence. They were first washed with PBS and then 
incubated with the trypsin/EDTA mixture at 37ºC.  The HACAT cells were first 
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incubated for 5 min with 0.02% EDTA at 37ºC and then incubated in 0.1% trypsin/ 
0.05% EDTA until separated from the plate surface. Media with 10% FBS were 
added to neutralise the trypsin (1:5). The cells were then centrifuged at 800 rpm for 5 
min and re-suspended in appropriate medium.  
 
All cells were preserved in liquid nitrogen in a freezing medium (RPMI 1640, 10% 
DMSO (Sigma), 10% FetalClone II) after a gradual dropping in temperature at -80°C 






 PUFA: The cells were treated with 5-8-11-14-17 eicosapentaenoic acid (EPA) and 
4-7-10-13-16-19 docosahexaenoic acid (DHA) (NU-CHEK, Minnesota, USA). The 
free fatty acids arrived as pure oil and were diluted in ethanol under nitrogen at a 
stock concentration of 0.5 M. The stock was aliquoted in dark coloured glass vials 
with screw tops (Agilent Technologies, Wokingham, UK) to protect from light and 
oxidation, and stored at -20
0
C for up to six months. 
 
Tocotrienols: Pure tocotrienols α, γ, δ and Tocomin®, a natural full spectrum 
Tocotrienol/Tocopherol 50% complex, were a kind gift from Mr. WH Leong 
(Carotech BHD, Perak, Malaysia). Tocomin® is a vegetable oil suspension of a 
naturally occurring mixture of tocotrienols and tocopherols extracted and 
concentrated from palm fruits. It contains approximately 115 mg/ml α-tocotrienol, 
15 mg/ml β-tocotrienol, 210 mg/ml γ-tocotrienol, 55 mg/ml δ-tocotrienol and 115 
mg/ml α-tocopherol. Pure tocotrienols and Tocomin® were also diluted in ethanol to 
a stock concentration of 0.5 M, aliquoted in dark coloured glass vials with screw tops 




Growth Factors: Insulin growth factor type 1 (IGF-1) (1-30 ng/ml), transforming 
growth factor alpha (TGF-α) (1-40 ng/ml), transforming growth factor beta 1 (TGF-
β1) (3-300 pg/ml), epidermal growth factor (EGF) (0.3-30 ng/ml) and acidic 
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fibroblast growth factor (FGF-a) (0.1–3 ng/ml), were obtained from the Sigma-
Aldrich Co. Poole Dorset, UK. Basic fibroblast growth factor (FGF-b) (0.1-3 ng /ml) 
was obtained from Invitrogen, UK and added to the growth medium RPMI at the 
indicated final concentrations in the presence of 3% v/v FBS. Cultures of HaCaT 
cells either received 0.1% ethanol alone (vehicle control), 50 μM DHA or 50 μM 
EPA. PUFA were also added to medium containing 10% v/v FBS, as a further 
control of the reduced effect of the lipids in these conditions. 
 
Antioxidants: The antioxidant n-tert-butyl-α-phenylnitrone (PBN) and α-tocopherol 
were obtained from Sigma (Poole Dorset, UK) and added to the growth medium 
(RPMI containing 3% v/v FBS or serum free KGM) to give final concentrations 
between 50 μM and 1 mM. 
 
Albumin: Human and bovine serum albumin (BSA) were purchased from the 
Sigma-Aldrich Co. and added to the RPMI medium containing 3% v/v FBS to give 
final concentrations of 0.1%, 0.3%, 1% and 3% w/v. 
 
Inhibitors: Several inhibitors were used in order to investigate the signalling 
pathways involved in PUFA effect. The caspase inhibitor Q-VD-OPh was from 
Calbiochem (EMD Biosciences, La Jolla, CA, USA). The MEK inhibitors, U0126 
was from Cell Signaling Technology (Danvers, MA, USA) and AZD6244 was from 
Selleck Chemicals (Houston, TX USA). The EGF-receptor inhibitor AG1478 was 
from Invitrogen (Paisley, UK). The EGFR blocking antibody (EGFR Mouse anti-
Human Monoclonal (Azide-free) (225) Ab) was from LifeSpan Biosciences (Seattle, 
WA, USA). The inhibitors were added in the culture for 1.5 hours before the 
addition of the EPA and DHA. After 2 hours since the PUFA were added, the lysates 
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2.3 MTT Assay 
 
The Thiazolyl Blue Tetrazolium Bromide (MTT) assay (Sigma) is a colorimetric 
assay which is based on the use of [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] to determine the number of viable cells (Mosmann, 
1983). It is based on the ability of viable cells to release the mitochondrial 
dehydrogenase enzyme which converts MTT to dark blue formazan crystals. The 
number of surviving cells is directly proportional to the level of formazan product 
generated. This assay was used to determine the number of viable cells after 
incubation in medium containing different concentrations of PUFA and tocotrienols. 
I have shown that the absorbance in the MTT assay has a linear relationship with the 




 cells per well. To determine the sensitivity 
of the MTT assay in detecting growth inhibition, HaCaT cells treated with 1 ng/ml of 
transforming growth factor beta (TGF-β), a powerful inhibitor of proliferation in this 
cell line, were included as controls in all experiments.  
 
A stock MTT (5 mg/ml) solution was prepared in sterile PBS and stored at 4ºC and 
used as needed. Then 0.5 mg/ml of MTT solution was prepared from the stock 
solution in serum free medium and filter sterilised. After the supernatants were 
aspirated, 1ml of the MTT solution was added into the culture wells of the 24-well 
plate (Nunc- VWR International Ltd, Lutterworth, UK) and the plate was incubated 
for 1 hour in a CO2 incubator at 37ºC. The media containing MTT was removed 
carefully using an aspirator. The purple formazan dye was dissolved adding 0.5 ml 
or 1 ml of DMSO in each well. Triplicates of 200 µl dissolved coloured aliquots 
from each well were transferred to a 96-well plate (Nunc-VWR). This was read at 
570 nm optical density (OD) using a FLUOstar OPTIMA BMG Labtech plate 
reader. The OD of the blank (just 200 μl DMSO) was subtracted from the sample 
OD. Cell viability was expressed as a percentage of the control cultures as: 
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2.4 Apoptosis Assay  
 
In the early stages of apoptosis, changes occur on the cell surface. One of these 
changes is the translocation of phosphatidylserine (PS) from the interior side of the 
plasma membrane to the outer layer. Annexin V is a Ca
2+
-dependent protein which 
binds to PS with high affinity and it is fluorescein-conjugated in this assay (Vermes 
et al, 1995). Since necrotic cells also expose PS as a result of lost membrane 
integrity, apoptotic cells must be differentiated from these necrotic cells. The 
simultaneous application of a DNA stain like DAPI allows the discrimination of 
necrotic cells from the annexin V positively stained cell cluster (figure 2-1). 
 
The control and treated cells were trypsinised and pelleted including any cells in 
supernatants. They were re-suspended in 500 μl of annexin V Binding Buffer 
(Becton Dickinson, Oxford, UK). Then, 4 μl/ml of Annexin-V-FLUOS (Roche 
Diagnostics Ltd, Burgess Hill, UK) and 200 ng/ml of DAPI (Sigma) viability dye 
were added and the cells were incubated at room temperature (RT) for 15 min. The 





2.5 3H-thymidine incorporation assay 
 
Cell proliferation was measured by incorporation of tritiated thymidine (
3
H-TdR). 
Cells were seeded at 4x10
2
 cells/ml/well into a sterile, 96-well flat-bottom tissue 
culture plates (Fisher Scientific, Edmonton, Alberta, Canada) and treated with 3 μM 
of EPA and DHA as described for the MTT assay (sub-chapter 2.3). Cell cultures 
were pulsed with 0.5 µCi/well of 
3
H-TdR (Amersham, UK) and incubated for 18 
hours. Cells were then harvested onto filters (Wallac Perkin Elmer, USA) using a 96-
well cell harvester (TOMTEC Harvester 96/Mach 3M). Scintillation fluid (Wallac) 
was added to the filter, which contains fluorophores that absorb radioactive energy 
and converts it into light that is then detected by the beta counter (Wallac). The 
results of the incorporated thymidine were expressed in counts per minute (CPM) 







and were a mean of triplicate. CPM were then expressed as a percentage of the 



























Figure 2-1. Schematic representation of the annexin V assay 
Annexin V-FITC binds to the PS that translocate to the outer side of the membrane during 
apoptosis. The staining of the DNA with DAPI discriminates the early from the late 
apoptotic or necrotic cell as it can only penetrate the plasma membrane when its integrity is 
breached. 
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2.6 Detection of protein expression 
 
2.6.1 Preparation of cell lysate  
 
The medium was removed from the adherent cells and washed twice in cold PBS. 
Radio-Immunoprecipitation Assay (RIPA) lysis buffer (1% NP-40, 0.1% SDS, 50 
mM Tris pH 7.3, 150 mM NaCl) (all Sigma, Poole, UK) and protease (cOmplete 
cocktail tablets) and phosphatase inhibitors (PhosSTOP cocktail tablets) (both Roche 
Diagnostics) were added to the cells on ice.  
 
After 20-minute incubation on ice, the cells were scraped with rubber cell scrapers 
and centrifuged at 15,000 rpm for 20 min, at 4
o
C. The supernatant was collected and 
the protein concentration was determined by the DC protein assay (Biorad, Hemel 
Hempstead, UK), according to the manufacturer‟s instructions. The DC Protein 
Assay is a colorimetric assay for protein concentration following detergent 
solubilisation. The protein concentration in each sample was estimated according to 
the standard curve which was calculated from the bovine serum albumin (BSA) 
standards. Total cellular protein (10-35 μg) from the samples were boiled for 5 min 
at 100°C  in SDS sample buffer (5X, 0.3 M Tris HCl, pH 6.8, 10% SDS, 50% 
glycerol, 20% 2-mercaptoethanol, 0.25% bromophenol blue) (all Sigma, Poole, UK). 
Lysates were stored at -80
o




2.6.2 Western blotting 
 
Total cellular protein from the cell lysates were separated by SDS PAGE on 4-12% 
resolving gels under denaturing and reducing conditions (NuPAGE Novex Bis-Tris 
Pre-Cast Gels, Invitrogen) at 130 V. 1x Running buffer was prepared using the 20x 
NuPage sodium dodecyl sulfate (SDS) running buffer (Invitrogen). Seven μl of 
ladder (Dual colour, Biorad) were also used for the protein molecular weight. The 
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proteins on the gels were transferred to 0.45 μm Immobilon PVDF membranes 
(Millipore, Watford, UK) that had been soaked in methanol (VWR, Lutterworth, 
UK) for 1 min and then in transfer buffer. Protein transfer took place at 30 V at 4ºC 
for 90 min using a transfer buffer containing 25 mM Tris, 190 mM glycine, and 20% 
methanol. The membrane was then blocked in 5% low fat (<1.5%) milk in Tris-
Buffered Saline and Tween 20 (TBS-T) (1 M TRIS pH 8.0, 5 M NaCl, 0.05% Tween 
20) (all Sigma) at RT for 1 hr. Primary antibody was added in 5% milk in TBS-T or 
5% BSA (PAA, Pasching, Austria) in TBS-T, according to the antibodies‟ 
manufacturer‟s instructions. The antibodies used are shown in Table 2.1. The 
membrane was incubated at room temperature for 2 hrs or overnight at 4°C and then 
washed extensively with TBS-T. The membrane was incubated in horseradish 
peroxidase-conjugated secondary antibody (Table 2.1) prepared in 5% milk in TBST 
at room temperature for 1 h and then washed four times with TBS-T. Antigen-
antibody complexes were detected and visualised by Amersham ECL 
Chemiluminescent detection reagent (GE Healthcare Life Sciences, Little Chalfont, 
UK) for strong signal, by Amersham ECL Plus (GE Healthcare Life Sciences) for 
medium-weak signal or by SuperSignal West Femto Maximum Sensitivity Substrate 
(Pierce, Thermo Fisher Scientific) for very weak signals (according to the 
manufacturer‟s instructions) on Amersham Hyperfilm ECL (GE Healthcare Life 
Sciences). The films were scanned and, when needed, the quantification of the 
difference between protein expression was carried out by densitometry using Scion 
Image software (Frederick, Maryland, USA). Corrections for the background were 
made. The amount of proteins was normalised using the estimated expressed 















Antibody Supplier Antibody type Dilution 
Cleaved caspase 3   Cell Signalling 1° rabbit polyclonal 1:1000 
Cleaved caspase 8 Cell Signalling 1° rabbit monoclonal 1:1000 
Cleaved caspase 9 (Asp330) Cell Signalling 1° rabbit polyclonal 1:1000 
Caspase 3 R&D Systems 1° goat polyclonal 1:1000 
Caspase 8 Cell Signalling 1° mouse monoclonal 1:1000 




Cell Signaling 1° rabbit monoclonal 1:1000 
p44/42 MAPK (ERK1/2) Cell Signaling 1° mouse monoclonal 1:2000 
Anti-Akt/PKB[pS
473
]  Biosource- 
Invitrogen 
1° rabbit polyclonal 1:1000 
Total Akt Cell Signaling 1° rabbit polyclonal 1:1000 
Cox-2  Santa Cruz 
Biotechnology 
1° goat polyclonal 1:200 
phospho-SAPK/JNK 
MAPK(Thr183/Tyr185)  
Cell Signalling 1°  rabbit monoclonal 1:1000 
GAPDH  Abcam 1° rabbit polyclonal 1:1000 
GAPDH  Abcam 1° mouse polyclonal 1:5000 
Phospho-p90RSK Cell signaling 1° rabbit polyclonal 1:500 
RSK 1/2/3 Cell signaling 1°  rabbit monoclonal 1:1000 
HRP-conjugated anti-rabbit IgG Pierce, Thermo 
Fisher Scientific 
2°goat polyclonal 1:2500 
HRP-conjugated anti-mouse IgG Pierce, Thermo 
Fisher Scientific 
2°goat polyclonal 1:3000 
HRP-conjugated anti-goat IgG   Sigma 2° mouse monoclonal  1:10000 
 
 
Table 2-1. Antibodies used for the western blot method 
Antibodies and suppliers are listed. The antibody types and the dilution used are also 
mentioned. The blots were usually incubated in the primary (1°) antibodies overnight 
shaking in 4°C and for 1 h into the secondary (2°) antibodies at room temperature.  
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2.6.3 Densitometry  
 
Scion Image software (Scion Corp, USA) was used for densitometry measures. 
Western blot films were scanned and uploaded in to Scion Image (figure2-2), the 
band of interest was selected and the mean intensity of the area (x) was measured 
(figure 2-2B). Similarly the background (y) was also measured (figure 2-2C), the 
results were displayed in a table (figure 2-2D) and the mean density of the band was 
calculated by subtracting the background (figure 2-2E). All western blot 
measurements were also corrected for the loading (GAPDH or total protein), which 




















Figure 2-2.  Measuring the density of band on a western blot band 
(A) Western blot bands were uploaded in to scion image, (B) the density of the band was 
measured, (C) the density of background was measured, (D) results were displayed in a 
table and the (E) mean density was calculated by subtracting the mean background density 
from the mean density of the band. 
Chapter 2. Material and Methods 
66 
 
2.7 Detection of reactive oxygen species (ROS) production 
 
2.7.1 Immunocytochemistry with 8-oxo-dG Antibody 
 
The anti-8-oxo-dG (Clone 2E2) antibody (Trevigen, Gaithersburg, USA) was used to 
detect reactive oxygen species (ROS) production. This mouse monoclonal antibody 
specifically binds to 8-hydroxy-2‟-deoxyguanosine. It can be used to detect oxidative 
damage by immunocytochemistry.  
 
The cells were plated on sterile chamber slides and were treated with PUFA. The 
staining was performed according to the manufacturer‟s instructions:  
 
Cells were plated on sterile Lab-Tek™ chamber slides (Thermo Fisher Scientific). 
After 24 h the medium was aspirated and the positive control cells were treated with 
100 μM tert-butyl hydroperoxide (TBHP) in medium, at 37ºC for 30 minutes. Then 
the medium was removed and fresh medium was added overnight. The cells in other 
wells of the chamber slides were also treated with PUFA. Following this, the cells 
were washed 3x with PBS, and fixed with 1:1 MeOH, acetone for 20 min at -20°C 
and allowed to air dry. Fixed cells were then treated with 0.05 N HCl for 5 min on 
ice and washed 3x with PBS for 5 minutes each and incubated with 250 μl of 100 
μg/ml RNAse in 150 mM NaCl, 15 mM sodium citrate for 1 hour at 37°C. The cells 
were then washed sequentially in PBS, 35%, 50% and 75% EtOH, for 3 minutes 
each and the DNA was denatured in situ with 250 μl 0.15N NaOH in 70% EtOH for 
4 minutes. Following two washes with PBS, the cells were then washed sequentially 
in 70% EtOH containing 4% v/v formaldehyde, 50% and 35% EtOH, and 1X PBS 
for 2 minutes each. Following incubation with 250μl of 5μg/ml proteinase K in 
20mM Tris, 1mM EDTA, pH 7.5 (TE) for 10 minutes at 37°C and several washes 
with PBS, the cells were incubated with 5% normal goat serum (Sigma) in PBS, 1 
hour at room temperature to block non-specific binding. After that, the cells were 
washed 3x with PBS, and incubated with 250 μl anti-8-hydroxyguanine antibody at a 
concentration of 1:250 diluted in PBS containing 1% BSA (PAA), 0.01% Tween-20 
(Sigma) at 4°C overnight in a humidified chamber. The next day, the cells were 
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washed several times with PBS containing 0.05% Tween 20 for 5 min each and 
incubated in 250 μl of fluorescent secondary antibody conjugate, goat anti-mouse 
IgG (Alexa Fluor 488) (Molecular Probes-Invitrogen) at 5 μg/ml in PBS containing 
1% BSA for 1 hr in the dark, at room temperature. After several more washes with 
PBS containing 0.05% Tween 20, the DNA off the cells was stained with 0.2 μg/ml 
Hoechst 33258 (Invitrogen Molecular Probes, Eugene, Oregon, USA) in PBS for 10 
minutes. Finally, the cells were washed several times with PBS, rinsed with de-
ionised water, mounted with appropriate mounting media (Thermo Scientific, 
Runcorn Cheshire, UK) before the analysis by fluorescence microscopy and 
visualised with a Leica DM5000 epifluorescence microscope under the x40 objective 
lens and x100 oil emersion lens, and analysed with Metamorph imaging software 




2.7.2 ROS detection by DCF or HE staining 
 
2′,7′-Dichlorodihydrofluorescein Diacetate (H2DCFDA) (Calbiochem-Merck, 
Nottingham, UK) is a cell-permeable fluorogenic probe that detects the reactive 
oxygen species (ROS) and nitric oxide (NO) in cells and it was used to determinate 
the overall oxidative stress in the cells. Upon cleavage of the acetate groups by 
intracellular esterases and oxidation, the nonfluorescent H2DCFDA is converted to 
the highly fluorescent 2',7'-dichlorofluorescein (DCF) (Yuan et al, 1993).  
 
Moreover, dihydroethidium (Invitrogen) was used to confirm oxidation. The 
dihydroethdium, also called hydroethidine (HE) is a superoxide indicator. Cytosolic 
HE exhibits blue fluorescence; however, once this probe is oxidised to ethidium, it 
intercalates within DNA, staining the cell nucleus a bright fluorescent red (Carter et 
al, 1994). HE is oxidised by superoxide to 2-hydroxyethidium and it is frequently 
used for mitochondrial superoxide detection (Zielonka et al, 2008). 
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DCF and HE were diluted in DMSO and stored at -20ºC in aliquots. The staining 
was performed as described below: 
 




/ dish). After two days, PUFA 
were added. The HFF cell line, which is a human fetal skin fibroblast cell line with 
low ROS levels, was used as negative control. Also, cells treated with 100 µM of 
tert-butyl hydroperoxide solution (TBHP), for 2 hours at 37ºC, were used as positive 
controls (as they cause oxidative stress). After the 2 hour treatment in TBHP, the 
medium was refreshed for the positive control cells. After 24 hours, the control and 
treated cells were trypsinised and pelleted, including any cells in supernatants. The 
cells were then re-suspended in medium with 1 μM of H2DCFDA or 5 μM HE, and 
250 ng/ml of DAPI in universal tubes and incubated for 30 min in 37
0
C. After that, 
the cells were washed in PBS twice (800 rpm for 5 min) and then re-suspended in 
PBS. Finally, the samples were analysed on a flow cytometer (LSR II BD 




2.8 Lipid analysis by gas chromatography 
 
The determination of the fatty acid composition of the cells or media samples 
involves several steps.  Firstly, the lipid component was extracted from the sample. 
Secondly, the phospholipids were isolated from the total lipid extract, and finally, the 
fatty acids of the phospholipids were transesterified to produce fatty acid methyl 
esters (FAMEs), which are suitable for analysis by gas chromatography.  
 
Different types of lipid solvent extraction methods are being used depending on the 
type of sample. For tissues and cells the Folch et al. method is used (Folch et al, 
1957), whereas the Bligh and Dyer method is more appropriate (Bligh & Dyer, 
1959) for samples with a high water content, such as incubation media. Due to the 
highly peroxidisable nature of PUFA the exposure to oxygen was minimised during 
the procedure, and the antioxidant 2,6-di-tert-butyl-p-cresol (butylated 
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hydroxytoluene, BHT) was added to all solvents at 0.05%. Moreover, some of the 
reagents which are prone to oxidation were changed regularly. 
 
 
2.8.1 Folch extraction 
 
Lipids were extracted using the Folch method  (Folch et al, 1957). The antioxidant 
2,6-di-tert-butyl-p-cresol (BHT) was added to the solvents used. The solvents that 
were used (chloroform/BHT 0.05%, methanol/BHT 0.05%, 
chloroform/methanol/BHT 0.05% (2:1 v/v), H2O/methanol, 0.88% KCl) were kept 
on ice during the procedure. The solvents were also stored in dark glass bottles and 
changed every two weeks. 
 
The treated and control cells were scraped from the culture dish, and transferred to a 
glass test tube. After centrifugation, the supernatant was discarded and 1 ml 
methanol/ BHT 0.05% was added. Following this, the cells were homogenised with a 
Polytron PG Kinematic AG homogeniser for 30 sec. Then 2 ml of chloroform/BHT 
0.05% were added and the process was continued for 2  30 sec, and the samples 
were centrifuged at 3500 rpm for 5 min at room temperature. Next, 2 ml of the 
supernatant were removed and added to a fresh glass test-tube. The pellet was re-
suspended in 2 ml chloroform/methanol/BHT 0.05% (2:1 v/v) and the centrifugation 
was repeated. Another 2 ml of supernatant were removed by Pasteur pipette and 
combined with the first supernatant in the glass test-tube. 1 ml of 0.88% KCl was 
added, everything was mixed gently by inversion and centrifugation was repeated. 
Next, 0.8 ml H2O/methanol was added to the combined supernatant and was mixed 
gently by inversion, and centrifuged. Again the upper layer was discarded. A sheet of 
Whatman phase separation filter paper (Whatman PS No 1) was then placed into a 
small glass funnel and was attached to a clamp above a 5 ml Reacti-Vial (Pierce, 
USA). The sample was evaporated under a stream of nitrogen using the Techne SC-3 
Sample Concentrator in fume hood. To do this the vial was placed under a rod with a 
gentle flow rate to prevent spillage and ensure even dispersal. When the solvent had 
evaporated, yellow oily residue was visible at the bottom of the vial which was re-
Chapter 2. Material and Methods 
70 
 
suspended in 40 l chloroform/BHT, capped under a gentle stream of nitrogen and 





2.8.2 Thin layer chromatography of total phospholipids  
 
The total phospholipid extracts were then separated by thin layer chromatography 
(TLC)  (Manku et al, 1983) by elution with petroleum ether/diethyl ether/acetic 
acid/methanol (85:15:2.5:1). Prior to running the TLC, the tank was equilibrated by 
adding the eluent to a depth of approximately 1 cm and leaving in the fume hood for 
several hours. Merck silica 60 g thin-layer 20x20 cm pre-coated chromatography 
plates were used in this procedure. A baseline was marked 2 cm from the bottom 
edge of a silica plate, using a pencil. Also a solvent front barrier was marked 1.5 cm 
from the upper edge of the plate and twelve 1.5 cm sample lanes into the silica. The 
procedure was carried out into the fume hood to avoid exposure to the toxic silica 
dust. Next, 20 l phospholipid were added on the baseline by superimposing 
successive 2 l drops from a Hamilton 10 l pipette onto the plate, and excess 
solvent was removed by cool air-drying every 3 to 4 spots with a hair-dryer and the 
plate was put into the tank for the 1 h elution (figure 2-3). The plate was removed, 
gently dried with cool air from the hair-dryer in the fume hood and then was sprayed 
with primuline at 0.1% in acetone/H2O (60:40 v/v). The phospholipids were 
visualised on a UV Transilluminator at 365 nm (figure 2-3). Phospholipids remain at 
the origin, whereas other lipid components elute up the plate. When the primuline 
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2.8.3 Transesterification  
 
The phospholipids form the silica plate spots were placed into 5 ml Reacti-Vials. The 
fatty acids were derivatised by transesterification (Morrison & Smith, 1964). The 
procedure was carried out in a fume hood wearing double gloves. 1 ml 14% 
BF3/methanol (toxic) was added to the TLC phospholipid samples using a glass 
pipette, and capped under a gentle stream of nitrogen. The vials were placed in the 
heating block at 100C for 20 min and then were allowed to cool for about 10 min. 
Next, 2 ml pentane and 1 ml H2O were added and capped under nitrogen, and the 
vials were vortexed for 10 sec. The caps were loosened slightly to release pressure, 
and centrifuged at 3500 rpm for about 20 sec. The upper pentane layer containing the 
FAMEs (fatty acid methyl esters) was transferred to an Agilent GC sample vial and 
was evaporated under nitrogen. The fatty acids were re-dissolved in 60 l of 
hexane/BHT (0.01% w/v). The samples where then stored at -20ºC until analysis by 




2.8.4 Gas chromatography coupled with mass spectrometry (GC-MS) 
 
Individual fatty acids were identified by gas chromatography coupled to mass 
spectrometry (GC–MS) (Agilent technologies, USA) using an SGE BPX70 capillary 
column (30m×0.25m×0.25mm i.d.). Lipid identity was confirmed by retention times 
compared to known standards and mass spectra comparison to the National Institute 
of Standards and Technology database. Quantification of peak area was by 
ChemStation software (Agilent Technologies, USA). Corrections were made for 
variations in the detector response and values of detected fatty acids were normalised 
to 100% and expressed as mol% (which were calculated by normalising the 
measured fatty acids values to 100% and then dividing by their molecular weights). 
Unless otherwise stated, all laboratory chemicals and reagents were of analytical 
grade, and purchased from Sigma–Aldrich (Poole, UK) or BDH (Poole, UK). 
Phospholipid and fatty acid standards were from Sigma–Aldrich. 































Figure 2-3.  Diagram of a TLC developing tank 
After the samples were added on the baseline, the plate was put into the tank for the 1 h 
elution. Phospholipids remain at the origin, whereas other lipid components elute on the 
silicon plate. After the thin layer chromatography (TLC) the plate is sprayed with primuline 
and the position of the phospholipid spots can be visualised at 365 nm (Meyers & Meyers, 
2008). 
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2.9 Statistical analysis 
 
The non-parametric Wilcoxon Mann-Whitney Rank test was used for the analysis of 
the data and the comparison between the normal, malignant and pre-malignant cells 
and the DCF experiment. One way Anova followed by post hoc Bonferroni test was 
used for the MTT assay, the apoptosis assay and the proliferation assay results. Both 
tests were performed via the SPSS statistical software (Version 17, Chicago, IL, 
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Several studies have shown that omega-3 PUFA have an antitumour effect by 
inhibiting the cell growth of various types of cancer in vitro.  EPA caused the 
inhibition of cell growth of hepatoma cells (Murata et al, 2001), the breast cancer 
cells MCF-7 (DeGraffenried et al, 2003) and the leukemic cell lines HL-60 and 
K562 (Chiu & Wan, 1999). Both EPA and DHA also showed an in vitro anti-cancer 
effect in various cancer cell lines, such as the colon adenocarcinoma DLD-1 (Eitsuka 
et al, 2005; Tsuzuki et al, 2007), CC531 and LT97 (Gutt et al, 2007; Habermann et 
al, 2009), breast cancer MDA-MB-231 (Schley et al, 2005), hepatocellular 
carcinoma (Schley et al, 2005) and lymphoma (Heimli et al, 2002). DHA has also 
inhibited the neuroblastoma cells SK-N-BE in vitro (Gleissman et al, 2010).  
 
 PUFA exert their anticancer effect through inhibiting proliferation or/and promoting 
cell death. There is accumulating evidence that they particularly promote apoptosis. 
But what exactly is apoptosis?  
 
a) Apoptosis 
The term „apoptosis‟ comes from the Greek word which means „drop off‟ or „fall 
off‟ and was used to describe leaves falling from the trees and petals from flowers 
(Alenzi & Warrens, 2003). It was adopted by Currie et al in 1972 to describe a 
common type of cell death observed in various cells and tissues (Hengartner, 2000; 
Kerr et al, 1972). Actually, apoptosis is a highly organised type of programmed cell 
death used to eliminate harmful, damaged or unwanted cells by phagocytosis, with 
minimal damage to the surrounding tissue and avoiding inflammation (Logue & 
Martin, 2008). The apoptotic cells undergo specific morphological changes: 
cytoplasm and nuclear shrinkage, convolution and blebbing of the cell surface, 
condensation of the nucleus and DNA degradation. The blebs break off in „apoptotic 
bodies‟, but the cells remain sealed so there is no leakage of the intracellular 
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components that could cause inflammation and damage to neighbouring cells (Alenzi 
& Warrens, 2003; Letai, 2008). The phosphatidyl serine (PS) that is normally 
restricted to the cytoplasmic face of the inner leaflet of the plasma membrane is 
exposed to the extracellular environment. PS and other induced signals allow 
recognition by phagocytic cells, which phagocytose apoptotic cells and rapidly 
remove them from their environment (Letai, 2008). The coordination and execution 
of the apoptotic process depend mainly on cystein aspartate-specific proteases 
known as caspases. They are expressed as inactive precursors (zymogens) and they 
become activated after proteolysis at internal aspartic acid residues (Logue & Martin, 
2008). There are 14 known human caspases and the ones involved in apoptosis can 
be divided into two groups: the initiator caspases (caspases 2, 8, 9 and 10) which 
initiate the caspase activation cascades, and the effector caspases (caspases 3, 6 and 
7) which are the executors of apoptosis and responsible for cell demolition.  
 
There are two main pathways in apoptosis: the intrinsic mitochondrial pathway and 
the extrinsic death-receptor pathway. There is also a third one called the granzyme B 
pathway: 
 
1. The intrinsic mitochondrial pathway 
The intrinsic mitochondrial pathway is triggered from various forms of cellular stress 
such as DNA damage, heat shock, oxidative stress and other types of damage. This 
pathway converges on mitochondria often via activation of a pro-apoptotic member 
of the Bcl-2 family. The Bcl-2 family is a large family of proteins that are important 
in the regulation of cellular life and death decisions (Cory & Adams, 2002). Each 
Bcl-2 family member has at least one BH domain. There are the pro-survival 
members, Bcl-2, Bcl-XL, Bcl-w, Bcl-b, Mcl-1 and A1, which typically contain four 
BH domains, whereas the pro-apoptotic members contain either one BH-3 domain 
(Noxa, PUMA (p53 up-regulated modulator of apoptosis), Bad, Bim, Bid, Bmf, Hrk 
and Bik) (Petros et al, 2004) or BH domains 1–3 (Bax, Bak and Bok). The balance 
of pro- and anti-apoptotic Bcl-2 family proteins controls the permeabilization of the 
outer mitochondrial membrane and the release of cytochrome c and other proteins 
(Logue & Martin, 2008). Efflux of cytochrome c from mitochondria drives the 
assembly of a caspase-activating complex in the cytoplasm known as the 
mitochondrial apoptosome (Wang, 2001). Apaf-1 detects the release of cytochrome c 
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and serves as the scaffold around which the apoptosome is built and recruits and 
activates caspase 9, which then causes the activation of the cascade of caspases (Li et 
al, 1997). In the absence of cytochrome c, Apaf-1 is a monomeric protein not able to 
interact with caspase 9, whereas cytochrome c and dATP promote Apaf-1 
oligomerization into a wheel-like structure which consists of seven Apaf-1 molecules 
and seven caspase 9 dimers (figure 3-1) (Acehan et al, 2002). Caspase 9 is directly 
responsible for the downstream activation of caspases 3 and 7 while caspase 3 
propagates the cascade further by activation of caspases 2 and 6 and by promoting 
further processing of caspase 9 (Slee et al, 1999). During the final stage of this 
cascade, caspase 6 catalyses the activation of caspase 8 and caspase 10 (Cowling & 
Downward, 2002; Logue & Martin, 2008; Slee et al, 1999). 
 
2. The extrinsic pathway 
The extrinsic death-receptor pathway is triggered by members of the death-receptor 
superfamily which share a domain within their cytoplasmic tail called „death 
domain‟. Some of them are CD95 (Fas) and tumour necrosis receptor I (TNF-1). 
When the ligands of these receptors, such as FasL/CD96L, TNF and TRAIL (TNF-
related apoptosis inducing ligand), bind to them, the death domain recruits adaptor 
proteins that recruit caspases into the receptor complex (Ashkenazi & Dixit, 1998; 
Logue & Martin, 2008). For example, when the CD95 ligand binds to CD95, it 
induces the formation of a death-inducing complex which binds to FADD (Fas-
Associated Death Domain protein).  This complex leads to procaspase-8 molecules 
recruitment and activation. Caspase 8 is the initiator caspase (or caspase 10 in some 
instances) and can subsequently cause the activation of executioner caspase-3, which 
results in apoptosis (Hengartner, 2000). This can be done by two alternative 
pathways downstream of caspase 8 activation. In most cells, stimulation of death 
receptors produces enough activated caspase 8 to cause sufficient caspase 3 cleavage 
and engage the full caspase cascade necessary to destroy the cell. Some cell types, 
though, do not manage to activate enough caspase 8 for the secure apoptosis of the 
cell. Therefore, the pro-apoptotic signal of caspase 8 causes the engagement of 
cytochrome c/Apaf-1 of the mitochondrial pathway after the proteolysis of Bid 
(Logue & Martin, 2008). 
 
 












Figure 3-1. The three major pathways of apoptosis 
The three apoptotic pathways (I) the extrinsic or death receptor pathway, (II) the intrinsic or 
mitochondrial pathway and (III) the granzyme B pathway, that cause  caspase activation 
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3. The granzyme B pathway 
A third pathway of apoptosis, called the granzyme B pathway, is initiated by the 
components of the cytotoxic granules released from the cytotoxic T cells (CTLs) and 
natural killer (NK) cells when they confront transformed or infected cells. These 
components include  perforin, which is a protein that forms pores to facilitate the 
delivery of the other components into the target cells, and granzyme B, which is a 
serine protease that cleaves after aspartic residues thus has the ability to activate the 
caspase cascade (Logue & Martin, 2008; Trapani & Smyth, 2002).  
 
b) Other forms of cell death 
Necrosis is a form of cell death which follows damage such as mechanical injury, 
ischaemia, extreme heat or cytotoxic drugs, and is not required during development 
unlike apoptosis. The morphological features of the initial phases of necrosis include 
clumping of the chromatin, dilatation of the endoplasmatic reticulum, and swelling 
of the mitochondria. In the final phase, the lysosomes rupture and hydrolases are 
released and disintegrate the cell which leads to the release of the intracellular 
contents causing an inflammatory response in the neighbouring tissues (Alenzi & 
Warrens, 2003). 
 
More recently, alternative mechanisms of programmed cell death have been 
described, supporting the idea that cells can „commit suicide‟ by mechanisms other 
than apoptosis. These alternative ways are the programmed necrosis and autophagy. 
In programmed necrosis, specific signals can trigger signalling pathways of the cell 
which initiate the necrosis process rather than accidentally. These signals could be 
DNA damage or an apoptotic receptor ligation (TNFR, Fas or TRAIL), when 
apoptosis is blocked by an anti-apoptotic drug or a virus (e.g vaccinia virus) (Chan et 
al, 2003; Edinger & Thompson, 2004). Many human tumours carry mutations that 
inactivate the pathways of apoptosis so they must be more sensitive to programmed 
necrosis, explaining how chemotherapy drugs induce cancer cell death (Edinger & 
Thompson, 2004). Autophagy is a Greek word which means that the cell „eats itself‟. 
Autophagy involves the vesicular sequestration of cytoplasmic proteins and 
organelles such as mitochondria, which results in a double-membrane vesicle called 
an autophagosome. Autophagosomes fuse with lysosomes and degrade the 
autophagosome contents. Although apoptosis and necrosis cause death irreversibly, 
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autophagy could either lead to cell death or help cells escape cell death, 
paradoxically contributing to cell survival (Amaravadi & Thompson, 2007). It 
promotes survival by serving as an intracellular mechanism used by the cells to 
dispose of damaged organelles and proteins (Gu et al, 2004) thus enabling the 
recycling of macromolecules to maintain energy (Lum et al, 2005).  
 
Several studies have demonstrated that EPA or DHA can cause apoptosis that may 
follow the extrinsic or intrinsic pathway. In colon cancer cells such as LS-174, colo 
201, HT-29 and Caco-2, DHA or fish oil appeared to trigger the intrinsic pathway of 
apoptosis by increasing the levels of the pro-apoptotic proteins Bak and Bcl-Xs and 
decreasing those of the anti-apoptotic proteins Bcl-2, Bcl-xL (Calviello et al, 1999; 
Danbara et al, 2004). The cleavage of caspase 3 and 9 but not caspase 8 has been 
reported in hepatocellular carcinoma lines by EPA and DHA (Lim et al, 2009) and in 
the lymphoma Ramos cell line by EPA (Heimli et al, 2002). EPA caused apoptosis 
detected by annexin V flow cytometric assay but also necrosis in HL-60 leukemia 
cells, by decreasing Bcl-2 and Bax protein expression (Chiu & Wan, 1999). 
However, in human Caco-2 colon cancer cells (Narayanan et al, 2001), DHA 
increased the expression of both caspases 8 and 9, and the activation of cytochrome 
c. Moreover, Habermann showed trends of caspase 8 and caspase 9 involvement in 
the apoptosis of human colon adenoma LT97 and colon adenocarcinoma HT29 
caused by EPA and DHA, by using caspase inhibitors, and also demonstrated 
cleavage of caspase 8 but also downregulation of Bid protein expression and Bcl-2 
mRNA (Habermann et al, 2009). Finally, EPA induced cytochrome c release from 
mitochondria and mitochondrial membrane depolarization in HL-60 leukemia cells, 
but additionally enhanced the activities of both caspases 8 and 9 and cleaved Bid 
expression (Arita et al, 2001).  
 
In summary, EPA and DHA and the combination of both (e.g in fish oil) can trigger 
cell death and specifically apoptosis in cancer cells. It is apparent that different 
pathways of apoptosis can be triggered by PUFA in different cells and by different 
types of PUFA and regimes of treatment. 
 





3.2.1 The effect of PUFA on SCC and normal keratinocyte growth 
 
In order to test whether PUFA specifically inhibit SCC (squamous cell carcinoma) 
growth at physiological concentrations, a panel of SCC lines were initially used 
which included the epidermal SCC-13 and the oral SCC-25, and the pre-malignant 
cell line SVFHK.  Normal keratinocytes (NHEK-131 and HEK-127) were also used 
as controls to test the cancer specificity of PUFA. The colorimetric MTT assay was 
used for this purpose. Specifically 10
5
 cells (or 2x10
5 
normal keratinocytes) were 
plated in 24-well plates and after 3 days were treated with different doses of EPA or 
DHA. 1 μl/ml of ethanol was added to the vehicle control and did not inhibit cell 
growth. The KGM medium with or without PUFA were refreshed every 2 days. 
 
DHA and EPA showed significant effects on the survival of malignant cells after 
only 4 days (figure 3-2). As regards oral cancer keratinocytes SCC-25 and 
premalignant keratinocytes SVFHK, nearly all the cells were dead at concentrations 
>3 µM. Epidermal squamous cell carcinoma cells SCC-13 were more resistant 
compared to the other two lines, however their growth was inhibited by the  PUFA s, 
specifically at concentrations >3 µM for DHA and at concentrations >5 µM for EPA. 
There were only 37% and 34% live cells left at 3 μM of DHA and EPA, respectively, 
and only 22% and 26% live SCC-13 cells at 5 μM.  
 
In the normal keratinocyte NHEK-131 and HEK-127 cultures (figure 3-2) there was 
very low viability at 10 μM, but 59% and 98% of NHEK-131 cells were viable in 3 
μM of DHA and EPA, respectively. As regards HEK-127, 64% and 111% cells 
(slight proliferative effect) were alive in 3 μM of DHA and EPA, respectively. DHA 
appeared to decrease normal cell growth at 5 μM, while EPA left 72-94% of the cells 
alive. These results demonstrate that EPA and DHA are able to eliminate SCC cells 
at a physiological dose (3 μM) without killing normal keratinocytes (P<0.05). Also, 
EPA eliminated SCC cells without killing the normal cells at 5 μM (P<0.05).  
 




































































































Figure 3-2. The effect of PUFA on keratinocyte cell growth 
 Means± S.E.M of 6 independent MTT experiments for SCC-13, SCC-25, SVFHK and 4 
experiments for NHEK-131 and HEK-127. Each experiment was conducted in duplicate. 
Cells were incubated in different DHA (A) and EPA (B) concentrations for 4 days in KGM 
serum-free medium. S.E.M=Standard error of means. * is significantly different from the 
mean value of untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** 
= <0.001 as measured by one-way ANOVA followed by post-hoc Bonferroni test). 
Malignant Pre-malignant    Normal 
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We extended our study in three oral dysplasia (premalignant) cell lines D17, D19 
and D20 (figure 3-3). DHA (figure 3-3A) strongly inhibited all the dysplasias at 
concentrations 3-10 μM except from D19 which was more resistant at 3 μM (76% 
viable cells) but was highly inhibited at 5-10 μM. As regards EPA (figure 3-3B), it 
was very potent inhibiting D20 cell growth at 3-10 μM while D17 and D19 were 
more resistant at 3 μM (53% and 57% viable cells respectively), but were eliminated 
at 5-10 μM. 
 
More normal cells were also included in the study. Three normal oral keratinocytes, 
NHOK-846, NHOK-881 and NHOK-810, were used and also the normal immortal 









4). DHA (figure 3-4A) appeared to inhibit all normal cells at concentrations higher 
than 5 μM. At 3 μM of DHA though, 73% of OKF6, 40% of NHOK-881 and 30% of 
OKF4 were viable. EPA (figure 3-4B) seemed friendlier to the normal cells 
compared to DHA at 3 μM, but affected cell growth more in concentrations higher 
than 5 μM. Even at that concentration of EPA, 46% of OKF4, 62% of OKF6, 28% of 
NHOK-881 and 26% of NHOK-810 were still viable. 
 
Figures 3-5 and 3-6 summarise the effect of EPA and DHA, respectively, on the 
growth of all the cells used in the study at the concentrations of 3 μM and 5 μM for 
EPA and just 3 μM for DHA. Overall, the most potent concentration of DHA was 3 
μM, which caused more death to malignant and premalignant cells (except from 
SCC-13 epidermal cells and D20 oral dysplasia) without completely eliminating all 
normal cells. As regards EPA, it appeared more selective, as it inhibited growth of 
premalignant and malignant cells more than in normal cells at 3 μM and 5 μM. 
Figure 3-7 compares the means±S.E.M of the considered malignant cells (SCC-13, 
SCC-25), premalignant (SVFHK, D17, D19, D20) and the normal cells (OKF4, 
OKF6, NHEK-131, HEK-127, NHOK-846, NHOK-881 and NHOK-810) showing 
selectivity of DHA (at 3 μM) and EPA (at 3 μM and 5 μM) in growth inhibition 
towards malignant and premalignant cells compared to normal keratinocytes. Figure 
3-8 shows the epidermal (figure 3-8A) and the oral (figure 3-8B) keratinocytes 
separately.  As regards the epidermal keratinocytes (figure 3-8A), the means± S.E.M 
of the malignant (SCC-13), premalignant (SVFHK) and the normal epidermal cells 
(NHEK-131, HEK-127) are demonstrated, showing selectivity of DHA (at 3 μM) 
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and EPA (at 3 μM and 5 μM) in growth inhibition towards malignant and 
premalignant cells compared to normal keratinocytes with the pre-malignant cells 
being more susceptible than the malignant ones. As regards the oral keratinocytes 
(figure 3-8B), the means± S.E.M of the malignant (SCC-25), dysplasias (D17, D19, 
D20), the normal immortal (OKF4, OKF6) the normal primary oral cells (NHOK-
846, NHOK-881 and NHOK-810) are shown. There is selectivity of DHA (at 3 μM) 
and EPA (at 3 μM and 5 μM) in growth inhibition towards malignant and 
premalignant cells compared to normal keratinocytes, with the malignant cells being 







































































































Figure 3-3. The effect of PUFA on cell growth in dysplasias 
 Means± S.E.M of 3 independent MTT experiments for dysplasias D17, D19 and D20. Each 
experiment was conducted in duplicate. Cells were incubated in different DHA (A) and EPA 
(B) concentrations for 4 days in KGM serum-free medium. S.E.M=Standard error of means. 
* is significantly different from the mean value of untreated control of each cell line 
(* = p<0.05 and ** = p <0.01 *** = <0.001 as measured by one-way ANOVA 
followed by post-hoc Bonferroni test). 





















































































Figure 3-4. The effect of PUFA on normal keratinocyte cell growth 
 Means± S.E.M of 3 independent MTT experiments for normal keratinocytes OKF4, OKF6, 
NHOK-846, NHOK-881 and NHOK-810. Each experiment was conducted in duplicate. 
Cells were incubated in different DHA (A) and EPA (B) concentrations for 4 days in KGM 
serum-free medium. S.E.M=Standard error of means. * is significantly different from the 
mean value of untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** 
= <0.001 as measured by one-way ANOVA followed by post-hoc Bonferroni test). 













































































Figure 3-5. Overview of the effect of EPA on keratinocyte cell growth 
 Overview of the means± S.E.M of the MTT viability test with EPA 3 μM (A) and 5 μM (B) 
for malignant cells, dysplasias/pre-malignant and normal keratinocytes used. 
S.E.M=Standard error of means. 
 
 






























Figure 3-6. Overview of the effect of DHA on keratinocyte cell growth 
 Overview of the means± S.E.M of the MTT viability test with DHA 3 μM for malignant cells, 






















































Figure 3-7. Overview of the effect of PUFA on keratinocyte cell growth 
 Overview of the means± S.E.M of the MTT viability test with DHA 5 μM and 3 μM and 5μM 
of EPA for malignant cells, pre-malignant and normal keratinocytes averages. 
S.E.M=Standard error of means. * is significantly different from the mean value of 
normal keratinocytes (* = p<0.05 and ** = p <0.01 *** = <0.001 as measured by 



























































































Figure 3-8. Overview of the effect of PUFA on epidermal and oral keratinocyte cell 
growth 
 Overview of the means± S.E.M of the MTT viability test with DHA 5 μM and 3 μM and 5μM 
of EPA for malignant cells, pre-malignant and normal keratinocytes averages of (A) 
epidermal keratinocytes and (B) oral keratinocytes. S.E.M=Standard error of means. * is 
significantly different from the mean value of normal cells while red star * is 
significantly different from the mean value of the immortal normal oral cells (B) (* = 
p<0.05 and ** = p <0.01 *** = <0.001 as measured by Mann-Whitney U rank test). 
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3.2.2 Detection of Apoptosis  
 
Initially, the flow cytometric annexin V/DAPI assay was performed in order to 
determine whether the cells were undergoing an apoptotic death after treatment with 
PUFA. This assay is very sensitive, because it is able to detect even the early 
apoptotic cells, as annexin V antibody binds with high affinity to PS (sub-chapter 
2.4). The results are the averages of three independent experiments that were 
performed, analysing at least 10,000 cells. The cells were incubated in DHA or EPA 
at 5 μM or 10 μM for 48 h before analysis.  
 
The assay showed a marked difference in the percentage of viable cells between 
untreated and treated cells after only 48 h treatment (figures 3-10 and 3-11).  The 
viable cell percentages appear to decrease significantly (figures 3-10 and 3-11) while 
the early apoptotic cell percentage (annexin V +ve and DAPI –ve) as well as the late 
apoptotic and necrotic cell percentage (annexin V +ve and DAPI +ve) are increasing 
(figure 3-12). It is obvious that the effect of PUFA on the cells is cytotoxic, as they 
appear to cause cell death which appears to be apoptosis. A representative FACS 
analysis experiment is shown (figure 3-9). 
 
In order to confirm the apoptotic cell death the apoptosis assay was followed by 
western blot analysis for detection of cleaved caspases. The SCC-25 cells were 
treated with 10 μM of DHA or EPA for 6, 17 and 24 hours and their lysates were 
obtained. A lysate of NHEK cells treated with cisplatin for 24 h was used as a 
positive control for high levels of cleaved caspase 3, while GAPDH was used as a 
loading control. Western blot analysis proved the cleavage of the apoptosis 
executioner caspase 3. Cleaved caspase 3 antibody detects the endogenous levels of 
the large fragments (17/19 kDa) of the activated caspase 3 resulting from cleavage. 
There is an up-regulation of cleaved caspase 3 after treatment of the SCC-25 cells 
with DHA for 5 h, and after treatment with EPA for 17 h. There was also an 
upregulation of cleaved caspase 8 (extrinsic pathway) and caspase 9 (intrinsic 
pathway) at the specific timepoints demonstrating the involvement of both apoptotic 
pathways (figure 3-13). 
 












































Figure 3-9: Apoptosis assay 
Representative flow cytometry plots for annexin V-FITC/DAPI for cellular viability. The 
scatter plot (A) is shown for the untreated control where SSC=side scatter and FSC= 
forward scatter and the fluorescence plots are shown for each sample (B, C, D). SCC-25 
cells were used in this example. Untreated control cells are shown in (B). Cells were treated 
with DHA 5 μM (C) and EPA 5 μM (D) for 48 h. Q3 shows the viable cell population 
(annexin V -ve, DAPI  -ve), Q4 shows early apoptotic cells (annexin V +ve DAPI –ve), Q2 
shows late apoptotic and necrotic cells (annexin V +ve, DAPI +ve) and Q1 shows only 


















































































































































Figure 3-10. Means of viable cells percentages in the apoptosis assay 
Means± S.E.M of 3 independent annexin V/DAPI experiments. SCC-13, SCC-25, SVFHK 
and HEK-127 cells were incubated in 5 μM and 10 μM of DHA for 48 hours in KGM serum-
free medium prior to trypsinisation. Then the cells were stained with annexin V and DAPI 
and analysed by flow cytometry. The percentages of viable cells (A) and the normalised with 
the control percentages (B) are shown. * is significantly different from the mean value 
of untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** = <0.001 as 
measured by one-way ANOVA followed by post-hoc Bonferroni test). 






























































































































































Figure 3-11. Means of viable cells percentages in the apoptosis assay  
Means± S.E.M of 3 independent annexin V/DAPI experiments. SCC-13, SCC-25, SVFHK 
and HEK-127 cells were incubated in 5 μM and 10 μM of EPA for 48 hours in KGM serum-
free medium prior to trypsinisation. Then the cells were stained with annexin V and DAPI 
and analysed by flow cytometry. The percentages of viable cells (A) and the normalised with 
the control percentages (B) are shown. * is significantly different from the mean value 
of untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** = <0. as 
measured by one-way ANOVA followed by post-hoc Bonferroni test). 














































































































































Figure 3-12. Means of early apoptotic and necrotic cells percentages of apoptosis assay 
Means± S.E.M of 3 independent annexin V/DAPI experiments. SCC-13, SCC-25, SVFHK 
and HEK-127 cells were incubated in 5 μM and 10 μM of DHA (A) and EPA (B) for 48 
hours in KGM serum-free medium prior to trypsinisation. Then the cells were stained with 
annexin V and DAPI and analysed by flow cytometry. The percentages of early apoptotic 
and necrotic cells are shown. * is significantly different from the mean value of 
untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** = <0.001 as 
measured by one-way ANOVA followed by post-hoc Bonferroni test). 
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Figure 3-13. Cleavage of caspases on western blot 
Representative western blots showing the cleavage of caspases 3, 9 and 8. Lysates are 
derived from SCC-25 cells treated with PUFA (10 µM). The experiment was repeated three 
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3.2.3 PUFA decrease proliferation of human oral cancer keratinocytes 
 
 
To assess whether omega-3 PUFA alter tumour cell proliferation, we investigated the 
effects of EPA and DHA on 
3
H-thymidine incorporation in SCC-25 cells. Treatments 
with 3 μM DHA and 3 μM EPA for 48 h significantly (p<0.001) decreased 
3
H-
thymidine incorporation compared to the untreated control (figure 3-14) which 
indicates a highly lower rate of DNA synthesis and proliferation following exposure 























































H-thymidine incorporation assay 
Means± S.E.M of 6 independent 
3
H-thymidine incorporation experiments. SCC-25 cells were 
incubated in 3 μM DHA and EPA for 48 hours in KGM serum-free medium and 
3
H-
thymidine was added 18 h prior to the incorporated thymidine measurement. The values 
were normalised to a percentage of the untreated control which was taken as 100%. * is 
significantly different from the mean value of the untreated control (*** = p<0.001 
as measured by one-way ANOVA followed by post-hoc Bonferroni test). 
 





3.3.1 Effect of PUFA on malignant SCC cells 
 
It is widely accepted that PUFA have a great anti-tumour effect and a potential to 
become successful prophylactic and therapeutic tools in cancer. As mentioned 
before, EPA and DHA have been observed to suppress cell growth and induce 
apoptosis in several types of human cancer cell lines like breast cancer 
(DeGraffenried et al, 2003; Schley et al, 2005) colon cancer (Chen & Istfan, 2000; 
Eitsuka et al, 2005; Habermann et al, 2009) lymphoma (Heimli et al, 2002), 
leukemia (Chiu & Wan, 1999; Finstad et al, 1998) neuroblastoma (Gleissman et al, 
2010) hepatoma (Murata et al, 2001), pancreatic cancer (Merendino et al, 2005) 
prostate cancer (Edwards et al, 2008) and several others (Edwards et al, 2008; 
Merendino et al, 2005; Serini et al, 2008).  
 
In this study, I examined whether PUFA specifically inhibit SCC growth at 
physiological concentrations, using the epidermal SCC-13 and the oral SCC-25 cell 
lines.  DHA and EPA showed significant suppressive effects on the survival of 
malignant cells after only 4 days at concentrations in the physiological range (figure 
3-2).  PUFA were particularly effective on oral cancer keratinocytes SCC-25 as they 
eliminated most viable cells at concentrations ≥3µM. The epidermal squamous cell 
carcinoma cell line SCC-13 showed higher resistance compared to SCC-25; 
however, their growth seemed to be significantly decreased by the PUFA as well, at 
concentrations >3µM. We showed, for the first time to our knowledge, that EPA and 
DHA affect oral and epidermal SCC cell growth. 
 
Our study was extended in the pre-malignant SVFHK cell line and three dysplasias, 
D17, D19 and D20. DHA and EPA showed great inhibitory effects on the survival of 
pre- malignant SVFHK cells after only 4 days, eliminating the viable cells at 
concentrations ≥3µM (figure 3-2). The dysplasias growth was also negatively 
affected by PUFA (figure 3-3).  D20 was very sensitive to both DHA and EPA ≥3 
μM. D17 was sensitive to DHA ≥3 μM and EPA ≥5 μM. However, 57% of the cells 
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were viable at 3 μM of EPA. D19 seemed to be the most resistant at 3 μM of the 
PUFA, especially for DHA (76% viability) but very sensitive at concentrations ≥5 
μM. Generally, PUFA were potent in inhibiting oral premalignant cells; however, 
some dysplasias were more sensitive than others. D19 which is severe lateral tongue 
erythroleukoplakia seems to be more resistant than D20, which is a moderate lateral 
tongue leukoplakia and very sensitive to PUFA. D17 which is buccal mucosa 
mild/moderate leukoplakia was more sensitive than D20 but less sensitive than D19 
to EPA. It seems that the degree of sensitivity of dysplasias to PUFA depends on the 
type (erythroplakia or leukoplakia) and stage of oral dysplasia (mild, moderate, 
severe), and the position of origin.  
 
Several studies carried out on cultured cancer cells in vitro have demonstrated the 
pro-apoptotic effect of EPA or DHA (Serini et al, 2009). The available data indicate 
that apoptosis induced by EPA or DHA may follow both the extrinsic (involving 
caspase 8 and 3) and intrinsic (involving mitochondria and caspase 9 and 3) 
apoptotic pathways. Some studies demonstrated that these compounds caused 
apoptosis by triggering only the intrinsic pathway. Some examples are the studies 
where PUFA increased the activity of caspase-3 and -9 in lymphoma cells (Heimli et 
al, 2002) and in hepatocellular carcinoma lines (Lim et al, 2009). However, in many 
studies the activation of both pathways of apoptosis is observed which agree with 
our results. In human colon cancer cells DHA has been reported to increase the 
expression of both the caspases 8 and 9, and the activation of cytochrome c 
(Narayanan et al, 2001), and both EPA and DHA caused cleavage of caspase 8 with 
additional downregulation of Bid protein expression and Bcl-2 mRNA. Tsuzuki 
reported induction of several genes associated with both pathways of apoptosis by 
conjugated EPA, such as those who encode for Fas, Bid, Bas, Bak, caspase 3, 8, 7 
and 9 by RT-PCR and microarrays (Tsuzuki et al, 2007). Which pathway of 
apoptosis is induced may be related to the different actions of these fatty acids in 
different cells, to the different omega-3 PUFA  used (EPA, DHA or fish oil) and to 
the different ways of administration. 
 
In the present study, the flow cytometric annexin V/DAPI apoptosis assay showed 
that the epidermal SCC-13, the oral SCC-25, and the pre-malignant SVFHK cell line 
cells were undergoing an apoptotic death after treatment with PUFA. As mentioned 
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before, annexin V detects the early apoptotic cells because it binds to PS which 
translocate from the interior side of the plasma membrane to the outer layer during 
the initial stages of apoptosis. DAPI detects the late apoptotic cells and the necrotic 
cells. Decrease of the viable cell population was detected after 48 h PUFA treatment 
(figures 3-10 and 3-11) and subsequent increase of the early apoptotic and late 
apoptotic/necrotic cell population (figure 3-12). This demonstrates that the growth 
inhibitory effect of PUFA on the cells is at least partially cytotoxic, as they appear to 
cause cell death via apoptosis. Western blot analysis confirmed that the PUFA cause 
apoptosis via the apoptosis cleavage of caspase 3. Caspase 3 is one of the key 
executioners of apoptosis as it is responsible for the engagement of the full caspase 
cascade necessary to destroy the cell (sub-chapter 3.1). The cleavage of caspase 8 
and caspase 9 were also detected, demonstrating the involvement of extrinsic and the 
intrinsic apoptotic pathways, respectively (figure 3-13). This could mean that both 
EPA and DHA trigger both apoptotic pathways at the same time in order to destroy 
the cells. However, there is another potential explanation. At the extrinsic apoptotic 
pathway, caspase 8 is the initiator caspase and can subsequently cause the activation 
of execution caspase-3 which results in apoptosis. As mentioned before (subchapter 
3.1), this can be done by two alternative pathways downstream of caspase 8 
activation: In most cells, stimulation of death receptors causes enough activated 
caspase 8 to result in caspase 3 cleavage activating the full caspase cascade 
necessary for the apoptosis of the cell. However, some cell types don‟t manage to 
activate enough caspase 8, so the pro-apototic signal of caspase 8 causes the 
proteolysis of Bid, the engagement of cytocrome c/Apaf-1 and caspase 9 cleavage of 
the intrinsic mitochondrial pathway (Logue and Martin 2008). It is possible that the 
same applies to our cells as well.  
 
In addition, it has been observed that PUFA inhibit cancer cell proliferation. Schley 
et al, showed that EPA and DHA significantly decreased breast cancer cell 
proliferation as estimated by decreased [methyl-3H]-thymidine uptake and 
expression of proliferation-associated proteins (proliferating cell nuclear antigen, 
PCNA, and proliferation-related kinase, PRK) as measured by western blotting 
(Schley et al, 2005). In addition, Schley et al showed an increase in DNA 
fragmentation, loss of mitochondrial membrane potential, and increased activity of 
caspase proteins supporting the hypothesis that omega-3 PUFA also induce apoptotic 
Chapter 3. Effect of PUFA on Cell Growth 
101 
 
cell death. The results of my study agree with these observations as it was observed 
that, in the oral cancer SCC-25 cell line, treatment with 3 μM of DHA and EPA for 
48 h significantly (p<0.001) decreased 
3
H-thymidine incorporation compared to the 
untreated control, indicating a highly lower rate of DNA synthesis and cell 
proliferation following exposure to omega-3 PUFA. The 
3
H-thymidine incorporation 
after DHA treatment was just 2.5% and after EPA treatment was 27% of the 
untreated control which demonstrates a marked decrease for both of them but bigger 
for DHA. Similarly to Schley et al, I already have shown that PUFA also cause 
apoptosis by the annexin V assay and via caspase cleavage. This means that DHA 
and EPA are not only cytotoxic but also cytostatic as it was demonstrated that 




3.3.2 Effect of PUFA on normal keratinocytes 
 
Different studies have investigated the ability of omega-3 PUFA to regulate the 
apoptotic process in normal cells. It appears that PUFA protect against chronic 
neurodegenerative diseases and atherosclerosis by inhibiting apoptosis. The 
beneficial effects of omega-3 PUFA have been documented in a variety of central 
nervous system disorders, including Zellweger‟s syndrome, schizophrenia, 
depression and Alzheimer‟s disease (Michael-Titus, 2007). Moreover, omega-3 
PUFA appear to have significant neuroprotective potential in spinal cord trauma. In 
rats, when DHA was administered intravenously 30 min after spinal cord injury 
(King et al, 2006) it induced significant neuroprotection, reducing neuronal cell loss, 
oligodendrocyte loss, and decreasing the apoptosis 1 week after the injury. It has 
been also demonstrated that treatment of resting human umbilical vein endothelial 
cells with DHA reduces oxidative stress and apoptosis (Pfrommer et al, 2006), 
explaining the atheroprotective effects of omega-3 PUFA.  
 
DHA is the most abundant fatty acid in the brain and generally the membrane of the 
neural cells are enriched in omega-3 fatty acids (Dyall & Michael-Titus, 2008). DHA 
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is an essential fatty acid during development and prevents neuronal cell death (Kim, 
2007). Even though normal nervous tissue has high levels of omega-3 PUFA, 
neuronal tumours, such as gliomas, are deficient in DHA (Martin et al, 1996). This 
suggests that DHA depletion could be an adaptation survival mechanism of neuronal 
tumours. In normal nervous tissue, the active lipid mediators of DHA, resolvins and 
neuroprotectins, decrease inflammation partly through the inhibition of oxidative 
stress and apoptosis (Mukherjee et al, 2004). In more detail NPD1 appear to up-
regulate the anti-apoptotic proteins Bcl-2 and Bcl-xL and down-regulate the 
expression of the pro-apoptotic proteins Bax and Bad in neurons and human retinal 
pigment epithelial cells (Bazan, 2005; Mukherjee et al, 2004). Gleissman showed 
that, in neuroblastoma cell lines, exogenous DHA is oxygenated to the monohydroxy 
fatty acids 17-HDHA, 14-HDHA, 7-HDHA, and 4-HDHA, but not to resolving 
RvD1 and protectin PD1 despite the presence of the enzymes required for this their 
production (Gleissman et al, 2010). Even though this mechanism might be tumour 
survival mechanism against resolution of inflammation, however makes the tumour 
cells more susceptible to DHA than the normal cells which actually convert it to 
resolvins and protectins. It is possible that something similar happens in our case 
where SCC cells more susceptible to PUFA induced apoptosis compared to the 
normal keratinocytes.  
 
On the other hand, PUFA may cause apoptosis in normal cells. A number of in vivo 
studies have demonstrated that omega-3 PUFA affect normal colonic mucosa cells 
by inducing apoptosis. This has been viewed as a chemopreventive effect, since this 
specific cell population is highly exposed to carcinogenic agents from the diet, and is 
subject to high turnover. In rats treated with EPA or DHA (Calviello et al, 1999) cell 
proliferation was suppressed, and the number of apoptotic cells in colon mucosa was 
increased, without altering the homeostasis of normal colonic mucosa. The enhanced 
colonocyte deletion in normal mucosa was observed also in humans treated with a 
mixture of EPA and DHA for 2 years (Cheng et al, 2003a). These findings support 
the hypothesis that the dietary intake of omega-3 PUFA, at appropriate levels, may 
display a strong chemopreventive action against colon cancer, and this protective 
action is based on the induction of apoptosis in colonocytes. It was also observed 
that DHA induces apoptosis in cultured rat mesenteric vascular smooth muscle cells 
(Diep et al, 2000). Since the apoptosis of these cells may affect the structure of blood 
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vessels, it has been suggested that this effect explains the blood pressure-lowering 
effect caused by omega-3 PUFA in hypertension. It has been also demonstrated that 
DHA induces apoptosis in proliferating human umbilical vein endothelial cells, 
which has been related to the anti-angiogenic and anti-tumoural effects of omega-3 
PUFA (Kim et al, 2005).  
 
In the present study, normal keratinocytes were used as controls, to test the cancer 
specificity of PUFA. In the normal foreskin epidermal keratinocytes NHEK-131 and 
HEK-127 initially tested (figure 3-2), while PUFA eliminated the viable cells at 10 
μM, they did not have a large effect on cell survival at smaller doses. Approximately 
60% and 100% of the cells were viable at 3 μM DHA and EPA, respectively. 
However, while EPA had little effect on the survival of normal cells at 5 μM, DHA 
seemed to negatively affect normal cell growth at that concentration. The flow 
cytometric annexin V/DAPI apoptosis assay confirmed that the higher 
concentrations of PUFA inhibit normal HEK-127 cells, causing apoptosis. The 
higher percentage of death in the annexin V/DAPI assay for the EPA treatment in 
figures 3-11 and 3-12B, even at the control cells, compared to the MTT is probably 
due to the trypsinisation of the cells before the flow cytometry. Primary cells are, 
generally, more delicate and sensitive to trypsinisation than the malignant cells. 
Also, the annexin V/DAPI assay detects the early apoptotic cells that are not 
recognised by the MTT assay.  
 
The study was later expanded in oral normal primary keratinocytes NHOK-810, 
NHOK-846 and NHOK-811 and also two normal immortal oral cell lines OKF4 and 
OKF6 (figure 3-4). MTT assays were performed using these cells. OKF6 was more 
resistant to PUFA inhibitory effect. There is even a growth stimulating effect at 1 
μM.  The growth is decreased very little at concentrations 3-5 μM of EPA and 3 μM 
of DHA. OKF4 is more sensitive, especially to DHA. However, a significant 
percentage of cells are viable at 3-5 μM of EPA (64% and 46%). The normal oral 
primary cells NHOK-810, NHOK-846 and NHOK-881 seemed more sensitive at 
PUFA higher concentrations >5 μM but more resistant at 3 μM of EPA. 
 
Overall, I can conclude that PUFA, at least at the free fatty acid form that were used 
in the present study, can be cytotoxic for normal cells. The apoptosis observed in 
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normal cells could be explained by the hypothesis that omega-3 PUFA may display a 
chemopreventive action against oral cancer, like in colon cancer, by induction of 
apoptosis in keratinocytes, similar to colonocytes, since this the oral tissue is highly 
exposed to harmful chemicals and carcinogenic agents from the diet, as well.  
 
However, PUFA are more tolerated by the normal cells than SCC cells, the 
premalignant cells and most of the dysplasias at doses 3-5 μM of EPA and 3μM of 
DHA (figures 3-5 and 3-6). Especially, EPA shows higher selectivity in killing 
malignant and premalignant more than normal cells. The selectivity of the most 
potent concentrations of DHA and EPA were demonstrated at figure 3-7 which 
summarises the means of the viable percentages of the cells comparing malignant, 
premalignant (SVFHK and dysplasias) and normal keratinocytes. The pattern 
observed is that PUFA inhibit malignant cells more, then premalignant and less of all 
the normal cells at 3 μM. At 5 μM of EPA premalignant cells are even more 
inhibited than the malignant ones and the normal cells are again the least suppressed. 
Figure 3-8 shows the selectivity of the same concentrations of PUFA separately for 
epidermal and oral keratinocytes, summarising the means of the viable percentages 
of the cells comparing malignant, premalignant (dysplasias) and normal 
keratinocytes. As regards the epidermal keratinocytes (figure 3-8A), EPA 3 μM and 
5 μM seem to be more potent eliminating the pre-malignant SVFHK cells, than the 
malignant SCC-13 and affecting a little or not at all (105% and 83% respectively) the 
normal keratinocytes. As regards the oral keratinocytes (figure 3-8B), again EPA 
seems to be the most potent and selective especially at 3 μM where preferably 
inhibits the growth of the malignant SCC-25, then the dysplasias and a lot less the 
immortal normal cells and the primary oral cells (75% and 64% respectively). 
 
In summary, EPA seemed to be better tolerated by the normal epidermal cells. For 
final conclusions, PUFA need to be tested on animal models in the future, as the 
normal cells proliferate more in culture than in vivo, so the differential effects on 
normal and SCC growth may be even greater. Also, the normal keratinocytes in 
culture are under stress compared to physiological conditions, making them more 
susceptible to death. It was obvious in our study, that the immortal normal cells 
OKF4 and OKF6, which seem to be under optimal conditions in culture, were less 
susceptible to PUFA death that the other oral primary keratinocytes. However, the 
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existing results are really promising as they demonstrate that EPA and DHA are able 
to eliminate SCC cells at a physiological doses (3 μM for both or 5 μM for EPA) 
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Telomerase was originally discovered by Elizabeth Blackburn and Carol Greider 
who recently shared the 2009 Nobel Prize in Medicine. Telomerase is an enzyme 
that maintains the ends of mammalian chromosomes (telomeres) by adding 
TTAGGG repeats to them (figure 4-1). This is the telomerase canonical function. 
Telomerase consists of a catalytic subunit called TERT and an RNA component, 
TERC, which serves as a template for nucleotide addition.  Telomerase function 
blocks telomere erosion and therefore suppresses cellular senescence and apoptosis 
and promotes tumour progression. It is not surprising that high levels of telomerase 
activity are detected in most tumours and specifically in 90% of cases of oral 
squamous-cell carcinoma (OSCC). Telomerase can also be detected at high levels in 
germ line cells, where the enzyme is active maintaining the lengths of telomeres, 
while in most somatic cells telomerase activity is very low (McCaul et al, 2002; 
Parkinson & Minty, 2007). It was observed that the correction of telomere 
dysfunction by the forced expression of TERT can reconstitute the function of 
telomerase activity (Weinrich et al, 1997) and lead to the extension of the lifespan of 
normal human cells (Bodnar et al, 1998). 
 
Apart from the canonical function of telomerase, namely telomere lengthening, the 
catalytic subunit TERT has also been investigated for “non-canonical” functions, 
which can either require the presence of TERC or not. TERT appears to play an 
important role in promoting the formation of skin (Gonzalez-Suarez et al, 2001) and 
mammary tumours (Artandi et al, 2002) upon chemical carcinogenesis in vitro, 
independently from telomere lengthening function. More evidence that TERT can 
function independently of the telomerase lengthening derives from the use of the 
TERT-HA gene construct. TERT-HA is a variant of TERT that contains a 
hemaglutinin (HA) epitope inserted at the C-terminus. The TERT-HA protein was 
catalytically active but not able to elongate telomeres or extend cellular replicative 
life span in fibroblasts (Counter et al, 1998). In addition, the ectopic expression of 
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TERT as well as TERT-HA imparted a tumourigenic phenotype in normal human 
cells that maintained telomeres by a telomerase-independent mechanism called 
Alternative Lengthening of Telomeres (ALT) (Stewart et al, 2002). In summary, 
telomerase activity does not necessarily depend on its ability to maintain telomeres 
(Cong & Shay, 2008; Parkinson et al, 2008). 
 
Eitsuka et al suggested that the omega-3 PUFA inhibit telomerase in cell free assays 
and cell culture experiments, using DLD-1 human colorectal adenocarcinoma cells. 
The athors also suggested that omega-3 PUFA inhibited the expression of the hTERT 
gene, in parallel with CMYC and protein kinase C (PKC) (Eitsuka et al, 2005). 
However, it is still unclear whether the growth inhibition by PUFA depends on 





















































Figure 4-1. Telomerase and telomeres 
(A) The telomerase complex consists of the reverse transcriptase component (TERT), the 
RNA component (TERC), the protein dyskerin, and other associated proteins (NHP2, 
NOP10, and GAR1). Telomerase adds telomeric repeats (TTAGGG) to the 3' hydroxyl end 
of the leading strand of the telomere, with a sequence in TERC serving as the template for 
nucleotide addition (Buckingham & Klingelhutz, 2011).  









4.2.1 Investigation of the possible telomerase activity inhibition 
induced by PUFA 
 
It has been suggested that the omega-3 PUFA inhibit telomerase in colon 
adenocarcinoma DLD-1 cells (Eitsuka et al, 2005), so I examined whether EPA and 
DHA inhibit immortal HaCaT keratinocyte growth and telomerase activity. 
Moreover, I investigated whether any growth inhibitory effects of PUFA are 
dependent on the transcriptional down regulation of TERT and/or its transcriptional 
activator CMYC.  The role of CMYC was tested by using HaCaT over-expressing 
CMYC (Cerezo et al, 2002) or the same cell line over-expressing hTERT, or an 
oncogenic hTERT variant that cannot lengthen telomeres. 
 
HaCaT and DLD-1 cells were incubated in different concentrations of DHA and 
EPA. After 5 days incubation, the MTT assay was used to determine the number of 
viable cells. The cells were incubated in RPMI 1640 medium containing 3% v/v FBS 
(Fetal Clone II serum) for 5 days. DHA and EPA, at concentrations >10 µM, had a 
marked effect on the cell viability of HaCaTs and DLD-1 (figure 4-2). The higher 
dose of PUFA (50 μM) showed 80-95% cell growth inhibition. According to the 
results, this effect does not seem to be related to TERT, TERT-HA and c-MYC over-
expression, as there is no significant difference between the viable cells of HaCaT-
Puro and HaCaT-TERT, -TERT-HA and –c-MYC (P>0.05) at 30 μM and 50 μM of 
PUFA.  
 
Surprisingly, when the cells were incubated in RPMI containing 10% FBS (figure 4-
3), PUFA did not appear to have any major effect on cell viability. This phenomenon 






































































Figure 4-2: The effect of PUFA on HaCaT and DLD-1 cell growth in 3% FBS medium 
Means± S.E.M of 3 MTT experiments. Each experiment was conducted in duplicate. HaCaT-
PURO, HaCaT-TERT, HaCaT-TERT-HA, HaCaT-c-MYC, and DLD-1 cells were incubated 
in 3% FBS medium with different (A) DHA and (B) EPA concentrations. 
 
 


































































Figure 4-3: The effect of PUFA on HaCaT and DLD-1 cell growth in 10% FBS medium 
Means± S.E.M of 3 MTT experiments. Each experiment was conducted in duplicate. HaCaT-
PURO, HaCaT-TERT, HaCaT-TERT-HA, HaCaT-c-MYC, and DLD-1 cells were incubated 
in 10% FBS medium with different (A) DHA and (B) EPA concentrations. 
 





4.3.1 Investigation of the possible role of telomerase activity on PUFA 
effect 
 
It has been suggested that the omega-3 PUFA inhibit telomerase in cell free assays 
and cell culture experiments with DLD-1 colorectal adenocarcinoma cells. 
Moreover, omega-3 PUFA appeared to inhibit the expression of the hTERT gene, in 
parallel with CMYC and protein kinase C (PKC) (Eitsuka et al, 2005). Acute 
inhibition of telomerase by short hairpin RNAs causes an immediate effect on cancer 
growth and survival in a telomerase-specific manner (Li et al, 2005). CMYC is a 
positive regulator of TERT transcription (Wu et al, 1999) but it is unclear whether 
CMYC mediates the repression of TERT by PUFA. Furthermore, it is still unclear 
whether the growth inhibition by PUFA is dependent on telomerase (or TERT) 
down-regulation and inhibition, or the reverse.  
 
In this study, I examined whether EPA and DHA inhibit immortal HaCaT 
keratinocyte growth, and whether any growth inhibitory effects are modified by 
over-expression of CMYC, TERT or TERT-HA which is an oncogenic TERT variant 
that cannot lengthen telomeres. In order to test this, we used HaCaT  over-expressing 
CMYC (Cerezo et al, 2002) or the same cell line over-expressing TERT, or TERT-
HA. DLD-1 cells were also used as a control, because the published experiments 
were performed using this cell line (Eitsuka et al, 2005). The hypothesis that TERT 
down-regulation and hence CMYC, as it regulates TERT, caused cytostasis and/or 
cell death would be supported if ectopic MYC or TERT expression blocked or 
reduced growth inhibition. DHA and EPA had a marked effect on cell viability of 
HaCaTs and DLD-1 after 5 days incubation in a 3% v/v FBS containing medium, 
however, the growth inhibition was not affected by TERT, TERT-HA and CMYC 
over-expression. This means that overexpression of TERT, TERT-HA and CMYC 
does not protect the cells from the growth inhibitory effect of PUFA and as a result, 
the down-regulation of TERT and CMYC, reported by others (Eitsuka et al, 2005), is 
most likely to be only a consequence and not the cause of PUFA-induced death at 
these doses. Further investigation is essential in order to determine whether the 
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inhibition of telomerase is the cause or the result of PUFA-induced cell death, 
examining the telomerase activity at doses of DHA and EPA that do not cause 
extensive cell death. However, due to time limitations, this possibility was not 
investigated further during this project. 
 
Interestingly, when the cells were incubated in RPMI containing 10% v/v FBS 
(figure 4-3), PUFA did not showed any marked cell growth inhibition. This 
observation indicates that one or more components of the serum seem to provide 
protection of the cells against DHA and EPA. This was investigated further and is 
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Oxygen is necessary for life but can be poisonous, so aerobic organisms survive its 
presence by antioxidant defence mechanisms (Halliwell, 2007a). Small amounts of 
potentially toxic reactive oxygen species (ROS) are generated in eukaryotic cells by 
oxidase and during electron transport in the mitochondria or the endoplasmic 
reticulum. Leaks of electrons can produce superoxide radicals (O2
-
), which may be 
reduced, giving rise to hydrogen peroxide (H2O2) (Girotti, 1998). 
 
Oxidative stress refers to a serious imbalance between ROS production and 
antioxidant defences, and it can cause damage to cells, often called „oxidative 
damage‟ (Halliwell, 2007a). Halliwell and Whiteman defined oxidative damage as 
“the biomolecular damage caused by attack of ROS upon the constituents of living 
organisms” (Halliwell & Whiteman, 2004). Oxidative damage can result either from 
oxidative stress or from defects in the repair systems (Halliwell, 2007a; Halliwell & 
Whiteman, 2004) 
 
PUFA and the long-chain omega-3 PUFA in particular, are susceptible to free radical 
attack that leads to lipid peroxidation. The formation of lipid hydroperoxides begins 
with the removal of hydrogen from the unsaturated fatty acids by ROS. The lipid 
radical which is produced then reacts with oxygen and forms a fatty acid peroxyl 
radical. This product is able to attack fatty acids in cell membranes, propagating lipid 
peroxidation (Biondo et al, 2008). Lipid peroxidation can injure the mitochondria, 
which results in further ROS generation (Catala, 2009). The major effects of the 
products of lipid peroxidation are inhibition of DNA synthesis, cell division and 
tumour growth, and induction of tumour cell death (Girotti, 1998). However, 
peroxidation of lipids can disturb the membrane assembly, changing the fluidity and 
permeability and inhibiting metabolic processes (Catala, 2009). Chemotherapy drugs 
belonging to the anthracycline family appear to induce tumour cell death partly by 
ROS formation, which can cause irreversible damage of cancer cells (Malhotra & 
Perry, 2003). The long-chain omega-3 PUFA appear to increase the potency of these 
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drugs by elevating the production of oxygen free radicals (Biondo et al, 2008). Also, 
several studies suggest that the increase in ROS generation might be one of the 
mechanisms of omega-3 PUFA anti-tumour action (Arita et al, 2001; Gleissman et 
al, 2010; Maziere et al, 1999; Tsuzuki et al, 2007). It seems as though the right 
amount of ROS is needed to promote cell proliferation and cancer; beyond a 































5.2.1 ROS detection after treatment with omega-3 PUFA  
 
In order to investigate if the omega-3 PUFA increase the levels of oxidation in the 
cells, we used several assays to determine the levels of ROS and oxidative damage in 
the cells before and after PUFA treatment. 
 
First, the DCF assay was used. This assay contains a cell-permeable fluorogenic 
probe that detects the reactive oxygen species (ROS) and nitric oxide (NO) in cells 
and it was used to determine the overall oxidative stress in cells. Firstly, the assay 
was used to determine the general oxidative levels in the different cell lines that had 
been used for MTT and apoptosis assays until then. So, I examined the oxidation 
levels of the oral and epidermal malignant cell lines, respectively, SCC-25 and SCC-
13, the pre-malignant epidermal cell line SVFHK and the normal epidermal 
keratinocytes HEK-127 and NHEK-131. The human fetal skin fibroblast cell line 
HFF, which has low ROS levels, was used as a negative control. The malignant and 
pre-malignant cells showed high levels of ROS and, surprisingly, the normal 
keratinocytes showed even higher levels but the difference is not significant (p>0.05 
as measured by the non-parametric Mann-Whitney U rank test) (figure 5-1). 
 
Then, the DCF assay was used to assess the oxidation in the SCC-25 cell line after 
treatment with DHA and EPA for 16 hours. The hydroethidine (HE) assay was also 
used for superoxide detection. Cytosolic HE exhibits blue fluorescence but once it is 
oxidised by superoxide to ethidium, it intercalates within DNA and stains the cell 
nucleus a bright fluorescent red (Carter et al, 1994). Again, the HFF cell line was 
used as a negative control and also the SCC-25 cells were treated with 100 µM of the 
oxidation inducer tert-butyl hydroperoxide (TBHP), for 2 hours at 37
0
C, and were 
used as positive controls. The DCF assay showed an increase in the oxidation levels 
of SCC-25 after treatment with EPA and DHA for 16 hours at the higher 
concentrations (figure 5-2). The ROS levels showed a 2.5-fold increase after EPA 5 
μM and a 3-fold increase after DHA treatment. However, as regards 3 μM, there was 
Chapter 5. Reactive Oxygen Species 
119 
 
only a slight increase during DHA treatment, but no increase when EPA is used. The 
HE assay showed a 10-20% increase in superoxide after treatment with both omega-




















































Figure 5-1. DCF oxidation levels assay for different cell lines 
The oxidation levels of the malignant cell lines SCC-25 and SCC-13, the pre-malignant cell 
line SVFHK and the normal epidermal keratinocytes HEK-127 and NHEK-131 were 
assessed by DCF staining and FACs analysis. The human fetal skin fibroblast cell line HFF, 
which has low ROS levels, was used as a negative control. Means of median DCF 
fluorescence ± STDEV of 5 independent experiments are shown. The difference between 
malignant/pre-malignant and normal cells is not significant (p>0.05 as measured by Mann-
Whitney U rank test). 
 
 

































































Figure 5-2. Oxidation levels measured by DCF assay in SCC-25 cells after treatment with 
PUFA 
(A) The oxidation levels of the oral malignant cell line SCC-25 after treatment with omega-3 
PUFA were determined by DCF staining and FACs analysis which measured the fluorescent 
intensity of DCF. Means of median DCF fluorescence ± STDEV of 3 independent 
experiments are shown. SCC-25 cells were incubated in different DHA and EPA 
concentrations for 16 hours in KGM serum-free medium. SCC-25 cells treated with the ROS 
inducer TBHP (for 2 hours) were used as a positive control, while human fetal fibroblasts 
(HFF) were used as a negative control. (B) Representative picture of DCF positive stained 
cells showing DCF staining (1), nuclear staining with Hoechst 33258 (2) and an overlay of 
the two (3). 
 



















































Figure 5-3. Oxidation levels measured by HE assay in SCC-25 cells after treatment with 
PUFA 
The oxidation levels of the oral malignant cell line SCC-25 the pre-malignant cell line after 
treatment with omega-3 PUFA were determined by HE staining and FACs analysis which 
measured the fluorescent intensity of HE.  Means of median HE fluorescence ± STDEV of 3 
independent experiments are shown. SCC-25 cells were incubated in different DHA and 
EPA concentrations for 16 hours in KGM serum-free medium. SCC-25 cells treated with the 
ROS inducer TBHP (for 2 hours) were used as a positive control, while human fetal 
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The oxidative damage levels were additionally assessed by the 8-oxo-dG assay. 8-
hydroxy-2'-deoxyguanosine (8-oxo-dG) is a modified nucleoside, which is a very 
commonly detected by-product of DNA damage (Halliwell, BJ 2007), caused by 
oxidative radicals. 8-oxo-dG can serve as a sensitive indicator of physiological and 
environmental damage to DNA. A mouse monoclonal anti-8-oxo-dG antibody was 
used for the detection of 8-oxo-dG by immunocytochemistry (figure 5-4). After the 
staining the cells were visualised by fluorescence microscopy and the pictures were 
analysed with the Metamorph imaging software (Sunnyvale, CA). HFF cells were 
again used as the negative control. A sample with no primary antibody and another 
with no secondary antibody were also used as negative controls. SCC-25 cells were 
treated with 100 µM of the oxidation inducer tert-butyl hydroperoxide (TBHP), for 2 
hours at 37
o
C and were again used as positive controls.  This assay measures the 
mean fluorescent intensity of the 8-oxo-dG antibody signal in the nucleus. It appears 
that SCC-25 cells already have oxidative damage in their nucleus without any 
treatment compared to the HFF negative control (figure 5-5). After treatment with 
EPA and DHA for 16 hours, the oxidative damage increased for both treatments. As 
regards DHA, we can see an approximate 30% increase in 8-oxo-dG intensity at both 
3 μM and 5 μM concentrations. As regards EPA, there was a 45% increase in 8-oxo-
dG intensity at 3 μM and a 1.5-fold increase at 5μM concentration. At the higher 





















                                                                                      
 
















Figure 5-4. Images of 8-oxo-dG staining after treatment with EPA 
Representative images of SCC-25 cells staining, strongly positive with the 8-oxo-dG 
antibody. The SCC-25 cells were incubated with EPA 10 μM for 16 hours prior to staining.  
(A) shows the nuclear staining with Hoechst 33258, (b) shows the 8-oxo-dG staining, and 
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Figure 5-5. Oxidation damage measured by 8-oxo-dG staining after treatment with PUFA 
The oxidation damage of the oral malignant cell line SCC-25 after treatment with omega-3 
PUFA were determined by 8-oxo-dG staining. Means of 8-oxo-dG antibody fluorescence 
intensity ± STDEV of 3 independent experiments are shown. SCC-25 cells were incubated in 
different DHA and EPA concentrations for 16 hours in KGM serum-free medium. SCC-25 
cells treated with the ROS inducer TBHP (for 2 hours) were used as a positive control while 
human fetal fibroblasts (HFF) were used as a negative control. 
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5.2.2 Treatment with antioxidants 
 
Since PUFA appear to have oxidative properties, I examined if PUFA inhibited cell 
growth through oxidation. To examine this possibility, I tested the effect of PUFA in 
the presence of the well-known anti-oxidant, α-tocopherol (α-TOC), added to the 
medium. MTT assays were performed using 40 μM of α-TOC in the incubation 
medium added just before the addition of the PUFA. In the presence of α-TOC, 
DHA and EPA showed an increase in the growth inhibition effect on the malignant 
cells at concentrations between 0-0.1 μM after 4 days (figures 5-6 and 5-7). So 
instead of protection, α-TOC showed an inhibitory effect. At higher doses, α-TOC 
offered a slight protective effect in some cases, but it was not high enough to fully 
protect from the effect of PUFA and rescue the cells. 
 
Then, the effect of another anti-oxidant on SCC-25 cells was also examined to 
confirm the results with α-TOC. I tested the effect of the antioxidant n-tert-butyl-α-
phenylnitrone (PBN) (Nakao et al, 1996). Two concentrations of PBN were used, 
600 µM and 800 µM. PBN anti-oxidant activity was tested and the concentration of 
800 µM was shown to reduce the frequency of oxidative damage and senescence in 
human fibroblast cultures, showing that PBN is effective at this concentration 
(Pitiyage et al, 2011). PBN was added to the KGM medium just before the lipids. 
However, at no dose did we see a protective effect of PBN against the omega-3 
PUFA (figure 5-8). Rather than protection, PBN at 600 µM concentration showed a 
stimulatory effect on SCC-25 cell growth in the untreated control but was unable to 























































































































Figure 5-6. The effect of a-tocopherol on the cell growth inhibitory effect of DHA 
Means± S.E.M of 6 independent MTT experiments without and 3 experiments with the 
addition of 40 μM of the antioxidant a-tocopherol (a-TOC) in SCC-25 (A), SCC-13 (B), 
SVFHK (C).  Each experiment was conducted in duplicate. Cells were incubated in different 
DHA concentrations for 4 days in KGM serum-free medium. S.E.M=Standard error of the 
mean.  











































































































Figure 5-7. The effect of a-tocopherol on the cell growth inhibitory effect of EPA 
Means± S.E.M of 6 independent MTT experiments without and 3 experiments with the 
addition of 40 μM of the antioxidant a-tocopherol (a-TOC) for SCC-25 (A), SCC-13 (B), 
SVFHK (C).  Each experiment was conducted in duplicate. Cells were incubated in different 
EPA concentrations for 4 days in KGM serum-free medium. S.E.M=Standard error of the 
mean.  
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Figure 5-8. The effect of PBN on the SCC-25 cell growth inhibitory effect of PUFA 
Means± S.E.M of 3 independent MTT experiments for SCC-25 with the addition of none, 600 
μM and 800 μM of the antioxidant PBN in KGM serum-free medium. Each experiment was 
conducted in duplicate. Cells were incubated in different DHA (A) and EPA (B) 
concentrations (3, 5 and 10 μM) for 4 days S.E.M=Standard error of the mean.  
 
 





5.3.1 ROS production by treatment with PUFA and its role in PUFA 
mechanism of action 
 
ROS have a great range of potential actions on cells. On the one hand, ROS can be 
considered pro-cancer and cancer-promoting as they appear to promote proliferation, 
invasiveness, angiogenesis and metastasis, and suppress apoptosis (Halliwell, 
2007b). In 1984, it was shown that when mouse fibroblasts are exposed to ROS they 
can be transformed (Zimmerman & Cerutti, 1984). The radiation induces 
carcinogenesis mainly via ROS production which causes DNA damage by the 
formation of the highly reactive hydroxyl radical (OH
•
) which attacks the DNA 
leading to the formation of 8-oxo-dG and other products (Halliwell, 2007b). 
However, on the other hand, too much ROS production can damage or kill the cell. It 
can also be considered anti-cancer by promoting cell-cycle arrest, senescence, cell 
death such as apoptosis and necrosis, and inhibiting angiogenesis. The same can be 
said about other types of reactive species, such as RNS (reactive nitrogen species) 
for example NO (nitric oxide) (Halliwell, 2007b). 
 
Generally speaking, moderate levels of reactive species (RS) tend to promote 
apoptosis in most normal cells (Chandra et al, 2000). However, in some malignant 
cells, RS can have the opposite effect, inhibiting apoptosis. For example, in the 
melanoma cell line M14, the decrease in superoxide radicals (O2
•-
) levels by 
CuZnSOD (a major cellular scavenger of O2
•-
) over-expression led to apoptosis, 
while the decrease in CuZnSOD levels inhibited apoptosis (Pervaiz et al, 1999). 
These „pro-survival‟ effects in malignant cells can be achieved by the oxidative 
inactivation of caspases and might sometimes occur for example via higher cytosolic 
pH that prevents caspase activation (Akram et al, 2006). In contrast, H2O2 promotes 
apoptosis by attacking and damaging the DNA and the mitochondria, but, 
additionally, by lowering the cytosolic pH (Akram et al, 2006).  
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It has been argued that some cancer cells use ROS as a survival mechanism to 
suppress apoptosis, induce proliferation, metastasis and angiogenesis, and promote 
genetic instability caused by the increased oxidative DNA damage (Halliwell, 
2007b; Mori et al, 2004; Radisky et al, 2005). Many malignant cells produce high 
levels of ROS in culture (Szatrowski & Nathan, 1991). As regards the present study, 
the DCF assay also showed that the malignant (SCC-13 and SCC-25) and pre-
malignant cells (SVHFK) used, had high levels of ROS compared to the human fetal 
fibroblast cell line (HFF). Do malignant cells have high ROS levels in vivo or just in 
vitro? Malignant cells from chronic lymphocytic leukaemia (CLL) patients showed 
increased ROS production compared to normal lymphocytes (Zhou et al, 2003) and 
many such studies have shown increased levels of 8-oxo-dG in human and other 
animal tumours (Halliwell, 2007b; Neeley & Essigmann, 2006; Sanchez et al, 2006). 
Halliwell proposes that increased oxidative damage levels in malignant cells could 
either result from: higher RS formation with no changes in the antioxidant defence 
mechanisms, unchanged RS formation with decreased antioxidant defences, or 
failure to repair oxidative damage, which leads to rise in levels, or any combination 
of the above (Halliwell, 2007b).  
 
However, we need to point out that cells in culture are in an abnormal state, as 
culture media are often deficient in antioxidants and antioxidant precursors. Also, 
most cells in the human body are, normally in an environment with low O2 levels 
(<10 mmHg O2). Most adherent cells are cultured as a monolayer under 95% air and 
5% CO2 which corresponds to a hyperoxic environment of around 152 mmHg O2. 
This is likely to increase ROS production in the cancer cells (Halliwell, 2007a; 
Halliwell, 2007b). In the present study, surprisingly high levels of ROS were 
observed in the normal epidermal keratinocytes NHEK-131 and HEK-127. A trend 
of higher ROS in the normal cells than the malignant and pre-malignant cell lines 
was observed but the difference was not significant (p>0.05). This, possibly, is a 
result of their presence in culture, because normal cells are expected to have lower 
levels of ROS and high anti-oxidant defences. If the increase in ROS by PUFA is 
one of the mechanisms that promotes cell death, maybe the effect in vivo is even less 
toxic to the normal cells, if their ROS levels are lower.  
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Several studies have suggested that PUFA can cause cell death in malignant cells via 
oxidation, in combination with chemotherapy drugs. Germain et al reported that 
doxorubicin efficacy toward MDA-MB-231 human breast cancer cells in culture 
were enhanced by the addition of DHA (29 μM). This effect was decreased by the 
addition of the anti-oxidant α-tocopherol (Germain et al, 1998). Also, in rats fed with 
DHA (approximately 0.7 g/day), for several weeks prior to and 6 weeks during 
chemotherapy, epirubicin was observed to have increased cytotoxicity toward 
mammary tumours, while this effect was decreased by the addition of α-tocopherol 
to the diet (Colas et al, 2006). Arsenic trioxide is an anti-cancer agent that has been 
used in the treatment of acute promyelocytic leukemia induced apoptosis by a ROS-
dependent pathway. The addition of DHA (25 μM) enhanced its cytotoxic effect and 
increased ROS production in leukemia cells in vitro and again this effect was 
reduced by the anti-oxidant vitamin E (Sturlan et al, 2003).  
 
Moreover, PUFA on their own have been reported to induce oxidation. Arita et al 
reported an increase in ROS generation in HL-60 leukaemia cells after treatment 
with EPA and other PUFA, hypothesising that this might be the mechanism that 
triggers apoptosis (Arita et al, 2001). Maziere et al showed that PUFA led to 
stimulation of intracellular ROS production and lipid peroxidation products in 
human fibroblasts, which was followed by activation of NFκB and was prevented by 
α-tocopherol (Maziere et al, 1999). Elevation of ROS after DHA treatment has been 
also reported in MCF-7 breast cancer cells in vitro and in vivo (Kang et al, 2010). 
Three anti-oxidants, including α-tocopherol (5 μM), protected the cells from DHA-
induced death. Tsuzuki suggested that conjugated EPA induces apoptosis of DLD-1 
colorectal adenocarcinoma cells via lipid peroxidation (Tsuzuki et al, 2007) while 
the increase in ROS was suggested as one of the possible mechanisms of PUFA- 
induced growth inhibition in neuroblastoma (Gleissman et al, 2010). However, 
Finstad et al showed that in Ramos lymphoma cells vitamin E could not reverse the 
EPA-induced apoptosis, while Raji lymphoma cells were protected from EPA by 
vitamin E (Finstad et al, 1998). This shows that, depending on the cell type, lipid 
peroxidation may not be the only mechanism of PUFA induced cell death. 
 
In the present study, our cells appear to already have increased ROS before any 
treatment with PUFA. After treatment with PUFA, the SCC-25 oral malignant cells 
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showed an increase in ROS after 16 hours, by DCF and HE flow-cytometric assays, 
especially at the higher concentrations of EPA and DHA used. Increased oxidative 
damage was also observed for the untreated cells by 8-oxo-dG staining. This damage 
appeared to increase after treatment with EPA and DHA. So, is this the mechanism 
or one of the mechanisms that EPA and DHA use to induce growth inhibition and 
apoptosis? When the two well-known anti-oxidants, α-tocopherol (α-TOC) and PBN 
were used, a protective effect was not observed in the MTT assay after 4 days. Both 
anti-oxidants failed to rescue the cells from the omega-3 PUFA inhibitory effect. 
Similar results were observed when different doses of PBN (50-1000 μM) were used 
on HaCaT cells (chapter 7), as PBN did not provide any protection against PUFA. 
This can have different explanations: First, it may mean that oxidation is not the 
mechanism that causes the PUFA-induced cytotoxicity. Second, it may mean that it 
is not the only or the main mechanism of PUFA action. Third, it could mean that the 
oxidation levels after the addition of PUFA are so high that the anti-oxidants fail to 
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Chapter 6: Molecular mechanism of PUFA-induced 
growth inhibition 
 
6.1 Background: Molecular mechanisms involved in omega-3 
PUFA growth inhibitory effect 
 
A number of signalling pathways have been reported as being differentially affected 
by omega-3 PUFA. The molecular mechanism of EPA and DHA tumour suppressive 
action is not fully understood and defined and it is becoming increasingly clear that 
they are actually pleiotropic (Berquin et al, 2008; Chapkin et al, 2008). The 
pleiotropic transcriptional alterations induced by omega-3 lipids were demonstrated 
by microarray analysis in vitro (Edwards et al, 2004) and in vivo (Berger et al, 2006; 




6.1.1 PI3K pathway 
 
The phosphatidylinositol 3-kinase (PI3K) affects a number of cellular functions 
including proliferation, apoptosis and differentiation. Specifically, activated PI3K 
promotes cell growth and survival and inhibits apoptosis. The activity of PI3K is 
elevated in many cancers where it results in a disturbance of the cell growth and 
survival control, giving a growth advantage and metastatic competence (Hennessy et 
al, 2005). There are three classes of PI3Ks. Class IA PI3Ks are implicated in cancer 
and consist of a regulatory sub-unit (p85) and a catalytic sub-unit (p110). There are 
three classes of p110 (p110α, p110β and p110γ) (Courtney et al, 2010). When PI3K 
is activated, it phosphorylates phosphatidylinositol-4,5-bisphoshate (PtdIns(4,5)P2 or 
PIP2) to produce PtdIns(3,4,5)P3 (PIP3). The tumour suppressor phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) dephosphorylates PIP3 to PIP2 
terminating PI3K-dependent signalling. Akt is a primary downstream mediator of the 
PI3K signalling pathway. Akt is a serine/threonine kinase which functions directly to 
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promote cell survival and protect cells from apoptotic death, by phosphorylating and 
inactivating several downstream targets (figure 6-1). The Pleckstrin Homology (PH) 
domain of Akt binds to PIP3 and it is recruited to the membrane, which results in 
conformational change allowing its phosphorylation. Akt is activated when it is 
phosphorylated on threonine 308 by phosphoinositide dependent kinase 1 (PDK1) 
and on serine 473 by PDK2 and has several downstream targets. It promotes cell 
survival by inhibiting the proapoptotic members of the Bcl-2 family Bad and Bax, 
and by negative regulation of the transcription factor NF-κB and forkhead 
transcription factors. Akt also phosphorylates Mdm2, which antagonises p53-
mediated apoptosis. Akt is also involved in the activation of mTOR, which leads to 
increased p70 S6 kinase activity (Courtney et al, 2010; Hennessy et al, 2005). 
 
There are reports of differential effects of omega-3 PUFA on the PI3K pathway. 
Some studies reported the decrease of phosphorylation and activity after EPA and 
DHA treatment (Lee et al, 2003; Schley et al, 2005), while others showed 
upregulation of Akt kinase activity via inactivation of its downstream target GSK3β 
after EPA treatment (Murata et al, 2001). Finally, no effect of DHA on p-Akt levels 




6.1.2 COX pathway 
 
Prostaglandins (PG) are a group of autocrine and paracrine hormones that mediate 
many cellular and physiological processes. Prostaglandin H2 (PGH2) is an 
intermediate in the formation of the prostaglandins. Cyclooxygenase (COX) is a 
prostaglandin synthase that catalyses the formation of PGH2 from AA (Bakhle, 
2001). There are two COX enzymes; COX-1 and COX-2. COX-1 is normally 
present in most types of cells and is a housekeeping enzyme, while COX-2 is 
normally absent from most cells. COX-2 levels increase rapidly and in large amounts 
in pathological situations like cancer or inflammation (Bakhle, 2001; Greenhough et 
al, 2009). COX-2 is overexpressed in cancer including colon cancer and head and 
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neck cancer (Chan et al, 1999; Greenhough et al, 2009; Mendes et al, 2009) but also 
in other types of tumours, such as lung, breast and prostate cancer (Bakhle, 2001), 
which is why there is a marked interest in studying the biology of COX-2 in relation 
to tumourigenesis. 
 
Initially, the COX enzymes catalyse the formation of the unstable intermediate PG2 
from AA, which is then converted into PGH2 by the peroxidase activity of COX. 
PGH2 is the precursor for several prostaglandins, which are formed by specialised 
prostaglandin synthases (Cha et al, 2006; Greenhough et al, 2009). The 
prostaglandins of series 2 which are synthesised by this pathway include the PGE2, 
PGD2, PGF2a, PGI2 (also known as prostacyclin) and thromboxane-A2 (TXA2) 
(Greenhough et al, 2009). However, as mentioned in chapter 1 (1.3.6), the COX 
pathway is involved in the metabolism of EPA to series-3 prostanoids 
(prostaglandins, prostacyclins and thromboxanes), which seem to be anti-
inflammatory or less inflammatory than the series 2 prostanoids produced from AA 
(figure 1-11) (Molendi-Coste et al, 2011). The anti-inflammatory omega-3 PUFA 
mediators, the resolvins, can also be produced by a COX-2-dependent pathway, in 
the presence of aspirin by generating their aspirin, triggered form (Serhan, 2009; 
Serhan & Chiang, 2008). So, the role of the COX pathway is more complicated than 
initially thought.  
 
Several studies support a critical role for COX-2 during colorectal tumourigenesis. 
The administration of the COX-2-selective nonsteroidal anti-inflammatory drugs 
(NSAID) celecoxib significantly suppressed the growth of existing adenomas and 
prevented the formation of new ones (Arber et al, 2006; Greenhough et al, 2009; 
Steinbach et al, 2000). The pro-tumourigenic effects of COX-2 in the colon largely 
depend on its role in producing high levels of PGE2 in human colorectal adenomas 
and carcinomas (Pugh & Thomas, 1994). In vivo studies have revealed that, when 
tissue prostaglandin levels were reduced through NSAID treatment, prevention of 
adenoma development in familial adenomatous polyposis patients was more 
effective (Giardiello et al, 2004). Removal of PGE2 by a PGE2 monoclonal antibody 
in mice inhibited the growth of transplantable tumours in vivo (Stolina et al, 2000). 
Treatment with a COX-2 inhibitor has been reported to reduce COX-2 mRNA and 
protein expression and synthesis of PGE2 in mammary and oral epithelial cells 
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(Mendes et al, 2009; Subbaramaiah et al, 2000).  The inhibition of COX-2 in an oral 
SCC cell line (NS-398) actually caused inhibition of proliferation of the cancer cells 
which were expressing COX-2 mRNA, via suppression of PGE2 production 
(Sumitani et al, 2001). Also inhibition of COX-1 and COX-2 caused increased 
terminal differentiation in mouse skin keratinocytes in vivo (Akunda et al, 2004). 
However, COX-2/PGE2 signalling is likely to act in combination with other 
signalling pathways that become deregulated in cancer, which need to be targeted in 
conjunction with the COX-2/PGE2 pathway for efficient cancer prevention and 
therapy.  
 
While good evidence suggests that the COX-2/PGE2 pathway is tumour-promoting 
and that its inhibition is useful in the prevention of different types of cancer, this 
does not appear to be the case under all circumstances (Greenhough et al, 2009). 
Most NSAIDs inhibit the COX-2/PGE2 pathway. However, some NSAIDs exert 
their antitumour effects in vitro independently of their ability to inhibit COX-2 or to 
decrease PGE2 (Elder et al, 1997; Hanif et al, 1996), and some other NSAIDs 
actually induce COX-2 expression (Paik et al, 2000; Pang et al, 2003). In addition, 
studies showed that the COX-2/PGE2 pathway may even act in a tumour suppressive 
manner under some circumstances (Bol et al, 2002; Murata et al, 2004; Patsos et al, 
2010; Wilson & Potten, 2000) and this issue is discussed later in more detail (sub-
chapter 6.3). Generally, the role of COX-2 and/or prostaglandins in cancer might not 
be as straightforward as initially proposed (Greenhough et al, 2009). 
 
Several studies have supported the inhibition of COX-2 by omega-3 PUFA in 
different types of cancer such as colon cancer (Narayanan et al, 2004), breast cancer 
(Horia & Watkins, 2007), cholangiocarcinoma cells (Lim et al, 2008) and 
hepatocellular carcinoma cells (Lim et al, 2009). Gleissman reported that DHA 
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6.1.3 MAPK pathway 
 
Mitogen-activated protein kinases (MAPK) are a widely conserved family of 
serine/threonine protein kinases involved in many cellular programs such as cell 
proliferation, differentiation, migration, and death (Dhillon et al, 2007). In 
mammalian cells, there are three well-defined MAPK pathways: the extracellular-
signal-regulated kinase (ERK) pathway, the JUN N-terminal kinase (JNK) pathway 
and the p38 pathway (figure 6-1). The signals that cause MAPK activation are 
usually initiated on the cell surface, primarily by membrane-bound receptors, such as 
EGFR. So, extracellular stimuli activate the MAPK pathways through mechanisms 
mediated by GTPases, including Ras, Rac, Cdc42 (cell-division cycle 42) and Rho 
(Ras homologue). MAPK pathways are activated via sequential phosphorylation 
events. Firstly, MAPK kinases (MAPKKs) are phosphorylated at two serine residues 
by MAPK kinase kinases (MAPKKKs), such as Raf, MEKK (MAPK/ERK kinase 
kinase) and TAK (TGFβ-activated kinase). Activated MAPKKs then phosphorylate 
MAPKs ERK (extracellular-signal-regulated kinase), JNK (JUN N-terminal kinase) 
and p38, on both threonine and tyrosine residues, which results in the catalytic 
activation of these MAPKs. The phosphorylation of the threonine and tyrosine 
residues on MAPKs results in a substantial conformational change of the protein that 
increases substrate accessibility and enhances catalysis. Activated MAPKs can 
translocate to the nucleus to phosphorylate a wide variety of downstream targets, 
including protein kinases and transcription factors, which facilitate the transcription 
of MAPK-regulated genes (Liu et al, 2007a).  
 
ERK signalling is deregulated in approximately one-third of all human cancers. The 
ERK1/2 (p44/42 MAPK) signalling pathway can be activated in response to a 
diverse range of extracellular stimuli including mitogens, growth factors, and 
cytokines, and it is associated historically with proliferation. However, it is now 
clear that deregulation of this pathway is linked to many other aspects of the tumour 
phenotype, so the precise molecular mechanism of ERK1/2 is still controversial 
(Dhillon et al, 2007). In cancer, where growth factors and mitogens activate ERK, 
ligand-mediated activation of receptor tyrosine kinases triggers guanosine 
triphosphate (GTP) loading of the Ras GTPase, which can then recruit Raf kinases to 
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the plasma membrane for activation. MEK1 and MEK2 are activated when 
phosphorylated by Raf (Raf-1, B-Raf and A-Raf) and then activate ERK1 and ERK2 
through phosphorylation of activation loop residues Thr202/ Tyr204 and 
Thr185/Tyr187, respectively (Dhillon et al, 2007).  
 
JNK and p38 pathways are activated preferentially by stress, DNA-damaging agents, 
oxidation and inflammatory cytokines. There are three genes – Jnk1, Jnk2 and Jnk3. 
Alternative splicing of these genes creates a total of 10 JNK isoforms. JNK 
activation requires dual phosphorylation (on tyrosine and threonine residues) by 
MEK4 and MEK7 (Dhillon et al, 2007). In response to stresses such as UVB 
radiation, oxidative stress and DNA-damage, JNK binds to and phosphorylates p53. 
This can result in an increase of p53 transcriptional activity and p53 stabilization 
(Cheng et al, 2003b; She et al, 2001). JNK seems to have a tumour suppressive 
function linked to its ability to promote apoptosis (Kennedy et al, 2003). In 
mammals, p38 isoforms are also strongly activated by environmental stresses and 
inflammatory cytokines. p38 is required for expression of TNFa and interleukin-1 
during inflammatory responses. There are four isoforms of p38 (α, β, γ and δ) which 
are phosphorylated by MEK3 and MEK6 (Dhillon et al, 2007). The phenotype of 
mice disrupted in the MEK3 and MEK6 genes or the p38a gene supported the idea 
that p38 functions as a tumour suppressor (Bulavin & Fornace, 2004). 
 
Traditionally, the activation of ERK is linked to cell survival and proliferation 
(Mansour et al, 1994; Xia et al, 1995). However, there are some studies which show 
that when cell death is triggered, activation of ERK is observed, which is as a 
survival mechanism and a final attempt of the cells to reverse their fate (Haase et al, 
2001; Persons et al, 1999; Wilson et al, 1999). However, more and more studies 
show that this is not always the case and activation of ERK could actually cause 
apoptosis or cycle arrest (Elder et al, 2002; Galve-Roperh et al, 2000; Pumiglia & 
Decker, 1997; Stanciu et al, 2000). In summary, ERK activation effect is not as 
straightforward as previously thought and it depends on the type, strength and 
duration of the stimulus and on the cell type (Elder et al, 2002). 
 
Some studies link the tumour suppressive action of PUFA with the MAPK pathway. 
Serini showed that PUFA can promote apoptosis through the up-regulation of 
Chapter 6. Molecular Mechanism of PUFA-induced Growth Inhibition 
140 
 
MAPK phosphatase-1 (MKP-1) and by reducing the levels of p-ERK1/2 and p-p38 
in lung cancer cells (Serini et al, 2008). Also, it was reported that DHA lowered the 
activation of Ras oncogenes and ERK activation in mouse colon cells (Collett et al, 
2001) and EPA decreased MAPK activity, inhibiting cell proliferation in hepatoma 








is one of the most versatile signalling mediators in cells and is required for the 
activation of many cellular processes (Chapkin et al, 2008). Increasing evidence 
indicates that changes in the intracellular homeostasis and compartmentalization of 
Ca
2+
 can result into cell death either through apoptosis or necrosis (Berridge et al, 
2000). Eukaryotic cells are able to increase their cytosolic Ca
2+
 levels via release 
from intracellular stores or influx via plasma membrane channels. The endoplasmic 
reticulum (ER) is the major storage organelle. However, functional 
compartmentalization of Ca
2+
 exists within the various cellular organelles such as 
mitochondria (Chapkin et al, 2008). In fact, it is now recognised that mitochondria 
play a key role in both apoptosis and necrosis by regulating energy metabolism, 
intracellular Ca
2+
 homeostasis, activation of caspases and the release of reactive 
oxygen species (ROS) (Jacobson & Duchen, 2002; Ott et al, 2007). It was recently 
shown that DHA and butyrate synergistically enhance both mitochondrial Ca
2+
 
accumulation and lipid peroxidation, which serve as triggers for apoptosis in a p53-
independent manner (Kolar et al, 2007). EPA has also been reported to affect 
intracellular homeostasis (Berquin et al, 2008). EPA induced a Ca
2+
 release from the 
intracellular Ca
2+
 stores and simultaneously inhibited Ca
2+
 influx via Ca
2+
 channels 
in the plasma membrane, resulting in a depletion of the intracellular Ca
2+
 stores 
which caused inhibition of translation initiation, and preferentially down-regulated 
oncogenes and G1 cyclins (Aktas & Halperin, 2004).  
 
 




















































Figure 6-1.  MAPK, PI3K and STAT signalling pathways 
MAPK, PI3K and STAT signalling pathways activated by epidermal growth factor receptors 
(EGFR) Akt is activated by PIP3, after PI3K activation, and phosphorylates several 
downstream targets. EGFR also triggers activation of GTPases, such as RAS which 
activates MAPKKKS. These MAPKKKs phosphorylate MAPKKs, which then activate the 
MAPKs, ERK1/2 p38 and JNK. Activated MAPKs translocate to the nucleus to 
phosphorylate a wide variety of downstream targets (protein kinases and transcription 
factors) which facilitate the transcription of MAPK-regulated genes. 
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6.1.5 NFκB pathway 
 
Another mechanism involved in the long-chain omega-3 PUFA action is NFκB 
activity.  PUFA have been reported to decrease NFκB activity and expression 
(Narayanan et al, 2003; Schley et al, 2005). Active NFκB promotes cellular survival 
and inhibits apoptosis, promoting tumourigenesis. NFκB exists as dimers usually 
located in the cytoplasm, associated with an inhibitor protein IκB which maintains 
NFκB in the cytoplasm by preventing the display of the nuclear localization 
sequence. After the right stimulus, IκB kinase-α phosphorylates IκB allowing 
dissociation from NFκB. Then, phosphorylated IκB is targeted for degradation 
through the ubiquitin- 26S proteosome pathway and NFκB is then free to localise to 
the nucleus. There, it initiates and regulates the transcription of various genes 
involved in cell growth control and inflammatory responces, for example pro-
inflammatory cytokine genes, such as TNF-α (Novak et al, 2003). It has been 
suggested that omega-3 PUFA modulate signalling involved in the activation of 
NFκB, such as Akt activation (Lee et al, 2003; Schley et al, 2005), TNF-α signalling 
(Novak et al, 2003; Weber et al, 1995), and IκBα phosphorylation (Novak et al, 




6.1.6 PPAR activation 
 
The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors 
consists of three proteins PPARα, β/δ, and γ, with different ligand specificity, tissue 
distribution, and developmental expression. PPARs ligands are primarily long chain 
unsaturated and polyunsaturated fatty acids and their metabolites (Edwards & 
O'Flaherty, 2008). PPARβ/δ plays a key role in lipid metabolism of peripheral 
tissues. PPARβ/δ is highly expressed in colon and promotes colon cancer (Michalik 
et al, 2004), after stimulation by arachidonic acid, upregulation of COX-2 leading to 
overproduction of prostaglandin PGE2 which causes growth of colon cancer cells. 
PPARγ has various effects on cancer. It controls fat metabolism by regulating genes 
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involved in lipogenesis, insulin sensitivity, and adipocyte differentiation (Edwards & 
O'Flaherty, 2008; Michalik et al, 2006). Although PPARγ activators have been 
widely shown to inhibit cancer growth in vitro, the effects are more complicated in 
vivo: they inhibit but sometimes promote cancer growth, depending on cellular 
conditions (Edwards & O'Flaherty, 2008). It was demonstrated (Sun et al, 2008) that 
DHA induced apoptosis in MCF-7 human breast cancer cells by the activation of 
PPARγ and consequent up-regulation of syndecan-1 (SDC-1) which is the major 
proteoglycan of plasma membrane produced by epithelial cells,  which regulates 
growth factor signalling and cell–cell and cell–matrix interactions. Ιn Ramos cells, 
irradiation and DHA were shown to synergise to induce apoptosis mediated at least 
in part via activation of PPARγ and suppression of NF-κB activation induced by 




6.1.7 Membrane structure and function and lipid rafts 
 
Omega−3 PUFA are rapidly incorporated into cells, primarily into membrane 
phospholipids (Chapkin et al, 1991; Stillwell & Wassall, 2003). Increasing evidence 
suggests that DHA is able to alter basic properties of cell membranes, such as acyl 
chain order and fluidity, phase behaviour, elastic compressibility, ion permeability, 
fusion, rapid flip-flop and resident protein function (Chapkin et al, 2008; Stillwell & 
Wassall, 2003). These DHA-induced alterations in membrane structure and function 
have been proposed to underlie its pleiotropic effects (Chapkin et al, 2008). 
Moreover, the plasma membranes of all eukaryotic cells contain specific regions in 
which key signal transduction proteins are localised. These regions are called “lipid 
rafts” and are composed mostly of cholesterol and sphingolipids, therefore do not 
integrate well into the fluid phospholipid bilayers and as a result form microdomains 
(Hancock, 2006). DHA and possibly EPA, being polyunsaturated, are incompatible 
with sphingolipid and cholesterol so they appear to alter lipid raft behaviour and 
protein function (Chen et al, 2007). 
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In summary, the omega-3 PUFA mechanism of action is very complicated and not 
clear yet as it is obvious that several different signalling pathways (some of them 





































6.2.1 Investigation of signalling pathways involved in the effect of 
PUFA on cancer cell growth 
 
In order to investigate the molecular mechanisms underlying the effect of PUFA on 
keratinocyte growth, some signalling pathways previously mentioned to be involved 
in EPA and DHA anti-cancer action were examined. The expression of different 
proteins was analysed by western blotting. The SCC-25 cells were firstly treated 
with 10 μM of DHA or EPA for 5, 17 and 24 hours. The higher dose of PUFA was 
chosen in order to observe the protein expression levels more easily taking into 
consideration that the effect would be longer and more visible. Lysates were 
obtained from the different conditions, as described in Chapter 2 (Materials and 
Methods). GAPDH was used as a loading control. Moreover, the protein expression 
of total proteins, such as total Akt and p44/42 MAPK (Erk1/2), is shown. Protein 
expressions were normalised with GAPDH or total protein expression when 
densitometry was used.  
 
In order to test if the PI3K pathway was involved, the expression of phosphorylated 
Akt was examined.  As mentioned before, Akt is a serine/threonine kinase, which 
promotes cell survival by inhibiting apoptosis when activated by phosporylation. 
Specifically Akt is phosphorylated on threonine 308 by PDK1 and on serine 473 by 
PDK2. Phosphorylation at serine 473 is required for full activation of Akt. Phospho-
Akt (Ser473) rabbit mAb detects endogenous levels of Akt only when 
phosphorylated at Ser473.  Total Akt was also examined. The results demonstrated 
that there was not a notable change of phospho-Akt (Ser473) after treatment with 
DHA and EPA after 5-17 hours (figure 6-2). 
 
Next, as COX-2 was previously mentioned to be affected by PUFA, I examined its 
expression in the SCC-25 cells. Surprisingly, treatment with EPA and DHA 
appeared to cause a 2-fold up-regulation in the expression of COX-2 after 5 hours. 
The up-regulation was reduced after 17 h for EPA. As regards the DHA treatment, 
1.5-fold up-regulation was observed after 17 h (figure 6-3). 




Next, I examined the MAPK pathway. Upon stimulation, MEK1 and MEK2 activate 
ERK1/p44 and ERK2/p42 through phosphorylation of activation loop residues 
Thr202/ Tyr204 and Thr185/Tyr187, respectively. Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) rabbit mAb detects endogenous levels of p44 and p42 MAP Kinase 
(Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 
and Tyr187 of Erk2), and singly phosphorylated at Thr202. The result was 
unexpected but striking. The expression levels of phospho-p44/42 MAPK (Erk1/2) 
appeared to be highly up-regulated after treatment with DHA or EPA for 5 h. The 
up-regulation was sustained until 24 h (figure 6-4).  
 
As the change in phospho-ERK1/2 expression was the most striking and sustained 
for a long period of time, I concentrated on this specific protein. Next, I investigated 
if there was the same result in the lower, more selective, concentrations of EPA and 
DHA and earlier time-points, in order to find out when the up-regulation starts. The 
results showed that the up-regulation of phospho-ERK1/2 starts as early as only 30 
min after treatment with the lower doses of EPA and DHA (figure 6-5). The increase 
in phospho-ERK1/2 is also obvious after 2 hours. I chose the 2 hour time point to 
continue my further analysis, as it is an early time point where the upregulation is 
obvious. 
 
I also examined if phospho-JNK was up-regulated after treatment with PUFA for 2 
h, as it belongs to the stress related part of the MAK pathway (figure 6-6). We can 
see that JNK is highly phosphorylated after treatment with both DHA and EPA at the 
higher doses (10 μM). At the lower dose of 5 μM, phospho-JNK levels are a lot 
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Figure 6-2: P-Akt protein expression levels 
Representative image of western blot assay showing the expression levels of P-Akt after 
treatment of SCC-25 cells with 10 μM of DHA or EPA for 5 and 17 hours. The protein levels 
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Figure 6-3: COX-2 protein expression levels 
A. Representative image of western blot assay showing the expression levels of COX-2 after 
treatment of SCC-25 cells with 10 μM of DHA or EPA for 5 and 17 hours. The protein levels 
of GAPDH housekeeping gene are also shown to examine if the loading is equal.  
B. Graph showing the quantification of the results by densitometry. The expression levels of 
COX-2 were normalised with GAPDH expression levels. The means± SEM of three 
independent experiments are shown. 
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Figure 6-4: Phospho-ERK1/2 protein expression levels 
A. Representative image of western blot assay showing the expression levels of phospho-
ERK1/2  (P-ERK1/2) after treatment of SCC-25 cells with 10 μM of DHA or EPA for 5, 17 
and 24 hours. The protein levels of total ERK1/2 and GAPDH housekeeping gene are also 
shown to examine if the loading is equal.  
B. Graphs showing the quantification of the results by densitometry. The expression levels of 
phospho-ERK1/2 were normalised with the total ERK1/2 expression levels. The means± 
SEM of three independent experiments are shown. 
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Figure 6-5: Phospho-ERK1/2 protein expression levels at earlier time-points at lower 
PUFA concentrations  
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2 (P-ERK1/2) after treatment of SCC-25 cells with 3 μM and 5 μM of DHA or EPA 
for 30 min and 2 hours. The protein levels of total ERK1/2 and the GAPDH housekeeping 
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Figure 6-6: Phospho-JNK protein expression levels  
Representative image of western blot assay showing the expression levels of phospho-JNK 
after treatment of SCC-25 cells with 5 μM and 10 μM of DHA or EPA for 2 hours. The 
protein levels of total ERK1/2 and GAPDH housekeeping gene are also shown to examine if 
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6.2.2 Investigation of the involvement of the MAPK pathway in PUFA 
induced apoptosis 
 
As the elevation of phospho-ERK1/2 was the most striking and early event after 
PUFA treatment, I hypothesised that it is involved in the PUFA induced growth 
inhibitory effect, which can include apoptosis or growth inhibition or both. In order 
to investigate this further, the use of several inhibitors was needed in order to see if 
the inhibition of ERK1/2 phosphorylation can block the PUFA-induced cell growth 
inhibition. First, the MEK inhibitor U0126 was used to block the ERK1/2 
phosphorylation mediated by MEK. I hypothesised that EGFR activation might be an 
earlier event which causes phospho-ERK1/2 elevation. In order to investigate this, 
the EGFR inhibitor AG1478 was used. Finally, the caspase inhibitor QVD-Oph was 
also included.  
 
Before the proliferation assays with the specific inhibitors, western blot assays were 
necessary to prove the inhibitors actually worked and to investigate the correct 
concentrations and timing.  
 
In the pilot experiment, AG1478 950 μM and QVD-Oph 10 μM were used to treat 
the SCC-25 cells (figure 6-7). The inhibitors were added in the culture for 1.5 hours 
before the addition of the EPA and DHA. Two hours after the addition of PUFA, the 
lysates were obtained. The first experiment with 10 μM EPA and DHA demonstrated 
that the EGFR inhibitor AG1478 successfully inhibited ERK1/2 phosphorylation 
without affecting the endogenous levels of the untreated control. The caspase 
inhibitor QVD-Oph did not affect the levels of phospho-ERK1/2, confirming that 
ERK1/2 phosphorylation is not a consequence of apoptosis. This was expected as the 
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Figure 6-7: Phospho-ERK1/2 protein expression levels after treatment with inhibitors and 
10 μM of PUFA in a pilot experiment 
Western blot image of pilot experiment showing the expression levels of phospho-ERK1/2  
(P-ERK1/2) after treatment of SCC-25 cells with 950 μM AG1478 EGFR inhibitor and 10 
μM QVD-Oph caspase inhibitor for 1.5 hours and then addition of 10 μM of DHA or EPA 
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In the subsequent experiment, the MEK inhibitor U0126 (5 μM or 2.5 μM) and a 
lower concentration of AG1478 (950 nM) were used (figures 6-8 and 6-9). Two 
concentrations of PUFA, 5 μM and 10 μM were used this time. Again, the inhibitors 
were added to the culture for 1.5 hours before the addition of the EPA and DHA. 
Two hours after the PUFA were added, the lysates were obtained. The EGFR 
inhibitor, AG1478 was very potent in knocking down p-ERK1/2 at this lower 
concentration, without affecting the endogenous levels of the untreated control. 
Again, the caspase inhibitor QVD-Oph did not affect the levels of phospho-ERK1/2. 
The MEK inhibitor U0126, at 5 μM for DHA and 2.5 μM for EPA treatment 
respectively, inhibited p-ERK in DHA treated cells but also reduced the endogenous 
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Figure 6-8: Phospho-ERK1/2 protein expression levels after treatment with inhibitors and 
DHA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2  (P-ERK1/2) after treatment of SCC-25 cells with 950 nM AG1478 EGFR inhibitor, 
5 μM U0126 MEK inhibitor and 10 μM QVD-Oph caspase inhibitor for 1.5 hours and then 
addition of 5 μM or 10 μM of DHA for 2 hours. The protein levels of total ERK1/2 and 
GAPDH are also shown to examine if the loading is equal.  
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Figure 6-9: Phospho-ERK1/2 protein expression levels after treatment with inhibitors and 
EPA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2  (P-ERK1/2) after treatment of SCC-25 cells with 950 nM AG1478 EGFR inhibitor, 
2.5 μM U0126 MEK inhibitor and 10 μM QVD-Oph caspase inhibitor for 1.5 hours and then 
addition of 5 μM or 10 μM of EPA for 2 hours. The protein levels of total ERK1/2 and 
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After the first assessments proved that the inhibitors used were potent, one more 
extended experiment was done, with different concentrations of the inhibitors, in 
order to decide which concentration to use in the cell assays. AG1478 (at 100 nM 
and 1 μM) and U0126 (at 2.5 μM, 5 μM and 10 μM) were used again. Two more 
inhibitors were added to our panel. Firstly, the EGFR blocking antibody (EGFR 
Mouse anti-Human Monoclonal (Azide-free) (225) Ab) (at 0.5 μg/ml, 1 μg/ml and 
10 μg/ml) was used, in order to confirm that EGFR inhibition reduces phospho-
ERK1/2 levels induced by PUFA. Secondly, another MEK inhibitor called AZD6244 
(30 nM, 100 nM and 300 nM) was also used. The inhibitors were added in the 
culture for 1.5 hours before the addition of PUFA. This time, SCC-25 cells were 
treated with the most selective PUFA concentration of 3 μM. Two hours after the 
PUFA were added, the lysates were obtained.  
 
During this experiment, apart from phospho-ERK1/2 and total ERK1/2, the protein 
expression levels of the phospho-ERK downstream target phospho-p90RSK and the 
total protein RSK1/2/3 were also examined. As expected, phospho-p90RSK was up-
regulated after DHA and EPA treatment following ERK1/2 phosphorylation. 
 
The EGFR blocking antibody (figure 6-10) was very effective in knocking down the 
PUFA induced phospho-ERK1/2 elevated levels, without affecting the endogenous 
basal levels of the control. Subsequently, phospho-p90RSK was also knocked down. 
EGFR blocking antibody seemed to be effective at even the lower concentration (0.5 
μg/ml), which appears to be appropriate to use for the cell assays. The EGFR 
inhibitor AG1478 (figure 6-11) was also very potent in knocking down phospho-
ERK1/2 and phospho-p90RSK levels, without affecting the endogenous levels of the 
control. Both concentrations used were successful, so the lower one (100 nM) 
appeared to be the most appropriate to use. 
 
The MEK inhibitor U0126 (figure 6-12) appeared to reduce ERK1/2 and p90RSK 
phosphorylation but it also affected the endogenous levels of the control.  It appeared 
that the middle dose of 5 μM was the most appropriate. The second MEK inhibitor 
AZD6244 appeared to be more potent than U0126. AZD6244 (figure 6-13) knocked 
down phospho-ERK1/2 and phospho-p90RSK levels without affecting the levels of 
the control, as much. The lower (3 nM) and the middle dose (30 nM) were probably 
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the most potent ones to use as they do not markedly affect the basal levels of 
phospho-ERK1/2. 
 
The next step would be to test whether the use of the inhibitors would reduce 
apoptosis after PUFA treatment. MTT or apoptosis assays could be used for this 
purpose. Unfortunately, due to time limitations, I was not able to perform these 
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Figure 6-10: Phospho-ERK1/2 and target phospho-p90RSK protein expression levels after 
treatment with EGFR blocking antibody and 3 μM of PUFA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2 and target phospho-p90RSK after treatment of SCC-25 cells with 0, 0.5 μg/ml, 1 
μg/ml and 10 μg/ml of the EGFR blocking antibody for 1.5 hours and then addition of 3 μM 
of DHA or EPA for 2 hours. The protein levels of total ERK1/2, total RSK1/2/3 and GAPDH 













Con     DHA      EPA 
3μM      3μM 
Con     DHA     EPA 
3μM     3μM 
Con  DHA    EPA 






- - - +      +     +     - - -
- - - - - - +    +     +
AG1478 100 nM:








Figure 6-11: Phospho-ERK1/2 and target phospho-p90RSK protein expression levels after 
treatment with AG1478 EGFR inhibitor and 3 μM of PUFA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2 and target phospho-p90RSK after treatment of SCC-25 cells with 0, 10 nM and 100 
nM of AG1478 EGFR inhibitor for 1.5 hours and then addition of 3 μM of DHA or EPA for 
2 hours. The protein levels of total ERK1/2, total RSK1/2/3 and GAPDH are also shown to 
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Figure 6-12: Phospho-ERK1/2 and target phospho-p90RSK protein expression levels after 
treatment with U0126 MEK inhibitor and 3 μM of PUFA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2 and target phospho-p90RSK after treatment of SCC-25 cells with 0, 2.5 μM, 5 μM, 
10 μM of U0126 MEK  inhibitor for 1.5 hours and then addition of 3 μM of DHA or EPA for 
2 hours. The protein levels of total ERK1/2, total RSK1/2/3 and GAPDH are also shown to 
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Figure 6-13: Phospho-ERK1/2 and target phospho-p90RSK protein expression levels after 
treatment with AZD6244 MEK inhibitor and 3 μM of PUFA 
Representative image of western blot assay showing the expression levels of phospho-
ERK1/2 and target phospho-p90RSK after treatment of SCC-25 cells with 0, 30 nM, 100 nM, 
300 nM of AZD6244 MEK  inhibitor for 1.5 hours and then addition of 3 μM of DHA or 
EPA for 2 hours. The protein levels of total ERK1/2, total RSK1/2/3 and GAPDH are also 









As mentioned before, the tumour suppressive action of EPA and DHA is pleiotropic 
and not clearly defined yet. Several reports involve different signalling pathways in 
omega-3 PUFA function. I attempted to investigate the involvement of some of these 
pathways in the growth inhibitory action of omega-3 PUFA in malignant oral 
keratinocytes. 
 
First, the PI3K pathway was examined. There are different reports regarding the 
effect of EPA on the PI3K activity. EPA and/or DHA decreased Akt phosphorylation 
and activity in breast cancer cells and the murine monocytes RAW264.7 (Lee et al, 
2003; Schley et al, 2005). DeGraffenried et al showed that EPA (0.2-200 μM) 
caused a dose-dependent decrease in p-Akt in higher doses. However, the lower 
doses of EPA resulted in an increase in phospho-Akt. Murata et al has also reported 
upregulation of Akt kinase activity via increased phosphorylation, and subsequent 
inactivation, of the downstream target GSK3β after EPA treatment of hepatoma cells 
(Murata et al, 2001). Finally, Lim et al showed no effect of DHA on p-Akt levels in 
the hepatocellular carcinoma cell line HCC and cholangiocarcinoma cells, while 
GSK3β levels of phosphorylation were decreased (possibly linked to β-catenin 
degradation) (Lim et al, 2009; Lim et al, 2008). My results agree with Lim et al, as 
there was no change in p-Akt levels observed after treatment of SCC-25 cells with 
EPA and DHA.  
 
Secondly, the COX-2 expression was investigated, as it is overexpressed in many 
types of cancer, including head and neck cancer (Bakhle, 2001; Greenhough et al, 
2009; Mendes et al, 2009). Several studies reported the inhibition of COX-2 by 
omega-3 PUFA. PUFA have been reported to have an apoptotic effect in colon 
cancer by down-regulating COX-2 (Narayanan et al, 2004). Moreover, omega-3 
PUFA reduced COX-2 and NFκB expression in MDA-MB-231 breast cancer cells 
(Horia & Watkins, 2007). DHA reduced the COX-2 promoter activity and the COX-
2 protein expression in cholangiocarcinoma cells (Lim et al, 2008) and 
hepatocellular carcinoma cells (Lim et al, 2009). Gleissman reported DHA decreased 
PGE2 production in neuroblastoma, and hence inhibited COX-2 activity (as COX-2 
produces PGE2) (Gleissman et al, 2010).  




In contrast to those studies, my results demonstrated a 2-fold increase in COX-2 
protein expression after 5 h of DHA and EPA treatment of oral SCC-25 cells. After 
17 h the levels declined for EPA, while for DHA there was a sustained over-
expression (1.5-fold) but the levels were also decreased. These results agree with one 
study that examined the effects of PUFA on HaCaT epidermal keratinocytes. They 
showed that EPA actually induced an almost 4-fold increase in COX-2 levels (Chene 
et al, 2007), mediated by PPARγ activation. They proposed that, despite the 
extensive literature documenting a deleterious role of COX-2 activity in various 
pathophysiological conditions, the induction of this enzyme by omega-3 PUFA may 
actually have an anti-inflammatory effect. 
 
The consequences of increased COX-2 expression in inflammation are complicated. 
They can be protective or deleterious depending on the balance between the pro-
inflammatory and the anti-inflammatory prostanoids produced by various cell types 
under different circumstances. On the one hand COX-2 produces series 2 pro-
inflammatory prostanoids from AA (Greenhough et al, 2009). However, it also 
produces series-3 prostanoids from EPA metabolism which are anti-inflammatory or 
less inflammatory than the series 2 prostanoids produced from AA (figure 1-11) 
(Molendi-Coste et al, 2010). Also, the anti-inflammatory omega-3 PUFA 
metabolites, the resolvins, can also be produced by a COX-2-dependent pathway, in 
the presence of aspirin (Serhan, 2009; Serhan & Chiang, 2008). Also, it has recently 
been shown that COX-2 is induced during the resolution of an inflammatory 
response, and leads to the production of anti-inflammatory but not pro-inflammatory 
prostaglandins, while inhibition of COX-2 at that point results in the persistence of 
the inflammation (Gilroy et al, 1999). Finally, the recently engineered fat-1 mice, 
can convert omega-6 to omega-3 fatty acids and have a lower ratio of omega-
6/omega-3 fatty acids their tissues compared to wild type (WT) mice.  Fat-1 mice 
showed a dramatic reduction in melanoma formation and growth. The level of 
omega-3 fatty acids and their metabolite PGE3 (which is produced via the COX 
pathway) were much higher than in the WT mice (Xia et al, 2006). Thus, COX-2 
appeared to be a bifunctional regulator of inflammatory processes. As inflammation 
is cancer-promoting, COX-2 can be tumour- promoting or tumour-preventing 
depending on different circumstances.  




Moreover, while several studies demonstrate an important role of COX-2 expression 
during tumourigenesis, others support the involvement of COX-2 in apoptosis. As 
discussed before (subchapter 6-1), COX-2- selective NSAIDS appear to significantly 
suppress the growth of existing colorectal adenomas and prevent the formation of 
new ones (Arber et al, 2006; Greenhough et al, 2009; Steinbach et al, 2000), while 
inhibition of COX-2 in a oral SCC cell line (NS-398) actually caused inhibition of 
proliferation of the cancer cells via suppression of PGE2 production (Sumitani et al, 
2001) and caused increased terminal differentiation in mouse skin keratinocytes in 
vivo (Akunda et al, 2004). While, most NSAIDs exert their antitumour effects by 
inhibiting the COX-2/PGE2 pathway, some NSAIDs exert their antitumour effects in 
vitro independently of their ability to inhibit COX-2 or to decrease PGE2 
(Greenhough et al, 2009). It was shown that NS-398, a COX-2 selective inhibitor, 
can cause apoptosis in colon carcinoma cells independently of COX-2, as it had 
similar effects in colon cancer cells that expressed and colon cancer cells that did not 
express COX-2 (Elder et al, 1997). Also, NSAIDs caused changes in proliferation 
and apoptosis in a colon cancer cell line that lacks COX transcripts and does not 
produce PGs, and in another one that does produce PGs (Hanif et al, 1996). 
Furthermore, some other NSAIDs actually induce COX-2 expression. The NSAID 
flufenamic acid induced COX-2 expression in colon cancer cells and murine 
macrophages (Paik et al, 2000), while three other NSAIDs induced COX-2 
expression in human airway smooth muscle cells independently of PGE2 production 
(Pang et al, 2003). 
 
In addition, several studies have shown that the COX-2/PGE2 pathway may even be 
tumour suppressive under specific circumstances. Wilson et al demonstrated a 
reduction in the number and size of intestinal tumours in vivo after the exogenous 
administration of the synthetic PGE2 analogue 16, 16-dimethyl-PGE2 (Wilson & 
Potten, 2000). A very recent study showed that the cannabinoid anandamide can 
induce cell death in the apoptosis-resistant HCT116 Bax-/- colorectal cell line in a 
COX-2 –dependent manner. Also, elevated COX-2 expression sensitised the SW480 
colorectal cancer cells (low endogenous COX-2) to anandamide-induced death, 
while COX-2 suppression via RNAi inhibited anandamide-induced cell death in the 
HCA7 colorectal cancer cells (high endogenous COX-2 expression) (Patsos et al, 
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2010). Finally, transgenic mice over-expressing COX-2 via the keratin 14 promoter, 
which causes COX-2 over-expression and elevated PGE2 levels in the skin, were 
more resistant to the development of induced skin tumours induced instead of being 
more sensitive, as it was initially expected (Bol et al, 2002). 
 
Generally, the role of COX-2 and/or prostaglandins in cancer might not be as 
straightforward as initially proposed (Greenhough et al, 2009) and could be tumour 
suppressive or tumour promoting under different circumstances. The elevation of the 
expression of COX-2 in SCC-25 cells in the present study after DHA and EPA 
treatment could be tumour suppressive, by causing apoptosis or growth arrest. Also, 
COX-2 can participate in the metabolism of EPA and DHA into anti-inflammatory 
and tumour suppresive prostanoids such as the series 3 prostanoids or resolvins or 
even new undiscovered metabolites of omega-3 PUFA. This remains to be 
investigated by the use of COX-2 inhibitors and their effects on keratinocyte growth 
and apoptosis.  
 
Some studies link the PUFA tumour suppressive action with the MAPK pathway. 
Serini showed that PUFA can promote apoptosis through the up-regulation of 
MAPK phosphatase-1 (MKP-1), which de-phopshorylates the two residues on 
activated MAPKs, and reduces the levels of p-ERK1/2 and p-p38 in lung cancer cells 
(Serini et al, 2008). Also, it was reported that DHA lowered the activation of Ras 
oncogenes and ERK activation in mouse colon cells (Collett et al, 2001), and EPA 
decreased MAPK activity and inhibited cell proliferation in hepatoma cells (Murata 
et al, 2001). Interestingly and unexpectedly, in our study the expression levels of 
phospho-ERK1/2) (phospho-p44/42 MAPK) were up-regulated after treatment with 
DHA and EPA and not down-regulated. The activity of ERK1/2 increases within 5 h 
of treatment with PUFA, continues to increase after 17 h and reaches maximal levels 
at 24 h. So there is a sustained and increasing ERK1/2 activity. The elevation of 
ERK1/2 phosphorylation was confirmed at the lower more selective concentrations 
of EPA and DHA, and started as early as 30 min after PUFA treatment. The 
activation of the downstream target of p-ERK, p-p90RSK was also demonstrated.  
 
Typically, the activation of ERK is supposed to promote cell survival and 
proliferation (Mansour et al, 1994; Xia et al, 1995). Activation of MAPK was 
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observed in basal and suprabasal keratinocytes of human and transgenic mouse 
psoriatic lesions and healing mouse skin wounds. The activation of MAPK 
stimulated proliferation and delayed terminal differentiation in keratinocytes 
expressing MAPKK-1, without exhibiting key properties of transformed cells (Haase 
et al, 2001). However, in some cases ERK is activated after the cell death stimulus, 
as a survival mechanism of the cells to reverse their fate (Haase et al, 2001; Persons 
et al, 1999; Wilson et al, 1999). A recent study demonstrated that treatment of 
adenocarcinoma HeLa cells with TRAIL induces cell death and in addition causes 
up-regulation of p-ERK1/2 (Lee do et al, 2006). They suggested that ERK1/2 
activation plays a protective role, as a cellular defence mechanism to survive, via the 
regulation of the Bcl-2/Bax ratio and several mitochondrial events during TRAIL-
induced apoptosis. Furthermore, the use of cisplatin in ovarian cancer cells caused 
elevation of p-ERK which, when inhibited, let to cisplatin-induced cytotoxicity 
enhancement (Persons et al, 1999). Other studies have also reported that ERK1/2 
activate cytoprotective mechanisms against Fas-induced cytotoxicity in Jurkat cells 
(Wilson et al, 1999) and against apoptosis induced by serum deprivation in PC12 
cells (Kim et al, 2000).  
 
Recent investigations, also, increasingly implicate ERK1/2 activation in cell death, 
depending on the type and duration of the stimulus and cellular context. Long-term 
ERK1 activation as a result of anchorage deprivation resulted in cell cycle arrest and 
telomerase inhibition in human stratified squamous epithelial cells (Crowe et al, 
2005). Similarly, increased MAPK activation was observed in lung cancer cell lines 
anchorage deprivation (Wei et al, 2001). Dose and time-dependent ERK activation 
was proved to be necessary for mediating cisplatin-induced apoptosis of human 
cervical carcinoma HeLa cells, as  MEK inhibitors PD98059 and U0126 and suramin 
(a growth factor receptor antagonist) prevented apoptosis, while pre-treatment of 
cells with TPA (activator of the ERK pathway) enhanced their sensitivity to cisplatin 
(Wang et al, 2000). Cannabinoids were shown to signal apoptosis by a pathway 
involving Raf1/extracellular signal-regulated kinase activation in glioma cells, 
prevented by PD98059 (Galve-Roperh et al, 2000). An inducible, activated form of 
the Raf-1 proto-oncogene resulted in a prolonged increase in MAPK activity and 
growth arrest of neuronal cells, with inhibition of CDK2 activity, while all these 
effects of were reversed by treatment of cells with PD98059 (Pumiglia & Decker, 
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1997). All these studies demonstrate that the early and sustained ERK activation I 
observe after omega-3 PUFA treatment in oral SCC cells would possibly be the 
mechanism of PUFA-induced apoptosis or cycle arrest or both. This remains to be 
proven by MTT and apoptosis assays after the inhibition of p-ERK. If ERK 
activation drives the growth inhibitory and apoptotic effect of PUFA, the inhibition 
of its activation should reduce these effects. 
 
Recently, Elder et al demonstrated that sustained ERK1/2 activation mediates 
apoptosis caused by the NSAID NS-398 in colon cancer cells, while the UO126 
MEK inhibitor protected the cells from these anti-proliferative effects and also 
reduced COX-2 protein levels (Elder et al, 2002). As the authors had previously 
shown that NS-398 caused apoptosis via COX-2 level elevation in colon cancer cells 
(Elder et al, 2000) they suggested that NS-398 cause ERK1/2 activation, which 
results in COX-2 elevation and the induction of apoptosis (Elder et al, 2002). As 
there is COX-2 activation 5 h after PUFA addition in our study, it is likely that 
COX-2 is linked to the ERK-induced growth inhibitory effect in this case as well. In 
order to investigate this, a COX-2 inhibitor should be used and the possible block of 
growth inhibition needs to be examined. 
 
Some studies have associated ERK activation and concomitant cell death to ROS and 
DNA damage induction. Tang et al showed that DNA damage stimuli activated 
ERK1/2 in various cell lines, which contributed to either cell cycle arrest or 
apoptosis in response to low or high intensity DNA insults, respectively. Inhibition 
of ERK activation by PD98059 or U0126 resulted in partial release of the cell cycle 
and strongly attenuated apoptosis (Tang et al, 2002). Stanciu et al showed that 
delayed and persistent activation of ERKs is associated with glutamate-induced 
oxidative toxicity in HT22 neuronal cells and immature primary cortical neurons, 
while U0126 protects the cells from glutamate toxicity. They suggest that glutamate-
induced ERK activation is downstream of a burst of reactive oxygen species (ROS) 
accumulation (Stanciu et al, 2000). In our case, DHA and EPA appeared to increase 
ROS production and DNA damage after 16 hours treatment (chapter 5). However, 
the use of two different anti-oxidants (α-tocopherol and PBN) failed to reverse the 
growth inhibitory effects of the omega-3 PUFA. Also, ERK activation happens very 
early after PUFA treatment, in contrast to the study of Stanciu (Stanciu et al, 2000). 
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So ROS induction might contribute to the ERK activation and growth inhibitory 
effect I observe. However, this is not supported by my current evidence. 
 
In conclusion, it is unclear yet if the up-regulation of p-ERK1/2 after treatment with 
PUFA in the present study is a survival mechanism or if it is involved in the 
apoptosis machinery. The first steps in investigating these possibilities were the use 
of two MEK inhibitors in order to examine their effects on ERK and p90RSK 
activation by western blot and to enable us to decide which are the best 
concentrations for the cell assays. U0126 reduced ERK1/2 and p90RSK 
phosphorylation, but it also affected the endogenous levels of the control.  AZD6244 
seemed more potent than U0126, as it inhibited phospho-ERK1/2 and phospho-
p90RSK levels without reducing the basal levels of the control as much. I also used 
the pan-caspase inhibitor QVD-Oph which did not affect the levels of phospho-
ERK1/2, demonstrating that ERK1/2 phosphorylation is not a consequence of 
apoptosis, reducing the possibility that it is just a survival mechanism.  
 
As the MAPK pathway can be triggered by epidermal growth factor receptor 
(EGFR) activation, I investigated whether blocking of EGFR activity can inhibit p-
ERK and p-p90RSK. An EGFR blocking antibody (EGFR Mouse anti-Human 
Monoclonal 225) and the EGFR inhibitor AG1478 were used. Interestingly, the 
EGFR blocking antibody inhibited the PUFA induced p-ERK1/2 and p-p90RSK 
very effectively, without affecting the endogenous levels of the control. The EGFR 
inhibitor AG1478 was also potent in reducing p-ERK1/2 and p-p90RSK levels, 
without affecting the basal levels of the control. Both were very effective even at the 
lower doses used.  
 
In 1978, EGFR was identified as a protein that showed increased phosphorylation 
when bound to EGF in the A431 squamous cell carcinoma cell line. The EGFR gene 
is located on chromosome 7p12-13 and codes for a 170 kDa receptor tyrosine kinase.  
This family consists of EGFR (also known as ERBB1⁄HER1), ERBB2 (HER2⁄NEU), 
ERBB3 (HER3) and ERBB4 (HER4). All proteins have four functional domains: an 
extracellular ligand-binding domain, a transmembrane domain, an intracellular 
tyrosine kinase domain and a C-terminal regulatory domain (Burgess et al, 2003; 
Mitsudomi & Yatabe, 2010). The extracellular domain consists of four domains. The 
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tyrosine kinase domain consists of an N-lobe and a C-lobe, and ATP binds to the 
cleft formed between these two lobes. The C-terminal regulatory domain has several 
tyrosine residues that are phosphorylated upon ligand binding (figure 6-14A). Eleven 
different ligands are known to bind to the ERBB family of receptors (Mitsudomi & 
Yatabe, 2010). The binding of ligands to the extracellular domain of EGFR generally 
leads to the formation of homodimers and heterodimers. The process is mediated by 
rotation of domains I and II, which results in the exposure of the dimerization 
domain (figure 6-14B) (Burgess et al, 2003). In the cytoplasm, the kinase domain 
dimerises asymmetrically in a tail-to-head orientation (figure 6-14C). Dimerization 
consequently stimulates the intrinsic tyrosine kinase activity of the receptors and 
triggers autophosphorylation of specific tyrosine residues within the cytoplasmic 
regulatory domain (Mitsudomi & Yatabe, 2010). These phosphorylated tyrosines 
serve as binding sites of adaptor proteins. Signal transducers then bind to these 
adaptors to initiate several signalling pathways such as the MAPK and PI3K/AKT 
pathways (figure 6-1) as well as the signal transducer and activator of transcription 
(STAT) 3 and STAT5 pathways (Mitsudomi & Yatabe, 2010).   
 
EGFR is expressed in a variety of human tumours, including those in the lung, head 
and neck, colon, pancreas, breast, ovary, bladder and kidney, and in gliomas 
(Mitsudomi & Yatabe, 2010; Ratushny et al, 2009). The fact that the EGFR antibody 
and the EGFR inhibitor block ERK1/2 phosphorylation and function in our SCC-25 
cells, as determined by the inhibition of the ERK1/2 target phospho-p90RSK, 
suggests that the PUFA may be causing apoptosis by increasing the secretion of an 
unknown EGFR ligand. As most SCCs possess increased levels of EGFR (Stanton et 
al, 1994) and are known to be inhibited from growing by levels of EGF that are 
optimal for normal keratinocytes (Gulli et al, 1996). I hypothesise that the release of 
EGFR ligand(s) by PUFA may lead to a suprastimulation of ERK1/2 and as a result 
trigger apoptosis.   
 
Omega-3 PUFA can also alter the lipid composition of the plasma membrane, which 
may affect the membrane fluidity and structure and the way growth factors, 
cytokines, and hormones interact with their receptors, and the resulting signal 
transduction. The microdomains, thought to play important roles in signalling, called 
„lipid rafts‟ are particularly interesting (Berquin et al, 2008; Chapkin et al, 2008). A 
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recent study indicated that EPA and DHA changed the lipid raft composition in 
MDA-MB-231 breast cancer cells, led to sustained phosphorylation of the EGFR 
receptor and downstream p38 MAPK pathway (even though it caused a marked 
decrease in EGFR levels in lipid rafts). The EGFR activation paradoxically caused 
reduction of cell growth (Schley et al, 2007). Thus, there is a possibility that the 
EGFR activation that causes ERK activation in our case is triggered by the 
alterations caused to the membrane lipid rafts by EPA and DHA. 
 
Furthermore, JNK phosphorylation was also observed, especially at the higher 
concentration of EPA and DHA.  As mentioned in the introduction of this chapter, 
the JNK and p38 pathways (MAPK sub-pathways) (figure 6-1) are activated 
preferentially by stress, DNA-damaging agents, oxidation and inflammatory 
cytokines (Dhillon et al, 2007). JNK is tumour suppressive as when activated can 
promote apoptosis (Kennedy et al, 2003). So probably, JNK activation can also 
participate in the PUFA induced apoptosis and could also be a result of EGFR over-
activation as well, or it could be triggered by ROS production. However, JNK 
activation was observed very early (after 2 hours treatment) so it is not clear if ROS 
was involved. p38 activation has not been investigated yet. 
 
It is also worth mentioning that the activation of ERK, JNK and p38 could be 
triggered after endoplasmic reticulum (ER) stress. Thiazolidinediones stimulate cells 
to activate p38, ERK1/2 and JNK (Edwards & O'Flaherty, 2008; Gardner et al, 
2005) by discharging Ca
2+
 from the ER to evoke an ER stress response; this activates 
Ca
2+
/calmodulin kinase II, proline-rich tyrosine kinase 2, protein kinases C, c-Src, 
EGFR, the ERK1/2 and JNK pathways, the double stranded RNA-activated protein 
kinase, and p38. Double stranded RNA-activated protein kinase inactivates 
eukaryotic initiation factor-2 (EIF-2), blocking protein translation (Gardner et al, 
2005; Palakurthi et al, 2001).  Also, as mentioned in the subchapter 6.1, EPA 
induced a Ca
2+
 release from the intracellular Ca
2+
 stores and simultaneously inhibited 
Ca
2+
 influx via Ca
2+
 channels in the plasma membrane, resulting in a depletion of the 
intracellular Ca
2+
 stores which caused inhibition of translation initiation, and also 
activated eIF2a kinase, which are signs of ER stress (Aktas & Halperin, 2004; 
Berquin et al, 2008). Other studies have also recently shown that EPA has similar 
 


























Figure 6-14: The EGFR protein 
(A) The structure of the EGFR protein is shown with the four functional domains; the 
extracellular ligand-binding domain, the transmembrane domain, the intracellular tyrosine 
kinase domain (with the N-lobe and a C-lobe) and the C-terminal regulatory domain. (B) 
The activation by rotation of the extracellular ligand-binding sub-domains and (C) the 
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effects on ER calcium discharge (Abedin et al, 2006; Palakurthi et al, 2000). 
Jackobsen et al found that, as an early response, in SW620 colon carcinoma cells, 
DHA induced the expression of different factors involved in ER stress response, 
such as XBP1, PERK, ATF4, ATF6 and phosphorylated EIF2a. However, it failed to 
induce apoptosis in their model (Jakobsen et al, 2008). My study showed activation 
of JNK and ERK pathways caused by EGFR activation, so it could be related to ER 
stress. However, no other features of the ER stress were investigated. The possible 
effect of omega-3 PUFA on ER-stress and ER-stress induced apoptosis is a quite 
unexplored issue, worth further investigation.  
 
 
Finally, some studies showed that EPA and DHA can actually trigger PPAR 
activation as mentioned in subchapter 6.1. DHA induced apoptosis in MCF-7 human 
(Sun et al, 2008) and in Ramos cells (combined with irradiation) (Zand et al, 2007) 
by the activation of PPARγ. Chene et al, also reported that EPA induced an increase 
on COX-2 expression (Chene et al, 2007) mediated by PPARγ activation proposing 
an anti-inflammatory effect. Moreover, PPARγ has been implicated in the activation 
of MAPK pathway and ER stress (Gardner et al, 2005). Taking all these together, it 
is possible that PPAR activation is also participating in the PUFA-induced growth 
inhibitory effect and apoptosis. This has not been investigated yet. 
 
In summary, my study showed that the omega-3 PUFA, EPA and DHA, cause high, 
early and sustained activation of ERK1/2. The activation of the ERK substrate, p-
90RSK, was also confirmed. EGFR appears to cause ERK1/2 activation. We 
hypothesise that EGFR which is over-expressed in SCC cells, is suprastimulated by a 
ligand that omega-3 PUFA release, resulting in ERK pathway activation which leads 
to apoptosis and/or growth arrest. EGFR activation can be also triggered by lipid raft 
alterations or ER stress. As COX-2 expression was also increased, COX-2 could be 
also implicated in the cell growth inhibitory effect of PUFA being a downstream 
target of ERK pathway during ERK-induced apoptosis, or could produce a tumour-
suppressive EPA and DHA derivative. The stress-related and tumour-suppresive 
JNK protein is also expressed, possibly participating in PUFA- induced apoptosis. 
These hypotheses remain to be proven in the near future by inhibition of the over-
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Chapter 7: Fatty acid interaction with serum and 
membrane incorporation 
 
7.1 Background: Fatty acid transport in the keratinocytes 
 
Lipid molecules have limited solubility in aqueous solutions. In order to overcome 
this limitation and be available for utilization by the various cells and tissues, lipids 
are either bound by specific carrier proteins, or are part of larger lipid-protein 
complexes called lipoproteins.  Therefore, the majority of the long-chain fatty acids 
are bound to plasma albumin in the circulation and to cytosolic proteins in the cell 
cytoplasm (Glatz et al, 2002). As mentioned in chapter 1, the uptake of fatty acids 
from the circulation into cells includes the sequence: adsorption, transmembrane 
movement and desorption. The albumin-bound fatty acids (FA) need to dissociate 
from albumin and either bind to plasma membrane proteins or integrate into the lipid 
bilayer. Following transport across the plasma membrane, the FA bind to other 
proteins in the cytoplasm (Doege & Stahl, 2006) (figure 7-1). The FA uptake process 
is still controversial and unclear. FA can be taken up by the cells by passive diffusion 
through membrane lipid via flip-flop mechanisms. The diffusion is thought to 
become more significant at high ratios of FA: albumin (> 2:1) as the concentration of 
unbound FA (FA dissociated from albumin) increases (Coburn et al, 2001). Studies 
with model membrane systems and intact cells (adipocytes), and using techniques 
such as dual fluorescence approaches, provided evidence that fatty acids diffuse very 
rapidly across the plasma membrane (Hamilton et al, 2002). However, under 
physiological conditions, the passive diffusional uptake of FA does not mean that a 
protein-facilitated FA uptake does not take place. Passive diffusion and protein-
mediated transmembrane transfer of FA seem to co-exist as separate ways of FA 
transport. These two routes seem to contribute to the overall rate of FA transport, 
which could depend on the nature of the membrane (plasma membrane organelle or 
vesicular membrane), cell type and functional state of the cell, FA availability and 
FA type, and different hormonal environment (Glatz et al, 2002; Khnykin et al, 
2011). Although the occurrence of both long chain FA uptake processes are now 
widely accepted, in recent years many studies have demonstrated that protein-
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mediated transport accounts for the majority of fatty acid  uptake by tissues with 
high long chain PUFA metabolism and storage (Doege & Stahl, 2006). The 
candidate proteins that have been proposed to be involved in the uptake process of 
PUFA include FA translocase (FAT/CD36) (Coburn et al, 2001), FA binding 
proteins (FABPs) (Storch & McDermott, 2009; Storch & Thumser, 2010), long 
chain fatty acyl-CoA synthetases (ACSL) (Gargiulo et al, 1999), long chain fatty 
acyl-CoA binding protein (ACBP) (Knudsen et al, 2000) and FA transport proteins 
(FATPs) (Doege & Stahl, 2006) (figure 7-1). 
 
 
The three major lipids in the stratum corneum of the epidermis are 15% free fatty 
acids, 25% cholesterol and 50% ceramides. Some FA (with carbon chains of up to 
C16) can be synthesised by keratinocytes de novo and, in addition, need to be taken 
up from the circulation, which is protein mediated. Several fatty acid transporters are 
expressed in skin.  A significant amount of the FAs produced or taken up from diet, 
are further elongated into very long chain FAs (C ≥18) (Jakobsson et al, 2006). 
During keratinisation, long-chain, highly saturated species (14-28 carbons) replace 
the short-chain FAs. The majority are ≥20 carbons, with 22–24 carbon lengths being 
the most abundant (Khnykin et al, 2011). 
 
Essential fatty acid deficiency leads to abnormalities in skin function, resulting in 
scaly dermatosis, permeability of skin to water and hair loss (Burr & Burr, 1929; 
Khnykin et al, 2011). As mentioned before, the human body cannot produce LA 
(C18:2, n-6) and LNA (C18:3, n-3). Also, AA (C20:4 n-6) of the epidermis, must be 
synthesised in the liver and transported into keratinocytes, as well as other LCFA 
and VLCFA that also have to be translocated across the keratinocyte plasma 
membrane. EPA and DHA can be obtained from dietary sources and are 
incorporated into the epidermal lipids (Ziboh et al, 1986). FAs have multiple roles in 
the epidermis. They can be part of triglycerides, phospholipids, glycosylceramides 
and ceramides, forming the epidermal permeability barrier. In addition FAs in 
keratinocytes play a role in energy generation and storage and can be potent 
signalling molecules (Khnykin et al, 2011). Inflammatory skin diseases, such as 
atopic dermatitis and psoriasis, are characterised by changes in FA composition in 























Figure 7-1. Free fatty acid uptake and action in mammalian cells 
Albumin-free fatty acids (FFAs) are generated from lipoproteins by the action of endothelial 
lipoprotein lipase (LpL). At physiological conditions, the majority of FFAs are bound to 
albumin, whereas the concentration of unbound FFAs in this equilibrium is low. FFAs are 
transferred via the plasma membrane into the cell mainly by a protein-mediated mechanism, 
either by interaction of the FFAs directly with FA translocase (FATP) complexes, or by 
binding to cell-surface proteins, such as CD36, which introduces them to the FATPs. On the 
cytosolic side, FFAs are quickly activated and coupled to CoA by the catalysis of ACSL or 
the by FATPs. Then, FA binding proteins (FABPs) or long chain fatty acyl-CoA binding 
protein (ACBP) facilitate the intracellular unloading of the transporters and the synthetases 
and function as an intracellular fatty acid buffer. Intracellularly, FFAs can have functions in 
energy generation and storage, membrane synthesis, protein modification, and activation of 
nuclear transcription factors. FFAs can also signal extracellularly, e.g., by stimulating 
GPR40 in β-cells to induce insulin secretion or by activating TLRs to initiate the innate 
immune response (Doege & Stahl, 2006). 
Chapter 7. Fatty Acid Interaction with Serum and Membrane Incorporation 
177 
 
keratinocytes, indicating their possible involvement in the modulation of 
inflammation (Sala-Vila et al, 2008; Ziboh et al, 1986). Moreover, free FA 
contribute to the acidic pH of the stratum corneum, regulating permeability and the 
antimicrobial barrier, inflammation and desquamation (Hachem et al, 2003). 
 
Studies have shown active uptake of FAs by keratinocytes, which preferably 
transport essential FAs, i.e., LA and AA than non-essential FA, such as oleic acid 
(C18:1, n9) (Schurer et al, 1994). It was demonstrated that FATP1, -3, -4 and -6, 
along with CD36/FAT, are expressed in adult murine epidermis and specifically 
FATP1 and -3 were expressed predominantly by keratinocytes (Schmuth et al, 
2005). FATPs expression in humans was comparable to that in mice and experiments 
with primary human keratinocytes showed that FATP4 was the most abundant FATP 
expressed in culture. The induction of differentiation resulted in approximately a 
50% reduction in the level of FATP protein. In contrast to human and mouse 
epidermis, neither FATP1, -3 nor -6 were expressed in primary cultures of 
differentiated and un-differentiated human keratinocytes (Schmuth et al, 2005). 
Moreover, CD36/FAT, plasma-membrane FABPs and ACSL are expressed at 
different levels in undifferentiated and differentiated human keratinocyte cultures 
(Harris et al, 1998).  
 
The essential role of protein FA uptake mediators was highlighted by a number of 
mouse models. CD36 knockout mice did not show any apparent skin phenotype, 
whereas muscles and adipose tissues had a defective LCFA uptake and utilization 
(Coburn et al, 2000; Febbraio et al, 2002). CD36-mediated uptake of FAs in 
keratinocytes can be compensated by other FA transporter proteins.  
 
FABP5 (KFABP) is predominantly expressed in keratinocytes, where it has been 
proposed to act as a cellular lipid chaperone in keratinocyte homeostasis (Krieg et al, 
1993). It has also been detected in tongue and thymus epithelia. It seems that FABP5 
is the only FABP detected in the epidermis (Krieg et al, 1993; Ogawa et al, 2011; 
Owada et al, 2002). Compared with other tissues, human keratinocytes contain lower 
levels of FABP5, while these levels increase with keratinocyte differentiation 
(Siegenthaler et al, 1994). Overexpression of FABP5 is associated with hyper-
proliferative skin diseases, such as psoriasis, atopic dermatitis and basal and 
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squamous cell carcinomas (Masouye et al, 1996). It is hypothesised that FABP5 
expression is increased in response to increased lipid traffic related to abnormal 
proliferation and differentiation of keratinocytes in these diseases. The skin of 
FABP5 knockout mice appears normal, but the water-barrier function of the 
epidermis is altered in these mice (Owada et al, 2002). It was also shown that 
FABP5 deletion disrupts keratinocyte migration, suggesting a role in cell motility 
(Kusakari et al, 2006). The absence of obvious skin phenotype could mean that other 
FABP members or other FA-transport proteins compensate for FABP5 deficiency. 
Ogawa et al showed that FABP5 deletion affects keratinocyte differentiation, but not 
proliferation (Ogawa et al, 2011). Total FA content in FABP5-deficient epidermis 
was decreased, including decreased saturated, monounsaturated and polyunsaturated 
FAs. Specifically, LA was significantly decreased, while AA and LNA levels were 
the same (Ogawa et al, 2011). In summary, the high expression of FABP5 in 
hyperproliferative skin conditions suggests that FABP5 may have a role in the 
pathogenesis of such diseases disrupting metabolism of FAs and their derivates. 
 
Several FATPs, including FATP4, are expressed in the epidermis (Schmuth et al, 
2005) and animal models suggest that FATP4 plays an important role in skin 
homeostasis. Recently, mutations in the FATP4 gene were found responsible for 
Ichthyosis Prematurity Syndrome (IPS) (Klar et al, 2009) which is a rare disorder of 
keratinization, characterised by premature birth, scaly erythroderma and neonatal 
respiratory complications. FATP4 knockout mice die either in utero (Gimeno et al, 
2003) or shortly after birth (Moulson et al, 2003) showing a disturbed epidermal 
barrier and hyperkeratosis, leading to very tight, thick skin (wrinkle free phenotype). 
It is very interesting that it was possible to rescue the FATP4 knockout mice from 
death by keratinocyte-specific transgenic expression of FATP4, leading to viable and 
fertile mice with only mild skin and hair abnormalities, demonstrating the 
importance of FATP4 in the epidermis (Moulson et al, 2007). However keratinocyte-
specific expression of FATP4, mutated in the acyl-CoA synthetase domain, did not 
rescue the skin phenotype, indicating the ability of FATP4 to activate fatty acids is 
crucial for its function (Moulson et al, 2007). Herrmann et al. created mice with 
conditional FATP4 deficiency in the epidermis which displayed structural changes in 
the epidermis and an impaired barrier function, but the phenotype was not nearly as 
severe as that seen in mutant neonates (Herrmann et al, 2005). The explanation for 
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this apparent difference could be that in adult skin FATP4 deficiency is compensated 
by other FATPs, thus FATP4 is more critical for the generation of the epidermal 
barrier and less important for its maintenance (Khnykin et al, 2011). 
 
Although the exact mechanism by which FAs are transported into keratinocytes is 
still unclear, all these studies show that different FA transporters play important roles 

































7.2.1 The omega-3 PUFA inhibit growth and induce apoptosis in pre-
malignant keratinocytes and colon carcinoma cells but their action is 
inhibited by FBS 
 
Although it had been reported that the omega-3 PUFA inhibited the growth of DLD-
1 (Eitsuka et al, 2005) we were unable to confirm these observations or extend them 
to HaCaT cells in medium containing 10% v/v FBS. Figure 7-2A shows the results 
of the MTT assays conducted on the pre-malignant cell line HaCaT and the colon 
carcinoma line DLD-1 after treatment of the cells for 4 days with DHA and EPA in 
medium containing 10% v/v FBS.  As FBS batches are variable, we hypothesised 
that our FBS might be rich in survival factors or antagonists of the omega-3 PUFA, 
and so re-tested the compounds in medium with reduced (3%) concentrations of 
FBS.  Figure 7-2B shows that under these conditions both HaCaT and DLD-1 were 
strongly inhibited by both omega-3 PUFA at 30 μM and 50 μM, supporting our 
hypothesis. 
 
Additionally, the SCC-25 oral cancer cell line was tested to examine the effect of 
PUFA on cell growth in 10% FBS medium (figure 7-3). Instead of the KGM serum 
free medium where SCC-25 are usually cultured in during our experiments(chapters 
3,5,6) in this case SCC-25 were cultured in FAD medium containing 10% FBS. The 
MTT assay was performed using the same conditions as the MTT assays in KGM 
medium. DHA and EPA were added at concentrations 3-100 μM, which is a much 
higher range than the one used in serum free medium (0.1-10 μM). It is obvious that 
the FBS also antagonised the effect of PUFA on SCC-25 growth inhibition. SCC-25 
cells were almost entirely dead at PUFA concentrations of >3 μM in the KGM serum 
free medium (figure 3-1), while only a small percentage of cells were dead at the 
medium containing 10% FBS (figure 7-3). Surprisingly, only EPA 5 μM seemed to 
be more inhibitory, but overall the serum protected the cells from the inhibitory 
effect of the PUFA. 
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Figure 7-2: Effect of PUFA on HaCaT and DLD-1 growth in 10% and 3% FBS medium 
HaCaT and DLD-1 cultures were plated on day 1 and allowed to attach in either RPMI 
containing 10% v/v FBS (A) or 3% v/v FBS (B). On day 2, DHA or EPA was added in 
increasing concentration 0.1-50 M. 0.1% v/v ethanol was used as a control. Ethanol alone 
had a negligible effect. Fresh lipids were added on day 5 and the MTT assay conducted on 
day 7. The bars represent the mean values ± SEM of 3 independent MTT experiments, 
conducted in duplicate. The red bars represent the 50 M DHA and the green bars 50 M 
EPA. * is significantly different from the mean value of 3% v/v FBS medium untreated 
control (* = p<0.05 and ** = p <0.01 *** = <0.001 as measured by one way ANOVA 
followed by post-hoc Bonferroni test). 
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Figure 7-3: Effect of PUFA on SCC-25 growth in 10% FBS medium 
SCC-25 cultures in 10% FBS FAD medium were plated on day 1 and allowed to attach for 3 
days. On day 4, DHA or EPA was added in increasing concentration 3-100 M. 0.1% v/v 
ethanol was used as a control.  Fresh lipids were added on day 6 and the MTT assay 
conducted on day 8 (after 4 days of PUFA treatment). The bars represent the mean values 
+/- SEM of 3 independent MTT experiments, conducted in duplicate. The red bars represent 




7.2.2 The protective effect of FBS against omega-3 PUFA is not related 
to serum growth/survival factors   
 
In medium containing 3% v/v FBS, 50 µM EPA and DHA each lowered the number 
of viable cells in the controls by approximately 60-80% (figure 7-4). However, at 
concentrations which encompassed the physiological range of these growth factors in 
serum and plasma, IGF-1 (1-30 ng/ml; figure 7-4A) (Seto et al, 2001), EGF (0.3-30 
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ng/ml; figure 7-4B) (Pietrzak et al, 1999), FGF-a (0.1–3.0 ng/ml; figure 7-4C) 
(Rizzino et al, 1988) FGF-b (0.1-3.0 ng /ml; figure 7-4D) (Pardo et al, 2002), TGF-α 
(1-40 ng/ml; figure 7-4E) (Pehlivan et al, 2001) and TGF-β1 (3-300 pg/ml; figure 7-
4F) (Wenisch et al, 1995) did not prevent the EPA or DHA from inhibiting the 
cellular proliferation FBS (M.Hassan and Z.Nikolakopoulou). As before, when the 
PUFA were added to medium containing 10% v/v FBS at the same concentration (50 
μM), they failed to show a significant growth inhibitory effect (figure 7-4G). EGF 
was slightly inhibitory in the HaCaT controls at a concentration of 30 ng/ml, but this 
was not statistically significant (p = 0.08). FGF-a and FGF-b showed a slight 
stimulation of HaCaT growth at higher concentrations, but again this was not 
statistically significant in either case.  TGF-α showed a slight relative protective 
effect but this was largely due to the inhibitory effect of TGF-α in the controls, at 
concentrations of 5 ng/ml and above. TGF-α caused a significant growth inhibition 
of 30-50% at 10-40 ng/ml (p < 0.05). TGF-β1 concentrations of 3-10 pg/ml showed a 
slight growth stimulatory effect in the HaCaT controls but at 30 pg/ml and above 
was progressively inhibitory and at 0.3 ng/ml significantly inhibited growth by 45-




7.2.3 The anti-oxidant n-tert-butyl-α-phenylnitrone (PBN) does not 
protect against the growth inhibitory effects of omega-3 PUFA 
 
Finally, as serum contains anti-oxidants, the effect of the known antioxidant n-tert-
butyl-α-phenylnitrone (PBN) was tested (Nakao et al, 1996). As omega-3 PUFA can 
produce oxidative damage in keratinocytes especially at higher doses (Chapter 5), we 
used different concentrations of PBN ranging from 50 µM to 1000 µM to test the 
effect of PBN on PUFA activity in a medium with 3% v/v FBS (M.Hassan and 
Z.Nikolakopoulou). However, there was no protective effect of PBN against the 
omega-3 PUFA (figure 7-5). We tried 2 different dose ranges; the first
 
one with 5 
different concentrations (50 µM, 100 µM, 200 µM, 400 µM and 600 µM- figure 7-
5A) and the second one with 800 µM, 900 µM and 1000 µM (figure 7-5B). 
However, at no dose did we see a protective effect. Rather than protection, PBN at 
Chapter 7. Fatty Acid Interaction with Serum and Membrane Incorporation 
184 
 
50 µM to 400 µM showed a slight stimulatory effect in HaCaT cell growth (figure 7-
5A). However, from 600 µM to 1000 µM PBN showed a gradual inhibition of 
cellular proliferation in HaCaT (figure 7-5B). PBN at 800 µM reduced the frequency 
of senescent cells and oxidative damage in human fibroblast cultures, showing that 
PBN is effective at this concentration (Pitiyage et al, 2011). Therefore, our data 
argue against an antioxidant effect being responsible for the antagonistic effects of 
FBS against omega-3 PUFA-induced HaCaT growth inhibition, in contrast to the 









































































































































































































































































Figure 7-4. Effect of growth factors on PUFA induced growth inhibition in 3% FBS 
medium  
Means± S.E.M of 3 independent MTT experiments in duplicate. HaCaTs were plated on day 
1 and allowed to attach in either RPMI containing 3% v/v FBS or 10% v/v FBS as a 
negative control. On day 2 50 M the omega-3 PUFA were added. 0.1% v/v ethanol was 
used as a control. Fresh lipids were added on day 5 and the MTT assay conducted on day 7. 
(A) –(F) show the effect of the lipids in different concentrations of the following growth 
factors in 3% v/v FBS; (A) IGF-1, 1-30 ng/ml, (B) EGF, 0.3 – 30 ng/ml, (C) FGF-a, 0.1 – 3 
ng/ml, (D) FGF-b, 0.1-3 ng/ml, (E) TGF-, 1-40 ng/ml (F) TGF-, 3-300 pg/ml, (G) 10% 
v/v FBS Control. 





































































































Figure 7-5. Effect of an anti-oxidant on PUFA induced HaCaT growth inhibition in 3% 
FBS medium 
The figure shows the effect of the omega-3 PUFA in two sets of different concentrations of 
PBN in RPMI with 3% v/v FBS. The protocol was the same as for figure 7-4. The blue bars 
represent the untreated controls, the red bars the 50 M DHA and the green bars the 50 M 
EPA. The bars represent the means of 3 experiments performed in duplicate +/- SEM. 
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7.2.4 Albumin is the major serum antagonist of DHA- and EPA-
induced growth inhibition 
 
The concentration of albumin in human blood and bovine serum is in the range of 3-
5% w/v (Corti et al, 1994) and so would likely be 0.3-0.5% w/v in medium 
containing 10% FBS but only 0.09-0.15% in medium containing 3% v/v FBS. Figure 
7-6A shows that BSA at an added concentration of 0.1-0.3% w/v in medium 
containing 3% v/v FBS (total concentration range 0.2-0.45% w/v BSA) was able to 
partially protect HaCaT cells from the growth inhibitory effects of both DHA and 
EPA. However, BSA was only able to protect to 50% of the level of 10% FBS (see 
figures 7-2A, 7-4G and 7-6C). At concentrations of 1-3% w/v, BSA alone caused 
considerable growth inhibition. 
 
Figure 7-6B shows that broadly similar results were obtained when BSA was 
substituted with human serum albumin, except that the optimum concentration was 
0.3-1.0% w/v and that the level of protection was 75% of that of 10% FBS (see 
figures 7-2A, 7-4G and 7-6C). This data supports the hypothesis that the interaction 
of dietary omega-3 PUFA with albumin in humans might mute their anti-cancer 
effects. At their optimum protective doses, both BSA and human albumin stimulated 
HaCaT cell growth in the control cultures at 10-20% and 20-40%, respectively. 
However, this did not account for their much greater effect on the omega-3 PUFA-
treated cells. 
 
Annexin V staining followed by FACS analysis showed that human albumin 
antagonises the growth inhibitory effect of 50 μM EPA or DHA by inhibiting HaCaT 
apoptosis (figures 7-7 and 7-8). There is a clear decrease in the early, late and total 
apoptotic populations after addition of 0.3% or 1% w/v human albumin in the 3% 
v/v FBS medium after only 72h (figures 7-7 and 7-8A) and a concomitant increase in 
viable cells (figures 7-7 and 7-8B). It is apparent that human albumin protects 
HaCaT cells from DHA- and EPA-induced apoptosis and that this partially accounts 
for its protective effect on HaCaT growth (figure 7-6).  
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Figure 7-6. Effect of human and bovine serum albumin on PUFA induced growth 
inhibition 
The figure shows the effect of the omega-3 PUFA on HaCaTs in different concentrations of 
(A) bovine (BA), and (B) human serum albumin (HA) in RPMI plus 3% v/v FBS. The effect 
of DHA and EPA in RPMI plus 10% v/v FBS is also shown (C).The protocol was the same 
as for figure 7-3. The blue bars represent the untreated controls, the red bars 50 M DHA 
and the green bars 50 M EPA. The bars represent the means of 3 experiments performed in 
duplicate +/- SEM. * is significantly different from the mean value of the 3% v/v FBS, DHA 
or EPA treated control, respectively, with no added albumin (* = p<0.05, ** = p <0.01 and 
*** = p<0.001 as measured by one way ANOVA followed by post-hoc Bonferroni test). 















































































































Figure 7-7. Representative apoptosis assay experiment that shows albumin protective 
effect against PUFA growth inhibition 
The figure shows the results of the annexin V apoptosis assay. The HaCaT cells were 
incubated for 72 hours, either untreated in 10% FBS RPMI or untreated, 50 μM DHA 
treated or 50 μM EPA treated in 3% FBS RPMI with 0%, 0.3% or 1% w/v human serum 
albumin. The cells were incubated with annexin V-FLUOS and DAPI and analysed by flow 
cytometry. A representative annexin V/ DAPI experiment is shown. Viable HaCaT cells are 
negative for both annexin V and DAPI; early apoptotic cells are positive for annexin V while 
being negative for DAPI; late apoptotic cells are positive for both annexin V and DAPI and 
necrotic cells are positive for DAPI while being negative for annexin V. 




























Figure 7-8. Mean percentages of apoptotic HaCaT cells in 10% medium or 3% medium 
supplemented or not with human albumin 
The bars represent the mean percentages of (A) the early apoptotic (blue bars) and the late 
apoptotic cells (red bars) combined together and (B) the live cells in 10% FBS RPMI, 3% 
FBS RPMI and 3% FBS RPMI with 0.3% or 1% w/v human albumin. The cells were either 
untreated, or treated with 50 M DHA or EPA. The bars represent the means of 3 
independent experiments +/- SEM. * is significantly different from the mean value of 3% v/v 
FBS treated control with no added albumin (*=p<0.05 and ** = p <0.01 as measured by 
one way ANOVA followed by post-hoc Bonferroni test). 
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7.2.5 Lipid analysis after PUFA treatment 
 
In order to determine the fatty acid composition of malignant and normal 
keratinocytes and investigate any changes that occur after PUFA treatment in their 
membrane, lipid analysis by gas chromatography was performed. Specifically the 
fatty acid composition of SCC-25 and NHEK-131 phospholipids was analysed. The 
malignant oral cells SCC-25 (8.7x10
4
 cells) and the primary oral cells NHEK-131 
(2x8.7x10
4
 cells) were plated in 60 mm culture dishes (VWR). After 3 days, the cells 
were treated with DHA 3 μM. After 48 h treatment, the lipids were extracted using 
the Folch method. Then, the phospholipids were isolated from the total lipid extract 
by TLC, and finally, the fatty acids in the phospholipids were transesterified to 
produce fatty acid methyl esters (FAME) which were further analysed by gas 
chromatography coupled with mass spectrometry. The values of the detected fatty 
acids were normalised to 100% and expressed as mol% which were calculated by 
normalising the measured fatty acids values to 100% and then dividing by their 
molecular weights.  
 
Table 7-1 shows the fatty acid composition of the malignant SCC-25 and the table 7-
2 the fatty acid composition of the primary epidermal keratinocytes NHEK-131. 
Also figure 7-9 shows the omega-3 and omega-6 fatty acid profile of the oral cancer 
cell line SCC-25 and the normal keratinocytes NHEK-131 (a). The changes in these 
profiles after DHA 3 μM treatment for 48 h are shownd in figure 7-10. Fatty acids 
are expressed in mol% and include LA, AA and adrenic acid/DPA 
(docosapentaenoic acid) omega-6 combined, EPA and DHA/DPA omega-3 
combined. 
 
These are preliminary data from one experiment, after the optimisation of the 
method. More repeats are needed for final conclusions. However, we can observe 
differences between malignant and normal keratinocytes (figure 7-9). The normal 
keratinocytes appear to have significantly higher amounts of omega-6 and omega-3 
fatty acids compared to the malignant ones. Specifically, as regards the omega-6 
fatty acids, the NHEK-131 have approximately 50% more AA and 3-fold higher  
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Fatty Acids SCC-25 Control 
mol% 
SCC-25 in DHA 3 μΜ  
mol% 
14:0 1.71 1.50 
16:0 38.48 36.93 
18:0 37.19 37.98 
18:1 6.60 5.66 
20:0 0.00 0.00 
20:1 0.00 0.00 
18:2n-6 (LA) 2.26 1.81 
20:4n-6 (AA) 4.86 4.10 
22:4/5n-6 
(Adrenic acid/DPA n-6) 
1.27 1.38 
20:5n-3 (EPA) 1.11 1.96 
22:5/6n-3 (DPA/DHA n-3) 6.51 8.69 
 
Table 7-1. Fatty acid composition of SCC-25 
The fatty acid composition of SCC-25 untreated and treated with DHA 3 μM for 48 h. The 
fatty acids are expressed in mol%. 
 
Table 7-2. Fatty acid composition of NHEK-131 
The fatty acid composition of normal oral keratinocytes NHEK-131, untreated and treated 
with DHA 3 μM for 48 h. The fatty acids are expressed in mol%. 
Fatty Acids NHEK-131 Control 
mol% 
NHEK-131 in DHA 3 μΜ 
mol% 
14:0 0.20 0.23 
16:0 28.58 29.79 
18:0 33.08 31.71 
18:1 4.55 3.77 
20:0 0.49 0.29 
20:1 0.40 0.27 
18:2n-6 (LA) 1.17 0.97 
20:4n-6 (AA) 7.28 8.75 
22:4/5n-6 
(Adrenic acid/DPA n-6) 
3.89 3.15 
20:5n-3 (EPA) 1.50 1.84 
22:5/6n-3 (DPA/DHA n-3) 18.87 19.24 
















































Figure 7-9. Omega-3 and omega-6 fatty acid composition of keratinocytes 
The fatty acid profiles of the oral cancer cell line SCC-25 and the normal keratinocytes 
NHEK-131 are shown. The fatty acids are expressed in mol% and include LA (linoleic acid), 
AA (arachidonic acid) and adrenic acid+DPA (docosapentaenoic acid) omega-6 combined, 




amount of adrenic acid/DPA (n-6) combined than SCC-25. However the normal cells 
have almost 50% less LA. As regards the omega-3 fatty acids, NHEK-131 have 
approximately 30% more EPA and almost 3-fold higher amount of DPA (n-3)/ DHA 
combination than SCC-25. 
 
After treatment with DHA for 48 h (figure 7-10A), SCC-25 showed a 30% increase 
in DPA n-3/DHA and 70% increase in EPA, and also a notable 15% decrease in AA. 
Also LA slightly decreased, while the combination of adrenic acid/DPA (n-6) stayed 
almost the same. As regards the normal NHEK-131 cells (figure 7-10B), DHA 
treatment for 48 h resulted in a slight (2%) increase in DPA n-3/DHA and a 22% 
increase in EPA, while AA had a 20% increase. The combination of adrenic 
acid/DPA (n-6) showed a 20% increase and also LA slightly decreased. 
 
































































































Figure 7-10. Omega-3 and omega-6 fatty acid composition of keratinocytes after DHA 
treatment 
(A) The fatty acid profiles of the oral cancer cell line SCC-25 and (B) the normal 
keratinocytes NHEK-131, after DHA 3 μM treatment for 48 h, are shown. The fatty acids are 
expressed in mol% and include LA (linoleic acid), AA (arachidonic acid) and adrenic 
acid+DPA (docosapentaenoic acid) omega-6 combined, EPA and DHA+DPA omega-3 
combined. 





7.3.1 Serum albumin antagonises DHA- and EPA-induced growth 
inhibition 
 
EPA, DHA have been observed to induce apoptosis in many human cancer cell lines 
(Chen & Istfan, 2000; Edwards & O'Flaherty, 2008; Eitsuka et al, 2005; Finstad et 
al, 1998; Heimli et al, 2002; Merendino et al, 2005; Schley et al, 2005; Serini et al, 
2008) and we extended these observations to the pre-malignant keratinocyte line 
HaCaT.  However, when we investigated the effect of DHA and EPA on the 
epidermal pre-malignant keratinocyte line HaCaT as well as the colon 
adenocarcinoma line DLD-1, we observed that the concentration of FBS in the 
growth medium greatly antagonised the growth inhibitory effect of both PUFA in 
both cell lines, even though Eitsuka et al had reported an inhibitory effect of the 
same concentrations of PUFA in DLD-1 cells cultured in 10% FBS medium (Eitsuka 
et al, 2005). 
 
Our first hypothesis was that anti-apoptotic survival factors such as IGF-1 in serum 
might be responsible for this observation, but extensive testing of IGF-1, EGF, FGF-
a, FGF-b, TGF- and TGF-1 did not support this hypothesis. 
 
Our second hypothesis was that anti-oxidants present in FBS, such as vitamin E and 
its derivatives, might be the antagonists because DHA and EPA do cause an increase 
in reactive oxygen species (ROS) production and increase the level of oxidative 
damage in keratinocytes (chapter 5). However, the antioxidant PBN showed no 
protective effect against DHA- or EPA-induced HaCaT growth inhibition, thus 
arguing against this hypothesis. 
 
Finally, as serum proteins such as albumin are known to be lipid-binding (Huang et 
al, 2005) and specifically albumin has three high–affinity binding sites for fatty acids 
(Hamilton & Kamp, 1999), we hypothesised that such proteins would sequester free 
omega-3 PUFA like DHA and EPA and reduce their effective concentration in FBS 
and hence in vivo. This hypothesis was supported by the observations that both 
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bovine and human serum albumin at concentrations of 0.3-1.0% w/v were able to 
inhibit the effects of  high doses of DHA and EPA without being toxic to the HaCaT 
cells and at least some of these effects were due to the inhibitory effect of albumin 
on omega-3 PUFA-induced apoptosis.  However, the protection afforded to omega-3 
PUFA-treated HaCaT cells by albumin was only 50-75% of that produced by 10% 
FBS, suggesting that other inhibitors of the apoptotic action of omega-3 PUFA are 
present in FBS.  It should also be noted that albumin increased the growth of control 
cultures slightly and although this was insufficient to explain the protective effects 
on omega-3 PUFA-treated cultures, these data may indicate that FBS contains some 
free fatty acids normally unbound to albumin that inhibit HaCaT growth. 
 
The concentrations of albumin we observed to protect against omega-3 PUFA-
induced apoptosis and growth inhibition are consistent with those found in human 
plasma and so are likely to be physiological.  Fatty acids are thought to bind to 
albumin which transports them to the cell plasma membrane. As discussed in 
subchapter 7.1, fatty acids have to be dissociated from albumin in order to integrate 
into the plasma membrane or bind to its proteins and then be transferred across the 
membrane by either diffusion (passive flip-flop) (Hamilton & Kamp, 1999) or by a 
protein-carrier (Doege & Stahl, 2006). Albumin binding may delay the process of 
adsorption into the cell membrane (Hamilton & Kamp, 1999) but it is not considered 
to be an inhibitor of fatty acid transfer into the cells but a carrier of them. Rather, 
there is the general perception that PUFA need albumin to enter the cells. That is 
why many scientists in the literature use fatty acids bound to albumin in their in vitro 
and in vivo experiments. In our study we identified albumin to be a major antagonist 
of omega-3 PUFA anti-cancer action, which has implications for the ability to 
achieve pharmacologically active doses of DHA and EPA in the target tissue. Our 
results agree with another recent study which showed that albumin lowered DHA 
cytotoxicity towards hepatocellular carcinoma HepG2 cells (Kanno et al, 2011). 
They showed that albumin can reduce the ROS production caused by DHA 
treatment. However, DHA did not affect the growth of two other hepatocellular 
carcinoma cell lines. If oxidation was the only mechanism of the DHA-induced 
cytotoxicity, we would expect DHA to inhibit the other two cancer cell lines, as well. 
As regards our keratinocytes, the addition of the antioxidant PBN (50-1000 μM) did 
not protect the cells from the DHA growth inhibitory effect indicating that the 
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oxidative stress does not appear to be the driving mechanism of DHA-induced 
cytotoxicity. 
 
According to our results, the free fatty acid fraction of DHA and EPA appears to be 
associated with efficacy in cancer and not the albumin bound fraction. So we 
hypothesise that when free PUFA are bound to albumin their anti-cancer effect is 
inhibited. This might mean that albumin binding inhibits the uptake of DHA and 
EPA into the cells. The design of new modified fatty acids that have a reduced 




7.3.2 Lipid profile of keratinocytes prior and after PUFA treatment 
 
The available preliminary data from one experiment are not sufficient for final 
conclusions. However, there were some clear differences between malignant and 
normal keratinocytes. The normal keratinocytes have significantly higher amounts of 
omega-6 and omega-3 fatty acids in their membrane compared to the malignant 
ones. As regards the omega-6 fatty acids, the NHEK-131 show higher levels of AA 
and adrenic acid/DPA than SCC-25 while the levels of LA are a lot lower. As 
regards the omega-3 fatty acids, NHEK-131 have 30% higher levels of EPA and 
almost 3 times more DPA (n-3)/DHA than SCC-25. This could explain, at least 
partially, the selectivity of PUFA induced inhibition towards malignant that normal 
keratinocytes. The high amount of omega-3 fatty acids incorporated in the normal 
keratinocyte membranes may mean that PUFA are not particularly toxic to the 
normal keratinocytes, at least at specific concentrations. However, the malignant 
cells have lower levels of PUFA which could be a survival mechanism that enables 
them to escape from death, as omega-3 PUFA are highly toxic to the cancer cells. 
 
The preliminary data which were collected after treatment with 3 μM DHA for 48 h 
showed some changes in the omega-3 and omega-6 levels. As regards the omega-3 
fraction, after the DHA treatment, SCC-25 showed an expected 30% increase in 
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DPA n-3/DHA levels and also a 70% increase in EPA. However, normal NHEK-131 
keratinocytes showed only a slight (2%) increase in DPA n-3/DHA and a 22% 
increase in EPA. The small DPA/DHA increase might mean that there is enough 
DHA/DPA in the membrane and that is why they were not incorporated in the 
membrane. It could mean that no or low amounts of DHA entered the membrane, 
that DHA was converted to EPA or that at least some of the DHA was just 
transferred in the cytoplasm before the 48 h time point. In summary, more 
experiments are needed to have a clear picture of the fatty acid profile of these cell 
lines and the changes that PUFA treatment causes, but if reproducible, this may offer 
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Chapter 8. General discussion and future plans 
 
8.1 General discussion 
 
Head and neck cancer, including oral cancer, is the sixth most common malignancy 
in the United Kingdom and worldwide, with squamous-cell carcinoma (SCC) being 
the most frequent type of head and neck cancer. The main risk factors for HNSCC 
are tobacco usage and alcohol consumption (Hunter et al, 2005; Morita et al, 2010). 
Despite a reduction in the number of people smoking, the number of cases is 
predicted to nearly double in certain parts of the UK by 2020, placing a significant 
burden on the health service. Each oral cancer patient costs £54,000 to treat and 
survival rates have barely improved in 40 years. Therefore, there is a strong health 
economic benefit for reducing the number of advanced cases in the UK but also 
worldwide, particularly in high-risk groups (Speight et al, 2006). 
 
At the moment, the main treatments available in oral cancer are surgery, 
chemotherapy and radiotherapy, or a combination of them  (Haddad & Shin, 2008) 
and all are aggressive types of treatment. The surgery can cause facial dysmorphia of 
the patient and generally these treatments could even create permanent functional 
impairments in eating, drinking, taste and speech. Chemotherapy also kills the 
normal cells along with the cancer cells and causes many side effects (e.g. hair loss, 
pain, weight loss). The biggest problem in SCCs is that they very often recur because 
of incomplete excision or the appearance of secondary cancers. SCCs arise from a 
generalised field of abnormal mucosa that can involve in widely separated areas of 
the aerodigestive tract. Second field or second primary cancers are a common cause 
of relapse (Braakhuis et al, 2002; Hunter et al, 2005; Slaughter et al, 1953; Tabor et 
al, 2002), suggesting that the cost-effective prevention of secondary tumours is an 
important priority.  
 
Cancers are directly linked to nutrition (Weisburger & Horn, 1982) so several studies 
are trying to identify natural products from nutritional sources for chemoprevention 
and therapy. Recent evidence suggests that natural dietary products, such as omega-3 
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fatty acids have anti-cancer activities. The most important dietary omega-3 fatty 
acids are the cis-5,8,11,14,17-eicosapentaenoic acid (EPA) (20:5n-3) and the cis-
4,7,10,13,16,19-docosahexaenoic acid (DHA) (22:6n-3). These lipids are contained 
in oily cold-water fish such as salmon, trout, mackerel, anchovies and sardines, while 
fish take them from phytoplankton and zooplankton (Larsson et al, 2004). Humans 
are able to produce EPA and DHA from the omega-3 fatty acid α-linolenic acid 
(LNA) but only 5–10% of LNA is converted to EPA (Jump, 2002), so EPA and 
DHA are mainly acquired through the diet. 
 
Long chain PUFA are essential components of the diet and they play a significant 
role in several physiological processes such as plasma membrane synthesis, 
metabolic energy production and storage, gene expression (Doege & Stahl, 2006; 
Jump & Clarke, 1999), innate immune responses (Li, 2004), insulin release via 
GPCR activation (Steneberg et al, 2005) and foetus development, especially of the 
brain and retina (Cunningham & McDermott, 2009; Herrera, 2002). It is widely 
accepted that EPA and DHA could play an important role in decreasing the 
incidence and development of a wide variety of diseases, including cardiovascular, 
inflammatory, neurodegenerative and immune disorders, and cancer (Calder, 2004; 
Dyall & Michael-Titus, 2008; Serini et al, 2009). 
 
EPA and DHA have been observed to induce apoptosis in various human cancer cell 
lines such as breast (Schley et al, 2005) and colon cancer (Chen & Istfan, 2000; 
Eitsuka et al, 2005),  lymphoma and leukaemia (Heimli et al, 2002) (Finstad et al, 
1998), lung, pancreatic and prostate cancer (Edwards et al, 2008; Merendino et al, 
2005; Serini et al, 2008). Animal studies have also demonstrated that there is a 
negative relationship between diets rich in omega-3 PUFA and breast, prostate, lung, 
and colon cancer (Bartsch et al, 1999; Edwards & O'Flaherty, 2008; Rose et al, 
1996; Tsubura et al, 2009; Yuri et al, 2003). Furthermore, several human studies 
have shown that consumption of a diet enriched in omega-3 PUFA can protect 
against a variety of malignancies, including breast (Sasaki et al, 1993), prostate 
(Terry et al, 2004) and colon cancer (Yang et al, 2003). 
 
Several studies have demonstrated that omega-3 PUFA are able to sensitise tumour 
cells to anticancer drugs in vitro (Biondo et al, 2008; Lindskog et al, 2006; Maheo et 
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al, 2005) and in vivo using cancer animal models (Cha et al, 2002; Colas et al, 2006; 
Hardman et al, 2002). Human clinical trials which have examined the effects of 
omega-3 PUFA on tumour response to chemotherapy have shown promising results, 
such as an increase in body weight and energy levels of advanced colorectal cancer 
patients during chemotherapy, after EPA and DHA enriched supplements (Read et 
al, 2007) and improved response to chemotherapy of breast cancer patients with 
higher concentrations of DHA in breast adipose tissue whereas low DHA levels were 
associated with no response or even tumour growth (Bougnoux et al, 1999).  The 
phase II clinical trial showed that the use of DHA during chemotherapy was devoid 
of adverse side effects and could improve the outcome of chemotherapy when it was 
highly incorporated into plasma phospholipids (Bougnoux et al, 2009). 
 
Very few studies have investigated the effect of omega-3 PUFA on oral or skin 
squamous cell carcinoma. Ellatar and Lin reported a decrease in the synthesis of the 
pro-inflammatory and tumour promoting series 2 prostaglandins, PGE2 and PGF2, 
after treatment of SCC-25 cells with EPA, DHA and other PUFA (Elattar & Lin, 
1989). Ramesh and Das examined the effect of topical omega-3 and omega-6 free 
fatty acids on two stage skin carcinogenesis in mice. EPA inhibited both the 
initiation and promotion stages of skin carcinogenesis whereas DHA inhibited the 
number of papillomas only in the initiation stage. No direct correlation between lipid 
peroxidation and papilloma formation was observed but a trend towards an increase 
in the formation of lipid peroxides in parallel with the inhibitory effect of fatty acids 
on papilloma development was noticed (Ramesh & Das, 1996). When the authors 
used fish oil as a treatment, in the same mouse model, papilloma formation was only 
inhibited during the promotion stage, and was associated with an increase in lipid 
peroxidation but no effect on cell proliferation (Ramesh & Das, 1998). Injected 
omega-3 PUFA decreased the mucosal/epidermal response to irradiation in mice. In 
the HEP-2 HNSCC xenograft transplanted in nude mice, a decrease of tumour 
growth was observed when treated with omega-3 PUFA or EPA alone but this effect 
was maximal when combined with irradiation. The effects were associated with 
inhibition of angiogenesis and tumour proliferation, and decreased expression of 
COX-2 (Wen et al, 2003). One clinical trial in head and neck cancer post-surgical 
patients was reported, during which omega-3 enhanced supplements were consumed 
for 3 months in order to explore any improvement in body weight. Only serum 
Chapter 8. General Discussion and Future Plans 
203 
 
protein levels improved, with good tolerance of the supplements (de Luis et al, 
2008). 
 
In my PhD project, I attempted to take this research further. I tested the potential of 
the omega-3 fatty acids DHA and EPA to act as selective chemopreventative and 
therapeutic agents against oral cancer and investigated the mechanism of action. In 
particular, I tested the ability of DHA and EPA to specifically inhibit pre-malignant 
and malignant keratinocyte growth, including epidermal and oral malignant 
keratinocytes. Additionally, I tested the effect of omega-3 PUFA on normal 
keratinocytes.  
 
Firstly, I examined whether PUFA specifically inhibit SCC growth at physiological 
concentrations, using the epidermal SCC-13 and the oral SCC-25 cell lines.  
Epidermal cells were added to this study because epidermal and oral keratinocytes 
are very similar, and also to gain insight regarding the effect of omega-3 PUFA on 
epidermal SCC. DHA and EPA suppressed the growth of the malignant cells after 
only 4 days, at concentrations within the physiological range. PUFA were very 
potent on the oral cancer keratinocytes SCC-25, as they eliminated most viable cells 
at concentrations ≥3µM, while the epidermal SCC-13 growth was also significantly 
decreased by PUFA, at concentrations >3µM, even though they were more resistant 
than SCC-25. 
 
DHA and EPA also proved to be effective in inhibiting the pre-malignant epidermal 
and three oral dysplasias. Generally, PUFA were potent in inhibiting premalignant 
keratinocytes; however some oral dysplasias were more sensitive than others. The 
degree of sensitivity of dysplasias to PUFA is likely to depend on the type, stage of 
oral dysplasia and the location of origin.  
 
Normal oral and epidermal keratinocytes were generally less sensitive than their 
premalignant and malignant counterparts, but somewhat more sensitive than the 
normal immortalised cells, possibly because senescence may make them more 
sensitive. 
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In summary PUFA, at least as the free fatty acid form, can be cytotoxic to normal 
cells, at higher doses. However, PUFA display selectivity towards neoplastic cells. It 
is also true that cell culture is not the optimal environment for normal cells as they 
are under stress and dividing rapidly, which may contribute to their susceptibility to 
PUFA treatment, so that in vivo, the selectivity may be greater. For example, EPA 
has been shown before to inhibit tumour promotion in mouse skin (Ramesh & Das, 
1996). In summary, my results are very promising as I showed that both the omega-3 
fatty acids DHA and EPA can eliminate oral cancer and pre-malignant cells at 
concentrations that do not kill normal healthy cells. Specifically, EPA seems to be a 
potent and a selective therapeutic tool in inhibiting SCCs and pre-malignant cells in 
both oral and epidermal cancer. The sensitivity of premalignant cells is important 
because it is these cells that would comprise the clinically relevant part of a cancer 
field. 
 
Several studies have provided evidence of the pro-apoptotic effect of EPA or DHA 
in different cancer cells in vitro (Serini et al, 2009). EPA or DHA were shown to 
trigger either the intrinsic (Heimli et al, 2002; Lim et al, 2009) or both the extrinsic 
and the intrinsic apoptotic pathways (Narayanan et al, 2001; Tsuzuki et al, 2007), 
probably depending on different cells, different omega-3 PUFA used (EPA, DHA or 
fish oil) and different regimes of administration. In my study, it was demonstrated 
that EPA and DHA caused an apoptotic cell death, by the flow cytometric annexin 
V/DAPI apoptosis assay and cleavage of caspase 3 by western blot analysis. The 
cleavage of caspase 8 and caspase 9 were also detected by western blot, 
demonstrating the involvement of the extrinsic and the intrinsic apoptotic pathways, 
respectively. This could mean that both EPA and DHA trigger both apoptotic 
pathways at the same time in order to destroy the cells, or that the extrinsic pathway 
is triggered but does not manage to activate enough caspase 8, so the pro-apoptotic 
signal of caspase 8 leads to the engagement of cytocrome c/Apaf-1 and caspase 9 
cleavage of the intrinsic mitochondrial pathway (Logue & Martin, 2008). 
 
In addition, it has been observed that PUFA inhibit cancer cell proliferation, in 
accordance to Schley et al who showed that EPA and DHA treatment caused 
decreased breast cancer cell proliferation and apoptotic cell death (Schley et al, 
2005). In the present study, treatment of SCC-25 with 3 μM of DHA and EPA for 48 
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hours significantly decreased 
3
H-thymidine incorporation, which indicates decreased 
DNA synthesis and cell proliferation following exposure to omega-3 PUFA. A 
marked decrease in 
3
H-thymidine incorporation was observed for both PUFA but 
bigger for DHA. As it was demonstrated that omega-3 PUFA both impair 
proliferation and induce apoptosis of oral cancer cells, I can conclude that DHA and 
EPA are not only cytotoxic but also cytostatic.  
 
The mechanism of EPA and DHA anti-tumour action is not fully understood, and 
many different possibilities have been reported. It is becoming increasingly clear that 
their action is actually pleiotropic (Berquin et al, 2008; Chapkin et al, 2008). I 
attempted to investigate some of the proposed mechanisms reported to be involved in 
EPA and DHA action. 
 
I investigated the fatty acid profile of the malignant oral SCC-25 and the normal 
epidermal NHEK-131 via gas chromatography (GC). It was observed that the normal 
keratinocytes have significantly higher amounts of omega-6 and omega-3 fatty acids 
in their membrane compared to the malignant ones. This difference could explain, at 
least partially, the selectivity of PUFA induced inhibition towards malignant that 
normal keratinocytes. The high levels of omega-3 fatty acids in the normal 
keratinocyte membranes may mean that PUFA are not particularly toxic to normal 
keratinocytes at specific concentrations while the malignant cells lower levels of 
PUFA could be a survival mechanism, as omega-3 PUFA are highly toxic to the 
cancer cells. After exposure to DHA for 48 h, the malignant cells showed a marked 
increase in DPA n-3/DHA levels (30%) and EPA (70%), while normal keratinocytes 
showed only a slight (2%) increase in DPA n-3/DHA and smaller increase in EPA 
(22%). These are only preliminary data so more experiments are needed to have a 
clear picture of the fatty acid profile of these cell lines and the changes that PUFA 
treatment causes. However it could provide a partial explanation of the differential 
sensitivity of SCC cells to PUFA. 
 
Another important issue was the discovery that albumin was an important antagonist 
of PUFA-induced apoptosis. This may lead to the design of modified lipids that do 
not bind albumin or to the substitution of bioactive PUFA metabolites for the PUFA 
themselves in order to increase their therapeutic potential. 
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Continuing the investigation of the PUFA anti-tumour mechanism of action, I 
examined the role of ROS. PUFA are susceptible to free radical attack that leads to 
lipid peroxidation (Biondo et al, 2008), which can injure the mitochondria and result 
in further ROS generation (Catala, 2009). This can cause inhibition of DNA 
synthesis, cell division and tumour growth, as well as induction of tumour cell death 
(Girotti, 1998). Some chemotherapy drugs induce tumour cell death partly by ROS 
formation (Malhotra & Perry, 2003). The long-chain omega-3 PUFA appear to 
increase the potency of these chemotherapy drugs, by elevating the production of 
ROS (Biondo et al, 2008; Colas et al, 2006; Germain et al, 1998; Sturlan et al, 
2003). Also, several studies suggest that the increase in ROS generation might be 
one of the mechanisms of omega-3 PUFA anti-tumour action (Arita et al, 2001; 
Gleissman et al, 2010; Kang et al, 2010; Maziere et al, 1999; Tsuzuki et al, 2007). 
 
Generally cancer cells seem to have high levels of ROS. Studies indicated that 
malignant cells from chronic lymphocytic leukaemia patients showed increased ROS 
production compared to normal lymphocytes (Zhou et al, 2003) and increased levels 
of 8-oxo-dG in human and animal tumours (Halliwell, 2007b; Neeley & Essigmann, 
2006; Sanchez et al, 2006). In my study, I showed that all the malignant epidermal 
and oral cell lines, the pre-malignant epidermal line and the normal epidermal 
keratinocytes, had high levels of ROS compared to the human foetal fibroblast cell 
line (HFF), which were used as a negative control. 
 
So, the cells already had increased ROS before any treatment with PUFA. After 
treatment with PUFA, SCC-25 cells were tested and an increase in ROS was 
observed after 16 hours by DCF and HE flow-cytometric assays, especially for the 
higher concentrations of EPA and DHA used. Oxidative damage was also observed 
for the untreated SCC-25 cells by 8-oxo-dG staining which increased after exposure 
to EPA and DHA. However, the two well-known anti-oxidants, α-tocopherol (α-
TOC) and PBN, failed to rescue the cells from the omega-3 PUFA inhibitory effect 
at the MTT assay.  A protective effect was not observed when PBN was used on 
HaCaT cells. This may mean that oxidation is not the mechanism that causes the 
PUFA-induced cytotoxicity or that it is not the only or the main mechanism of 
PUFA action in SCC. However, ROS production may be responsible for the toxicity 
to normal keratinocytes at higher doses. Generally, normal cells are under stress in 
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culture and this might contribute to the fact that they showed high levels of ROS in 
vitro. However, it could also mean that the oxidation levels after the addition of 
PUFA were so high that the anti-oxidants failed to reverse the induction of apoptosis.  
 
It has also been reported that EPA and DHA can downregulate telomerase activity 
by inhibiting the expression of CMYC, and this was accompanied by slowed growth 
(Eitsuka et al, 2005), but in this study there was no distinction between cause and 
effect. I showed that HaCaT cells that were ectopically expressing CMYC or TERT 
under the control of a heterologous promoter were just as sensitive to growth 
inhibition by PUFA as the controls, strongly indicating that the inhibition of 
telomerase activity was an indirect result of growth arrest or death. 
 
A number of signalling pathways are reported being differentially affected by 
omega-3 PUFA. PUFA have been reported to inhibit (Lee et al, 2003; Schley et al, 
2005) or upregulate the PI3K pathway, inhibit COX-2 (Horia & Watkins, 2007; Lim 
et al, 2008; Narayanan et al, 2004) and decrease the levels of its product, PGE2 
(Gleissman et al, 2010), modulate MAPK pathway by inhibiting p-ERK1/2 and p-
p38 (Serini et al, 2008) or inhibit Ras and ERK activation (Collett et al, 2001). It has 
been suggested that omega-3 PUFA modulate signalling by decreasing the activation 
of NFκB, (Novak et al, 2003; Weber et al, 1995) and promoting the activation of 
PPARγ (Sun et al, 2008) which can induce apoptosis (Zand et al, 2007). 
Furthermore, it has been suggested that omega-3 PUFA affect intracellular Ca
2+
 
homeostasis, triggering apoptosis (Aktas & Halperin, 2004; Kolar et al, 2007) and 
also alter basic properties of cell membranes, such as fluidity, phase behaviour, rapid 
flip-flop and resident protein function (Stillwell & Wassall, 2003) especially 
affecting lipid rafts by altering their behaviour and proteins function (Chen et al, 
2007). 
  
I investigated the involvement of some of the above signalling pathways in the 
PUFA growth inhibitory mechanism of action on SCC-25 cells.  
 
In contrast to other studies, my results demonstrated a 2-fold increase in the COX-2 
protein expression after 5 h of DHA and EPA treatment in oral SCC-25 cells. After 
17 h the levels declined for EPA, while for DHA there was a sustained over-
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expression (1.5-fold) but the levels also decreased. My results agree with one study 
that examined the effects of PUFA on HaCaT epidermal keratinocytes and reported 
an increase in COX-2 levels. While several studies demonstrate an important role of 
COX-2 expression during tumourigenesis and its tumourigenic role (Arber et al, 
2006; Giardiello et al, 2004; Greenhough et al, 2009; Mendes et al, 2009), others 
support a tumour-suppressive role under some circumstances (Arber et al, 2006; Bol 
et al, 2002; Giardiello et al, 2004; Greenhough et al, 2009; Mendes et al, 2009; 
Murata et al, 2004; Patsos et al, 2010; Wilson & Potten, 2000). I hypothesise that 
COX-2 is involved in the cell inhibitory effect of PUFA. COX-2 could be causing 
apoptosis or growth arrest or producing anti-inflammatory and tumour suppressive 
EPA and DHA metabolite. 
 
Unexpectedly, the phosphorylation of ERK1/2 was rapidly up-regulated (within 30 
mins) after treatment with different doses of DHA and EPA and was sustained and 
increased for 24 h. The activation of the downstream target of p-ERK, p-p90RSK 
was also observed. Typically, the activation of ERK is expected to promote cell 
survival and proliferation (Mansour et al, 1994; Xia et al, 1995). Increased ERK 
phosphorylation is sometimes reported after a cell death stimulus as a survival 
mechanism (Lee do et al, 2006; Persons et al, 1999). Recent studies implicate the 
ERK pathway activation in cell death or cycle arrest depending on the type and 
duration of the stimulus and cellular context (Elder et al, 2002; Galve-Roperh et al, 
2000; Persons et al, 1999; Pumiglia & Decker, 1997; Stanciu et al, 2000; Wang et al, 
2000). As in the present study the omega-3 PUFA-induced ERK1/2 activation 
happened early and it was very strong and sustained, I hypothesise that it actually 
triggered apoptosis. The use of the pan-caspase inhibitor QVD-Oph did not affect the 
increased levels of p-ERK1/2 demonstrating that ERK1/2 phosphorylation is not a 
consequence of apoptosis, and that it is not just a survival mechanism.  
 
In order to investigate whether the PUFA-induced up-regulation of p-ERK1/2 causes 
apoptosis, I needed to test if the inhibition of p-ERK blocks the apoptosis caused by 
PUFA. First, two MEK inhibitors were used in order to examine their effects on 
ERK and p90RSK activation by western blot and determine the optimum 
concentrations for the cell assays. They both reduced p-ERK1/2 and p-p90RSK 
levels, however AZD6244 seemed more potent than U0126, as it inhibited phospho-
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ERK1/2 and phospho-P90RSK levels without reducing the basal levels of the control 
as much. The use of an EGFR blocking antibody and the EGFR inhibitor, AG1478 
also inhibited the PUFA induced p-ERK1/2 and p-p90RSK very effectively without 
affecting the endogenous levels of the control, demonstrating that EGFR is the 
activator of the ERK pathway. I hypothesise that the omega-3 PUFA are causing 
apoptosis by increasing the secretion of an unknown EGFR ligand. Most SCCs have 
increased levels of EGFR (Stanton et al, 1994) and are inhibited from growing by 
levels of EGF that are optimal for normal keratinocytes (Gulli et al, 1996), so the 
release of EGFR ligand(s) by PUFA may lead to a suprastimulation of ERK1/2 and 
as a result trigger apoptosis (figure 8-1). 
 
There was no change in p-Akt levels observed after treatment of SCC-25 cells with 
EPA and DHA, and this coupled with the sustained and early activation of ERK1/2 
could indicate the type of signalling imbalance known to cause apoptosis or 
senescence.  
 
Furthermore, JNK phosphorylation was also observed, especially at the higher 
concentration of EPA and DHA, which is activated preferentially by stress and can 
promote apoptosis (Kennedy et al, 2003). JNK phosphorylation was higher during 
DHA than EPA use. So, JNK activation can also participate in the PUFA induced 
apoptosis and could also be a result of EGFR over-activation as well, or it could be 
triggered by ROS production. 
 
The beneficial effects of omega-3 PUFA in the treatment of cancer may involve a 
multitude of mechanisms but the accessibility of the aerodigestive tract cancer to 
potential therapeutic aerosols or gels makes it an attractive site to test the therapeutic 
and prophylactic potential of omega-3 PUFA. The safety and tolerability of these 
compounds has already been documented in other clinical indications. I propose that 
the manufacturing of an omega-3 containing spray or gel will be greatly beneficial, 
used on its own or in combination with the current treatments to improve the 
therapeutic outcome. More importantly, such a preparation could also be used by 
former oral cancer patients as a chemopreventive strategy in order to prevent relapse. 
This type of therapy would be inexpensive and easily accessible, so any patient could 
be treated at a very moderate cost. In conclusion, the present study demonstrated the 
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great potential of the omega-3 fatty acids, EPA and DHA, for oral (and epidermal) 































Figure 8-1. Hypothesis of PUFA-induced SCC inhibition by secretion of an EGFR ligand 
Schematic representation of my hypothesis that omega-3 PUFA induce secretion of an 
EGFR ligand which leads to over-activation of EGFR (which is overexpressed in HNSCC). 
EGFR suprastimulation leads to MAPK activation, such as ERK and JNK pathways, and 
subsequent apoptosis and/or growth arrest. The image also shows where the different 
inhibitors used in the study act, blocking their targets. 
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8.2 Short term future plan 
 
8.2.1 Test the link between the EGFR ligand, the EGFR/MAPK/ERK 
pathway and omega-3 PUFA-induced apoptosis 
I will continue the experiments with the EGFR blocking antibody, the inhibitors 
A1478, AZD6244 and U0126 and a COX-2 inhibitor, to test the extent to which the 
induction of ERK1/2 phosphorylation through stimulation of the EGFR is linked to 
omega-3 PUFA-induced apoptosis. Apoptosis and MTT assays with the use of the 
optimal concentrations of the MEK and the EGFR inhibitors (determined by the 
western blot assays) and additional omega-3 PUFA treatment will assess the effect of 
EGFR and ERK activation on the PUFA growth inhibitory effect and apoptosis. 
 
I will transfect small interfering RNAs (siRNAs) and establish the time interval over 
which the candidate molecules are knocked down. Alternatively, short hairpin RNAs 
(shRNAs) against the candidate EGFR ligand(s), ERK1, ERK2, COX-2 will be used 
and checked by western blotting to reduce expression by 70%.  The knocked down 
SCC-25 cells will be treated with omega-3 PUFA and tested for the levels of total 
target protein, induced ERK1/2 phosphorylation and apoptosis.  These experiments 
will establish the extent to which any potential secreted candidate ligand and 
ERK1/2 phosphorylation are required for omega-3 PUFA-induced apoptosis. If the 
pharmaceuticals that block ERK phosphorylation do not inhibit omega-3 PUFA-
induced apoptosis in the pilot experiments, I will continue to survey candidate pro-
apoptotic pathways and design experiments to inhibit ERK1/2 and these pathways in 
concert, to establish the key molecular events required for omega-3 PUFA-induced 
apoptosis and hence their chemopreventative and therapeutic action 
 
 
8.2.2 Identification of the EGR ligand(s) induced by omega-3 PUFA in 
OSCC cells  
I will treat the SCC-25 OSCC line with EPA, DHA and the ethanol vehicle control in 
serum-free medium, containing EGF or not and collect conditioned medium from the 
cells after 24 hours. The conditioned medium from radioactively-labelled SCC-25 
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cells treated with either the vehicle (ethanol) or EPA or DHA will then be sent for 
custom-made antibody arrays assay (Coppe et al, 2008) that carry antibodies against 
all the known EGFR ligands, with the purpose of identifying which ligands are up-
regulated by omega-3 PUFA, and are candidates for inducing apoptosis or if these 
are not available, screen for them by using qPCR. 
 
 
8.2.3 Lipid profile of keratinocytes prior and after PUFA treatment 
I have already optimised the technique and have obtained preliminary data of the 
lipid analysis of the malignant SCC-25 and normal keratinocytes NHEK-131 after 
DHA treatment using gas chromatography (GC). The available preliminary data 
demonstrated clear differences between malignant and normal keratinocytes. The 
normal keratinocytes have significantly higher amounts of omega-6 and omega-3 
fatty acids in their membrane compared to the malignant ones. These experiments 
need to be repeated with cells untreated and also treated with EPA and DHA, cells 
for final conclusions about the lipid profile of the cells and also the alterations after 
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8.3 Long term future plans 
 
8.3.1 Test the chemopreventative and chemotherapeutic potential of 
omega-3 PUFA in vivo 
 
8.3.1.1 Test the ability of omega-3 PUFA to prevent squamous tumour 
formation 
EPA seemed to be the more selective of the two omega-3 PUFA, so it is possible that 
the in vivo experiments will continue with just EPA. I will test the potential of EPA 
in vivo using the mouse two-stage epidermal tumourigenesis system which is a well 
characterised animal model where the genetics, cell and molecular biology of the 
initiation event and tumour progression events are known (Kemp, 2005; Payne & 
Kemp, 2005). EPA will be applied topically prior to each twice weekly application 
of the tumour promoter 12-O-tetradecanoylphorbol, 13-acetate (TPA) for a total of 
12 weeks, as described before (Ramesh & Das, 1996). In other experiments EPA will 
be added to the animal feed.  The pre-malignant (papillomas) and malignant 
(carcinomas) lesions will be counted and measured prior to sacrifice. Then, the 
tumours will be snap frozen in liquid nitrogen for histological confirmation, 
immunohistochemical analysis and lipid analysis. The experiments will test whether 
omega-3 PUFA are chemo-preventative for squamous neoplasia in vivo when orally 
administered or topically applied, and also will provide material to study the effect of 
EPA on apoptosis and ERK1/2 phosphorylation on normal and neoplastic epidermal 
tissue. 
 
8.3.1.2 Test the ability of omega-3 PUFA to inhibit squamous tumour 
growth 
I will then perform experiments on pre-formed papillomas.  The size of papillomas 
and their rate of progression to carcinomas will be assessed as above. These 
experiments will test the effectiveness of EPA in inhibiting tumour growth and also 
its effect on tumour progression. The experiments will also test the potential of EPA 
as chemotherapeutic agent for squamous neoplasia.  In these experiments mice will 
be sacrificed before the administration of EPA and at various times thereafter. The 
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tumours will be used for histological, immunohistochemical analysis, lipid analysis 
and also for protein extraction prior to western blot analysis. The samples will be 
subject to standard histological analysis to confirm the benign or malignant status, 
and also to examine the tumours for signs of angiogenesis and other requirements for 
tumour growth and invasion. The tumours will be checked for apoptosis, 
proliferation and ERK phosphorylation in frozen sections by immunofluorescence 
Commercial antibodies against cleaved caspase 3 will be used to measure apoptosis, 
and Ki67 to measure cell proliferation, as well as phospho- and total ERK1/2. 
Double labelling will be performed to determine whether ERK phosphorylation is 
associated with apoptosis and growth arrest by directly labelling the phospho-
ERK1/2 antibody with a different fluorochrome to Ki67 or cleaved caspase 3.    
 
8.3.1.3 Do endogenously produced omega-3 PUFA inhibit squamous 
neoplasia? 
I will also test the role of endogenously generated omega-3 PUFA in suppressing 
squamous neoplasia by comparing the frequency of papillomas and carcinomas 
forming in a 12 week period in the fat-1 transgenic mouse which converts omega-6 
to omega-3 fatty acids endogenously and has high tissue levels of the latter (Kang et 
al, 2004). We will test heterozygotes and wild types by using the two stage 




8.3.2 Extend my study to the potential of other natural products to 
inhibit squamous cells carcinomas; use of tocotrienols 
 
Vitamins are prominent among the natural compounds considered to be beneficial in 
cancer Vitamin E exists in nature as two classes of compounds: tocopherols (Toc) 
and tocotrienols (T3s). Humans are unable to synthesise vitamin E and therefore 
must obtain the compound from plant sources. Toc is present in nuts and vegetable 
oils, whereas T3 are primarily derived from palm oil, oat, rye, wheat germ, barley 
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and rice bran (Constantinou et al, 2008; Hiura et al, 2008). Vitamin E is relatively 
nontoxic and well tolerated by humans, and the various isoforms have been reported 
to lower blood cholesterol and have cardioprotective effects, immunoregulatory 
activities, antioxidant activity, potent neuroprotective effects and antitumour activity 
(Jemal et al, 2006; Sen et al, 2006).  
 
T3 have also been reported to have anti-tumour activity. In vitro, T3 showed 
apoptotic or antiproliferative activities against various cancer cells such as hepatoma 
Hep3B (Sakai et al, 2006), breast carcinoma MCF7 (Nesaretnam et al, 1995) 
colorectal adenocarcinoma DLD-1 (Eitsuka et al, 2006), prostate cancer (Srivastava 
& Gupta, 2006) and chronic myelogenous leukemia KBM-5 cells (Ahn et al, 2007). 
The anticancer properties of T3s were also evaluated in vivo. In these studies they 
inhibited liver and lung carcinogenesis (Iqbal et al, 2004; Wada et al, 2005) breast 
tumours (Nesaretnam et al, 2004) and suppressed angiogenesis in mice bearing 
human colorectal cancer cells (Nakagawa et al, 2007). γ-T3 enriched diet decreased 
tumour weight and prolonged the survival rate of C57BL female mice transplanted 
with melanoma (He et al, 1997).  
 
In humans, the antitumour properties of vitamin E were first suspected when studies 
showed that the risk of colon cancer is lower for people in the Mediterranean area, 
who consume diets rich in vitamin E isoforms, than for people in Northern Europe 
and USA (Berrino & Muti, 1989; Khlat, 1995). Another study showed that low 
dietary intake of vitamin E increases the incidence of prostate cancer (Eichholzer et 
al, 1996). In Malaysia palm oil is the main dietary fat consumed, which is a 
particularly rich source of T3s. The levels of the δ-T3 in adipose tissue of Malaysian 
women showed a significant reduction in malignant compared to benign tissue 
(Nesaretnam et al, 2007).  
 
I investigated the potential of T3s in SCC and obtained some interesting and very 
promising preliminary data. Pure tocotrienols α, γ, δ and Tocomin®, a natural full 
spectrum Tocotrienol/Tocopherol complex (Carotech BHD, Perak, Malaysia) (see 
Chapter 2) were used. I investigated whether T3s specifically inhibit SCC growth 
using the epidermal SCC-13 and the oral SCC-25, and the pre-malignant cell line 
SVFHK. Treatment with increasing concentrations of T3s for 4 days caused a dose-
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dependent inhibition of growth as determined by the MTT assay (APPENDIX 1). γ- 
and δ-tocotrienols were more potent, causing 80-95% growth inhibition at a 
concentration of 10 μM, with γ-tocotrienol having a marked effect even at lower 
concentrations. Tocomin® was also very effective in the SCC cell lines. To our 
knowledge, I showed that T3s strongly affect oral and epidermal SCC cell growth for 
the first time. Moreover, under the same culture conditions, the T3s seemed to have 
little or no effect on the two types of normal epidermal keratinocytes, NHEK-131 
and HEK-127, at doses that killed the malignant cells, as showed by the MTT assay.  
 
I also used the flow cytometric annexin V/DAPI apoptosis assay to determine 
whether the epidermal SCC-13, the oral SCC-25, and the pre-malignant SVFHK cell 
lines cells were undergoing an apoptotic death after treatment with T3s. There was a 
marked difference in the percentage of viable cells between treated and untreated 
cells after only 48 h treatment, for SCC-25 and SCC-13 (APPENDIX 2 and 3). 
SVFHK seemed to be more resistant to T3s‟ effect after 48h. However, the 
percentage of early apoptotic cells (annexin V +ve/DAPI –ve) did not increase much 
so it is unclear if the cells were undergoing apoptosis, necrosis, terminal 
differentiation or a combination of them. The experiment needs to be extended to 
more time points and western blotting needs to be performed in order to investigate 
whether apoptotic molecules are activated. However, from these early results it 
appears that T3s do not inhibit SCC growth by the same mechanism as PUFA. 
 
These preliminary data are very promising showing that T3 have a potential as a 
chemopreventive and therapeutic tool for SCC. However, further investigation is 
required regarding the type of cell death and the possible growth arrest, and also in 
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Appendix 1. The effect of tocotrienols (T3s) on keratinocyte cell growth 
Means± S.E.M of 3 independent MTT experiments for SCC-13, SCC-25, SVFHK, NHEK-131 
and HEK-127. Each experiment was conducted in duplicate. Cells were incubated in 
different concentrations of α, γ, δ tocotrienols and tocomin mix for 4 days in KGM serum-
free medium. S.E.M=Standard error of means. * is significantly different from the mean 
value of untreated control of each cell line (* = p<0.05 and ** = p <0.01 *** = 
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Appendix 2. Apoptosis assay 
Representative flow cytometry plots for annexin V-FITC/DAPI for cellular viability. The 
scatter plot is shown for the untreated control where SSC=side scatter and FSC= forward 
scatter and the fluorescence plots are shown for each sample SCC-25 cells were used in this 
example. Untreated control cells and cells treated with 10 μM α, γ, δ tocotrienols and 
tocomin for 48 h are shown. Q3 shows the viable cell population (annexin V -ve, DAPI  -ve), 
Q4 shows early apoptotic cells (annexin V +ve DAPI –ve), Q2 shows late apoptotic and 







































































































































Appendix 3. Means of viable and non-viable cells percentages in the apoptosis assay 
Means± S.E.M of 3 independent annexin V/DAPI experiments. SCC-13, SCC-25, SVFHK 
were incubated in 10 μM α, γ, δ tocotrienols and tocomin  for 48 h in KGM serum-free 
medium prior to trypsinisation. Then the cells were stained with annexin V and DAPI and 
analysed by flow cytometry. The percentages of viable cells (A) and the normalised with the 
control percentages (B) are shown. 
